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Abstract 
 
Gastrointestinal cancer is thought to be primarily a disease of stem cells, whereby a 
tumorigenic stem cell clone can expand within an individual colonic crypt and then 
within the epithelium to form an adenoma - the pre-malignant lesion of the colon. 
However, data demonstrating stem cell populations and the dynamics of clonal 
expansion in human intestinal crypts is lacking. Naturally occurring, somatic clonal 
mutations in mitochondrial DNA were used to identify the progeny of a putative single 
stem cell lineage within crypts; this allowed the visualization of putative stem cell 
clones arising and expanding within human colon and small bowel crypts. 
Immunohistochemistry for lineage specific markers, to confirm multi-potentiality, and 
in-situ hybridisation for stem cell markers was then performed to phenotype clones 
further and to demonstrate a single stem cell lineage and their direct progeny within the 
human crypt. By combining clonal somatic mutations in mitochondrial DNA with 
methylation signatures, the dynamics of clonal expansion within normal colon crypts 
and the epithelium was studied, and using mathematical modeling the time course of 
these events was able to be estimated. By applying the same techniques, in addition to 
studying genomic mutations, the dynamics of human adenoma growth was investigated; 
this suggested that adenomas appear to grow in a punctuated manner, with episodes of 
rapid clonal expansion being followed by periods of relative quiescence. 
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Chapter 1. Introduction 
 
?????? ??????? ??? ???? ?????? ????? ??????? ??????? ??? ???? ???? ???? ??????? ?????
?????????????????????????????????????????????????????????????????????????????
????? ????????? ????? ??? ??????????? ???? ???????? ??? ???? ??? ??? ????? ?????????????
???????????? ?????????? ???? ?????????? ??? ???? ???????? ???????????? ????? ???????? ?????
???????? ???? ???????? ?????????????? ??? ???? ????? ?????? ???? ?????? ???????? ????
????????????????????????????????????????????????????????????????????????????????????
?????????? ????????? ?????? ??????? ???? ????? ????? ?????? ????? ??????????? ??????????
???? ??????? ??????? ???? ???????????? ??? ???? ?????? ???? ???????? ??? ????????? ??? ????
???????????????????????????????????????????????????????????? ?????????????????????
???? ???????? ?????? ????????? ??? ???? ?????????? ??? ?????? ?????????? ??????????????
???????? ??????????????????
 
1.1 The intestinal crypt 
 
The human colonic epithelium consists of a single layer of columnar cells that form the 
functional unit of the gut – the crypt – via finger-like projections into the underlying 
connective tissue, with a population of approximately 2000 cells per crypt (Figure 1.1). 
The terminally differentiated epithelial cell types that constitute the epithelium are: (i) 
Columnar absorptive cells – colonocytes; (ii) Mucous-secreting goblet cells; (iii) 
Endocrine cells, also known as neuroendocrine or enteroendocrine cells, that secrete a 
variety of peptide hormones in an endocrine or paracrine manner and (iv) Paneth cells - 
granular epithelial cells found in abundance at the base of the small intestinal crypt, but 
only occasionally seen in the colonic epithelium in the ascending colon and some 
disease states. The true function of Paneth cells is still unclear: They are thought to have 
an important role in innate immunity and secrete a number of defensins and anti-
microbial peptides 
3
, in addition there is now emerging evidence that they can be very 
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long-lived and recently it has been suggested that, in the small bowel at least, they may 
be crucial for supporting the stem cells within the niche at the base of the crypt 
4
. 
 
The concept that these differentiated cells arise from a single multi-potential stem cell 
through a number of committed progenitors was first formulated by Cheng and Leblond 
as the Unitarian Hypothesis in 1974 
5
, and is well founded in animals 
6, 7
. The first few 
generations of stem cell divisions are known as transit-amplifying cells, these divide 
rapidly to significantly increase the number of progeny that result from a single stem 
cell division, as cells then move up the crypt from the base toward the luminal surface 
they become committed to a certain lineage - committed progenitor cells, as further 
migration up the crypt axis occurs cells are increasingly differentiated until when they 
reach the luminal surface terminally differentiation has occurred 
8
 (Figure 1.1).  Once at 
the luminal surface, differentiated cells are shed 5-7 days after their initial conception in 
the lower crypt 
9
. 
 
1.1.1 Multi-potential stem cells are housed within a basal niche 
 
All the experimental evidence to date supports the theory, originally proposed by 
Williams et al 
10
, that adult tissue-specific multi-potential stem cells are positioned at 
the base of the intestinal crypt within a stem cell niche. The niche is a micro-
environment that consists of the stem cells themselves and a sheath of surrounding 
mesenchymal cells, of the myofibroblast lineage - pericryptal myofibroblasts, separated 
by the basal lamina.  Interactions between the pericryptal myofibroblasts and niche stem 
cells via paracrine secretion of cytokines and growth factors are thought to be important 
for maintaining the various cell phenotypes. Activation of the Wnt and Notch cascade 
signalling pathways is required to maintain the undifferentiated ‘stem-like’ state 
11, 12
, 
and, along with factors such as the bone morphogenetic protein (BMP) antagonists 
gremlin 1 and gremlin 2 – shown to be secreted by the myofibroblasts 
13
, are involved 
Chapter 1. Introduction 
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in the maintenance of the stem cell habitus and cell migration and differentiation 
8, 11, 14
 
(see section 1.1.4).  
 
However, the extent to which the niche micro-environment, created by the surrounding 
stromal and mesenchymal cells, plays in maintaining basal crypt stem cells is not clear: 
Sato et al 
15
 were able to extract individual crypt stem cells from mouse small intestine 
and, using only a laminin matrigel and a uniform distribution of a few growth signals, 
they were able to form self-renewing crypt-villus like structures with stem and Paneth 
cells located at the base. Thus, the intrinsic (epi)genetic programming within the stem 
cells themselves may well determine the differential response of crypt cells to external 
signalling pathways, such as Wnt and Notch. More recently, studies in mice have also 
suggested a potential role for basal Paneth cells in supporting intestinal stem cells 
within the niche via the expression of Wnt and Notch ligands 
4
. 
 
????? ???????????? ??????????? ????? ?????? ???? ?????? ?????? ?? ????????????? ????
?????????????
????? ????????? ???? ???? ?????????? ??? ???? ??????????? ?????? ???? ????? ????? ???????
?????????????????????????????????????????????????? ????????????????????????????
?????????????????????????????? ??????? ??????????? ???????????????????????????????
??????????? ????????? ???? ??????????? ????? ????? ???????? ??? ???? ?????? ??? ?????
????????????? ??????? ??????? ?????????? ??? ?????? ????? ???? ?????? ????????? ??? ???? ??????
??????????????????????????????????????????????????????????????????????????????
 
Evidence that the intestinal crypt is supported by a number of stem cells residing within 
a niche, rather than a single stem cell as initially thought 
16
, first came from a mouse 
study by Williams et al 
10
. They marked cells via mutagen-induced loss of the X-linked 
enzyme glucose-6-phosphate dehydrogenase (G6PD) in crypt cells, and compared the 
time-course of mutated phenotypes in both the small and large intestine. A short time 
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after administration of the mutagen a high frequency of partially-mutated crypts were 
observed, over time a rapid increase in wholly-mutated crypts was observed that 
reached a plateau at the same time that partially-mutated crypts disappeared. The time 
taken for the appearance of wholly mutated crypts in the large intestine was 
approximately 4 weeks, but 21 weeks in the small intestine. The authors concluded that 
their results were consistent with several stem cells supporting a crypt niche, and that 
the number of stem cells may differ between the small and large colon, with a greater 
number of niche stem cells in the small intestine to explain the time differences 
observed. The hypothesis that the intestinal crypt is maintained by a stem cell niche 
housing multiple related stem cells has since been supported by further studies in both 
the mouse and human 
17-20
. 
 
It is not possible to morphologically differentiate stem cells from other cells within the 
crypt, however there have been a number of markers which have been previously 
proposed as markers of stem cells in the intestine: these include molecules such as 
Musashi-1, an RNA-binding protein thought to be involved in stem cell divisions during 
Drosophila neural development 
21, 22
, and DCAMKL-1, a Ca (2+)/calmodulin (CaM)-
dependent protein kinase 
23
.  The evidence for such claims is limited, being based 
mainly on the finding of a small number of cells labelled with the marker in the putative 
stem cell position towards the base of the crypt. However, location is not a marker of 
stemness and recent experimental approaches have used the unique ability of stem cells, 
once clonally-marked, to re-populate the crypt with clonal descendants in all cell 
lineages - clonal replacement or monoclonal conversion (Figure 1.2C), to demonstrate 
the two key properties that define stem cells: Self-renewal and multi-potency.  Thus 
Barker et al 
19
 were able to demonstrate that Lgr5 (leucine-rich-repeat-containing G-
protein-coupled receptor 5, also known as Gpr49), an intestinal Wnt target gene, 
showed exclusive expression in cycling crypt base columnar cells (CBCs), previously 
identified many years ago as potential stem cells at the very base of the murine small 
intestinal crypt between the Paneth cells 
5, 24, 25
. Additionally, and very importantly, they 
used an inducible Cre knock-in allele under the control of the Lgr5 promoter, and the 
Rosa26-lacZ reporter strain to irreversibly label Lgr5-expressing cells and demonstrated 
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that the Lgr5-positive (Lgr5
+
) CBCs generated all epithelial lineages over a 60-day 
period.  Thus clonal replacement or monoclonal conversion is a very powerful tool for 
the identification of stem cells, the location of stem cell niches, and for the analysis of 
lineage relationships in the gut and elsewhere. 
 
In the Barker et al 
19
 Lgr5 study expression was limited to 6-8 CBCs located in-between 
the basal Paneth cells in the small intestinal crypt, and a few CBCs at the bottom of the 
colonic crypt. Previous DNA-label retention studies 
26, 27
, proposed as surrogate markers 
of stem cells, had identified the stem cell niche in the small intestine as being above the 
basal Paneth cells, around cell position +4 – the “+4 position model” (Figure 1.1A). 
Thus the findings of Barker et al 
19
 argued against this, and was in favour of the “stem 
cell zone” model proposed by Leblond and colleagues 
5, 24
 (Figure 1.1A). Hans Clevers 
and colleagues then performed further experiments studying the clonogenic capacity of 
Lgr5+ CBCs 
15
: single Lgr5+ cells isolated from mouse small intestine were able to 
generate long-lived organised crypt-villus structures in culture that contained all 
differentiated cell types, further supporting Lgr5 expression as a specific marker of 
intestinal stem cells. They were able to grow and maintain the crypt-villus structures 
using a culture system containing only a laminin based matrigel, epidermal growth 
factor (EGF), the Wnt agonist R-Spondin 1 and the BMP inhibitor noggin, and 
concluded that a non-epithelial cellular niche is not required for the formation of an 
organised intestinal crypt. The same group then further challenged the role of the peri-
cryptal myofibroblasts in maintaining stem cells, by providing evidence that small 
intestinal Paneth cells and basal Paneth-like cells in the mouse colon produce Wnt and 
other niche signals and are essential for the maintenance of intestinal stem cells 
4
. 
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Figure 1.1 Small and large bowel crypt structure 
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The cycling of stem cells has been an area of much controversy: It has been proposed 
that, in order to protect their DNA, stem cells rarely cycle 
26
, and this was a property 
that many long-term DNA label retention studies used in order to identify putative stem 
cells in the +4 position of the small intestinal crypt 
26, 27
 – termed label retaining cells 
(LRCs).  However the CBCs identified by Barker et al 
19
 in the mouse were actively 
cycling, with bromodeoxyuridine (Brdu) labelling of Lgr5+ cells suggesting an average 
cycling time of one day in the small bowel. A second study by Sangiorgi and Capecchi 
20
 used a similar mouse genetic construct to permanently label cells expressing the gene 
Bmi1, known to be involved in self-renewal of haematopoietic and neuronal stem cells, 
and their progeny. Bmi1-expressing cells were predominantly seen around the +4 
position in the proximal small intestine and were able to self-renew and generate all cell 
lineages. Interestingly, the Bmi1+ cells did not appear to be as actively cycling as those 
in the Barker et al 
19
 Lgr5 study, and were only found in the duodenum and jejunum. 
However, it may be that these two putative stem cell populations overlap, as Lgr5+ cells 
also express the highest levels of Bmi1 
28
. A recent study by Montgomery et al 
29
 
demonstrated that expression of mouse telomerase reverse transcriptase (mTert) marks 
slowly cycling cells, in a distribution similar to LRCs - predominantly around cell 
position +4, that give rise to all differentiated cell types and are distinct to the Lgr5
+
 
population. Interestingly, the mTert-expressing putative stem cells co-expressed Bmi1 
and have previously been shown to also mark long-term Brdu-retaining cells in the 
small intestinal crypt 
30
. Thus, there is now evidence for active and quiescent 
populations of stem cells co-existing in the intestinal niche, as has been shown for other 
mammalian tissues 
31
. 
 
A series of experiments by Potten and colleagues 
27, 32, 33
 utilised the sensitivity of stem 
cells to very small doses of radiation to reduce crypt stem cell numbers to differing 
extents; subsequent measurements of apoptotic cells and the regenerative ability of the 
crypt enabled estimates of the numbers and location of clonogenic cells in the crypt. 
This led the authors to conclude that, in the mouse small intestine, each crypt consists of 
approximately 300-450 cells with 4-6 ultimate–lineage ancestor stem cells in the +4 
position, above the Paneth cells. A hierarchical stem cell structure within the crypt was 
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proposed, with a further two tiers of transit-amplifying cells above the ancestor stem 
cells retaining clonogenic stem cell properties and having the ability to repopulate the 
crypt epithelium and regenerate the lower tier stem cells if the lower cells are damaged. 
In the large intestine the results were broadly similar but a differing regional 
distribution of the putative stem cell niche was noted. The caecum appeared more 
similar to the small bowel, however the highest levels of apoptosis were seen at the base 
of the crypt in the mid-colon and rectum. Numbers of clonogenic cells estimated for the 
large intestine varied from 5-36, depending on the radiation dose used. 
 
Thus the differing locations and dynamics of putative stem cells detected by authors in 
the murine small bowel may be due to the fact that overlapping heterogeneous sub-
populations of stem cells are being identified by the respective stem cell markers 
employed. There also appears to be significant differences between both the small 
intestine and proximal and distal colon. 
 
1.1.3 Stem cell dynamics – niche succession 
 
Results accrued from several tissues in a number of organisms indicate the existence of 
stem cell niches 
34-37
, each containing a small number of self-renewing stem cells.  
There is good evidence that in some niches, such as the Drosophila ovary and testis, 
stem cells undergo asymmetric cell divisions, giving rise to one stem cell and one cell 
committed to differentiation 
38, 39
, this is termed a lineage mechanism or intrinsic 
asymmetry 
34, 40
. It was previously argued that the majority of stem cell divisions in the 
intestine were asymmetric, with the stem cell always retaining the template strand of 
DNA as this would protect against the accumulation of replication errors – termed the 
Cairns or immortal strand hypothesis 
41
. 
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However, stem cells can also divide symmetrically, producing two cells committed to 
differentiation or two stem cells, enabling gain or loss of one stem cell lineage from the 
niche 
34
 (Figure 1.2A). More recently, evidence from the mouse points to stem cell 
homeostasis within the intestinal niche exhibiting what is termed population asymmetry 
37, 42, 43
, whereby stem cells are either lost or gained via symmetrical divisions on an 
equal basis, in order to maintain homeostasis and a constant stem cell population. 
Snippert et al 
43
 followed the fates of clonally labelled Lgr5+ cells by generating a 
multi-colour cre-reporter mouse that allowed for the identification and distinction of 
individual Lgr5+ stem cells within the niche. Short and long-term clonal tracing data 
was consistent with the majority of stem cell divisions being symmetrical, with neutral 
competition between stem cells due to space and number restriction within the niche 
resulting in neutral drift dynamics, whereby clones expand and contract randomly until 
one stem cell lineage inevitably takes over the niche 
42
 (Figure 1.2B). Of course, there 
may be other stem cell populations within the crypts, such as those marked by Bmi1 and 
mTert expression, that have different dynamics with a higher proportion of asymmetric 
divisions. 
 
1.1.4 Methylation patterns enable insights into the human intestinal niche 
 
It is by the process of symmetrical divisions, in addition to random apoptosis of stem 
cells, that one stem cell lineage can, stochastically by neutral drift or by a selective 
advantage incurred as a result of a mutation, come to dominate a niche, a process 
known as niche or clonal succession (Figure 1.2B). The progeny of this stem cell will 
then go on to occupy the whole crypt – termed monoclonal conversion (Figure 2C). The 
approach by Shibata and colleagues has given considerable insights into the existence of 
a stem cell niche and the mechanisms of niche succession in the human colon
 18, 44, 45
.  
Realising that the detection of a stem cell niche has a requirement to distinguish 
between cells, and given the morphological identity between basal crypt cells in the 
human, they proposed that stem cell lineages might be distinguished from each other by 
the methylation status of CpG islands within the coding sequence of non-expressed 
genes, known to increase with age in normal human colon
 46, 47
. Methylation at CpG loci 
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exhibits somatic inheritance and they become polymorphic with ageing 
48, 49
, therefore 
cell populations or stem cell lineages that are closely related should share similarities in 
these epigenetic sequences, as they are not under any selective pressures. The rate of 
change of methylation status (methylation or de-methylation) at these CpG sites is low, 
and has been estimated at approximately 2 x 10
-5
 per CpG site per division 
18, 44
, thus it 
is possible to re-create cell histories by comparing these epigenetic tags between cell 
populations as they act as a molecular clock. Studying methylation patterns of such 
CpG islands in non-expressed genes in the colon, they concluded that, due to the 
variance of methylation tags within crypts, age-related methylation is consistent with 
human crypts being maintained by niches containing multiple related stem cells, rather 
than by immortal stem cells. The data indicated that successive niche succession cycles 
take place in human colonic crypts: a natural consequence of the existence of symmetric 
stem cell divisions and neutral drift within the niche 
37
, and the authors estimated that 
after approximately every 8 years all stem cell lineages within a crypt niche except for 
one become extinct - some 9 to 10 times in a lifetime 
44
. Thus clonal succession is an 
inherent characteristic of a niche.  The appreciation that clonal succession can occur in 
a stem cell niche in the absence of mutation is a crucial one: even if early genetic 
changes, critical for tumorigenesis, do not give growth advantages, such mutations 
might ‘hitchhike’ to dominate the niche through such niche succession cycles 
50
. 
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Figure 1.2 Clonal succession is inherent to the niche 
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Wnt glycoproteins are a large family of secreted growth factors that produce a wide 
range of biological effects by binding to their corresponding receptor families frizzled 
(FZD1-8) and low-density lipoprotein receptor-related protein (LRP5 or LRP6) 
53-55
. 
Canonical Wnt signalling (?-catenin/T-cell factor [TCF] dependent) is restricted to 
epithelial cells 
56
 and high levels of Wnt signaling are found at the crypt base, the 
location of the stem cell niche, and this is thought to be crucial for maintaining cells in 
the proliferative and undifferentiated ‘stem-like’ state 
8, 57
. In the absence of canonical 
Wnt ligand a complex consisting of the Adenomatous Polyposis Coli (APC) protein, 
axin, casein kinase I and glycogen synthase kinase 3? induces phosphorylation of the N-
terminal of ?-catenin, targeting it for ubiquitin-proteosome mediated destruction 58, 59. 
Once Wnt ligands bind and activate the FZD/LRP receptors, the ?-catenin destruction 
complex is inactivated and ?-catenin translocates to the nucleus where it binds 
TCF/Lymphoid enhancer factor (LEF) transcription factors and drives the expression of 
Wnt target genes 
8, 57
.  
 
Notch genes encode trans-membrane receptors that are important in regulating 
communication between cells, and, in combination with Wnt, Notch signalling is also 
crucial for maintaining proliferation and determining lineage commitment within the 
crypt 
57
. Inhibition of Notch results in a large loss of proliferative crypt cells, and both 
Wnt and Notch pathway activation appears to be required in combination in order to 
maintain the stem cell phenotype at the crypt base 
11
. However, activation of the bone 
morphogenic protein (BMP) pathway, involving long and short-range signalling 
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between mesenchymal and epithelial cells, serves to antagonise crypt formation, 
suppresses Wnt signalling and inhibits stem cell renewal 
60-62
.  
 
Wnt signalling is thought to have a variety of important roles, being not just essential 
for cellular proliferation but also having a role in determining cell fate and the physical 
location of cells within the crypt.  Ablation of the ?-catenin gene in mice results in the 
rapid (days) loss of proliferating cells and crypt structures 
12
, and Tcf4 null mice have 
intestinal crypts consisting of only differentiated goblet and absorptive cells 
63
. 
Mutations in the adenomatous polyposis coli (Apc) gene result in over-activation of Wnt 
signalling and formation of multiple polyps that consist of huge numbers of giant crypts 
that grow without limit 
64
. Wnt signalling has also been shown to control the expression 
of the EphB2 and EphB3 receptors (EphB) and their ligands, Ephrin-B1 and Ephrin-B2, 
that are involved in maintaining cellular boundaries 
14, 65 
. Wnt switches on expression 
of EphB2 and EphB3 receptors and inhibits Ephrin B1/B2 production, this restricts 
these cells to the crypt base; as one moves up the crypt axis there is a gradient of 
increased Ephrin ligand expression and loss of Wnt signalling/EphB receptor expression 
that serves to prevent downward migration of cells due to repulsion between EphB 
receptors and Ephrin-ligands. EphB2 and EphB3 null mice have proliferative and 
differentiated cells intermingled throughout the crypt, and selective deletion of EphB3 
results in Paneth cells scattered throughout the crypt-villus axis 
14
. 
 
Blocking of Wnt signalling results in the loss of secretory cell lineages, but enterocyte 
differentiation appears to be unaffected 
65
, and excessive Wnt activation in mice 
promotes Paneth cell differentiation via transcriptional effects of ?-catenin/Tcf-4 on 
specific Paneth cell markers 
66
. Notch signalling also has an inhibitory effect on 
secretory differentiation and it is thought that cells escaping Notch inhibition are able to 
commit to a secretory lineage, production of Notch Delta/Jagged ligands by these cells 
then results in lateral inhibition of neighbouring cells from following the same lineage 
pathway 
8
. Math1 was first identified as a transcription factor important for the 
differentiation of neuronal cells 
67
, and has since been shown to be expressed in the gut 
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epithelium with Math1 protein being required for secretory cell differentiation 
68
. Hes1 
is a Notch signalling component and a negative regulator of secretory cell 
differentiation - deletion of Hes1 results in increased numbers of secretory cell types 
and elevated Math1 expression 
69
. 
 
Thus, in summary, Wnt signalling drives the expression of Notch pathway components, 
those cells that become committed to the secretory lineage escape Notch activation via 
expressing the Delta/Jagged ligands with subsequent inhibition of Hes1 and increased 
Math1 expression (Wnt
+
/Notch
-
); Wnt
+
/Notch
+
 cells continue to proliferate to produce 
undifferentiated daughter cells, however the pool of Wnt
+
 cells is limited, thus some are 
forced out and lose Wnt (Wnt
-
/Notch
+
), under lateral inhibition from committed 
secretory progenitors, activated Notch signalling up-regulates Hes1 with resulting 
suppression of Math1 and commitment to an absorptive fate. 
 
Little is currently known about the intermediate progenitor cell types in the crypt, 
Bjerknes et al 
17
 used chemical mutagenesis to randomly mark crypt cells by somatic 
mutation of the Dib-1 locus in SWR and F1 mice, thus they were able to identify and 
study the dynamics of mutant clones containing only mucus cells, only columnar cells 
and clones that contained a mixture of cell types. The authors concluded that both short 
and long-lived mucus and columnar cell progenitors exist in the crypt, with long-lived 
progenitors located in the lower third of the crypt and short-lived progenitors seen 
higher up the crypt axis. In this study, over 90% of persisting mutant clones containing 
a mixture of cell types were seen to arise from a crypt base columnar cell in the colon – 
supporting this as the location for the stem cell. 
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There is a large body of evidence to support the theory that adult individual crypts are 
monoclonal, containing cell populations ultimately derived from a single multipotential 
stem cell, and we have already discussed how niche succession with subsequent 
monoclonal conversion is inherent to the dynamics of a stem cell niche.  
 
Studies utilizing mouse chimeras have given valuable insights into the clonal evolution 
of intestinal crypts 
10, 17, 70, 71
. Utilising differential binding of the lectin Dolichos 
biflorus agglutinin (DBA) to B6-derived and not SWR-derived cells, Schmidt et al 
70
 
created C57BL/6J Lac (B6) ? SWR mouse aggregation chimeras in order to assess 
crypt clonality in the developing mouse small intestine. Mixed crypts containing cells of 
both genotypes were seen in the neonatal period, but by day 14 these had all 
disappeared and only crypts containing cells of a single genotype were observed. Thus, 
intestinal crypts are polyclonal at birth but by day 14 all crypts are monoclonal, with 
crypts undergoing an apparent purification during the rapid growth and high rates of 
crypt fission occurring at this time. Further mutagenic studies to randomly mark crypt 
cells observed the disappearance of partially-mutated crypts occurring at the same time 
as the appearance of the wholly-mutated phenotype, consistent with clonal purification 
17, 71, 72
. 
 
XO/XY mosaicism is very rare in humans, yet these cases do permit clonal analysis of 
human crypts. In a study by Novelli et al 
73
 non-isotopic in-situ hybridization studies for 
the Y chromosome in an individual who had undergone a prophylactic colectomy for 
Familial Adenomatous Polyposis Coli (FAP), and was also an XO/XY mosaic, 
demonstrated that colonic crypts were comprised exclusively of either XO or XY cells. 
Thus, crypts are clonal and derived from a multipotential stem cell. Additional studies 
on human tissue in individuals heterozygous for naturally occurring polymorphisms of 
the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean mutation (563 C>T) 
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and the gene encoding for the enzyme O-acetyl transferase (OAT), have confirmed the 
conclusion that human intestinal crypts are clonal populations 
74, 75
. 
 
Recently it has been shown that intestinal stem cells accrue non-pathogenic mutations in 
their mitochondrial DNA (mtDNA), specifically mutations causing a deficiency in 
cytochrome c oxidase (CCO) - a component of complex IV of the respiratory chain, that 
are relatively common and increase with age 
76-79
. These mutations are then passed on 
to their progeny. The mitochondrial genome is prone to mutation due to high oxidative 
stress, a lack of protective histones and poor DNA repair mechanisms. Non-pathogenic 
mtDNA mutations can expand stochastically within a stem cell by genetic drift, and 
over time cells will become either homoplasmic – all the mitochondria in the cell are 
mutated, or heteroplasmic – the cell contains a mixture of mutated and wild-type 
mitochondria 
80
. This stochastic expansion is a lengthy process, and for a mutated 
cellular phenotype to be observed homoplasmy or a high degree of heteroplasmy must 
be present 
81
, thus stem cells are the only cells that have a sufficient life-span to 
accumulate these mitochondrial mutations to a level that results in a biochemical 
deficiency. Two-colour enzyme histochemistry can be used to simultaneously detect the 
mtDNA-encoded cytochrome c oxidase and nuclear DNA-encoded succinate 
dehydrogenase (SDH), a component of complex II of the respiratory chain. Three 
different types of crypts are observed: wild-type brown crypts, wholly CCO-deficient 
crypts and partially CCO-deficient crypts containing both CCO-deficient and wild-type 
cells. Laser micro-dissection on wholly CCO-deficient crypts followed by PCR coupled 
with mtDNA sequencing confirm the presence of conserved clonal mitochondrial 
mutations within colonic crypts 
76, 77
, confirming that crypts are clonal populations, as 
here a crypt has been repopulated from a single mutated stem cell via niche succession 
and monoclonal conversion. There is no evidence for a selective advantage offered by 
these mtDNA mutations: Studies using CCO-deficiency as a marker of clonal 
populations in human stomach and small intestinal have shown CCO-deficient glands or 
crypts to appear no different to neighbouring crypts 
78, 79
, when examining for 
differentiated cell types and proliferative indices. A study by Noteboom et al 
82
 did 
Chapter 1. Introduction 
 32 
show evidence of a small, but significant decrease in proliferation as assessed by Ki-67, 
and increase in apoptosis in CCO-deficient human colon crypts versus wild-type. 
 
The time taken for a stem cell lineage to be either lost or become dominant within the 
niche is known as the clonal stabilization time 
74
. We have already discussed that this 
has been shown to differ between the small and large intestine in the mouse, being only 
4 weeks in the colon as opposed to 12-20 weeks in the small bowel 
10, 71
. Campbell et al 
74
, by using loss of O-acetylation of sialomucins after pelvic irradiation in patients 
heterozygous for O-acetyltransferase gene activity as a clonal marker, estimated the 
clonal stabilization time in humans to be approximately one year; this was supported by 
modelling studies using methylation patterns of CpG islands that gave an estimated 
clonal stabilisation time of 220 days in human crypts 
18
. 
 
In summary, within the human intestinal crypt, multiple stem cells reside within a basal 
niche – possibly greater than 8 in number; stem cells predominantly undergo symmetric 
divisions to produce daughter cells that leave the crypt and form the population of 
transit-amplifying cells. Cells then become committed to a certain lineage, and in the 
lower part of the crypt a population of long-lived committed precursors exist, with their 
progeny subsequently undergoing further differentiation and migrating to the luminal 
surface.  The exact life-span of committed progenitor cells in the human crypt is 
unknown, although it is thought this could be many years. Within the niche, the 
processes of niche succession and monoclonal conversion enable a single stem cell line 
and its progeny to completely re-populate the crypt, with successive niche succession 
cycles taking place over the life-time of a crypt. 
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The adenoma-carcinoma sequence is well established as the pathway for colorectal 
tumorigenesis (see section 1.4), in this section the initiation of the earliest detectable 
dysplastic lesion – the monocryptal adenoma, and their subsequent progression to 
microadenomas and a macroscopically visible adenoma will be discussed (Figure 1.4). 
 
1.2.1 The monocryptal adenoma 
 
The basic cellular hierarchical structure of the colonic crypt consists of a basal stem cell 
niche that has niche succession and monoclonal conversion as inherent properties, and it 
is via this process that mutations in stem cells that confer no selective advantage can 
come to dominant the niche and, subsequently, their progeny occupy the whole crypt. 
Now consider a somatic mutation in the tumour suppressor gene APC, which is thought 
to be the initial genetic change in most colorectal adenomas, resulting in a niche stem 
cell that is APC+/-. Random genetic drift or natural selection - if haplo-insufficiency 
confers an advantage - may lead to the mutated stem cell becoming fixed within the 
crypt 
44
. APC encodes a large, multifunctional cytoplasmic protein that binds and down-
regulates ?-catenin – vital in the regulation of Wnt signalling, maintenance of apoptosis, 
cell cycle progression and chromosomal stability 
83
, and mutations in this gene can be 
identified in up to 80% sporadic colorectal carcinomas 
84
. Although crypts filled with 
APC+/- cells appear normal 
44
, there is evidence that haplo-insufficiency confers an 
increased ability of these crypts to divide and an expansion of the crypt basal cell 
population 
83, 85
. Thus, APC+/- crypts are able to divide and expand faster than wild-
type crypts, with a resulting field of mutated crypts with increased numbers of stem 
cells at risk for a further, crucial mutation in APC. 
 
The loss of both alleles for APC is thought to be sufficient for the development of an 
adenoma 
86
. Once the second APC allele is lost, niche succession and monoclonal 
Chapter 1. Introduction 
 34 
conversion results in a dysplastic APC-/- crypt surrounded by otherwise histologically 
normal tissue – the monocryptal adenoma 
87
. Monocryptal adenomas are the earliest 
detectable precursors in the adenoma-carcinoma sequence, they frequently occur in 
mucosa of FAP patients 
73
 and can also be seen in sporadic cases 
88
. These lesions are 
clonal 
73
, as would be expected from our knowledge of the monoclonality of individual 
colonic crypts. 
????? ???????????????????????????????????????????????????????????????
 
Slaughter et al. 
89
 originally proposed the term field cancerisation to explain the 
presence of multifocal head and neck cancers developing out of a field of precancerous 
change that had developed as a consequence of carcinogen exposure. The theory was 
further expanded by Braakhuis et al 
90
, who proposed that the field was in fact a 
clonally-expanded area of mutated cells. Thus, the field cancerisation hypothesis 
91
 
requires the generation of a field lesion of genetically altered cells as a specific stage in 
epithelial carcinogenesis. There has been debate over the next stage to account for field 
cancerisation in the intestine, and the progression of a monocryptal adenoma to an 
established adenoma: whether dysplastic cells spill over to invade and colonize the 
territory of adjacent crypts – a top-down process 
92
, or whether the monocryptal 
adenoma spreads by crypt fission, whereby the crypt divides from its base to form two 
daughter crypts – the bottom-up proposal
 93
 (Figure 1.3). While it is difficult to obtain 
definitive dynamic proof in humans, clonal expansion by crypt fission appears to be the 
prominent mode of spread of an adenomatous crypt
 94
, and is now generally accepted as 
the most important mechanism for clonal expansion in early adenomas
 95
 (Figure 1.3).  
In conditions where there is mucosal damage or injury, such as ulcerative colitis, repair 
by epithelial restitution with migration, proliferation and differentiation of epithelial 
cells to form new crypts, may also offer a chance for mutated clones to develop and 
expand.  However, in ulcerative colitis increased rates of crypt fission are observed 
96
, 
therefore crypt re-population and epithelial repair may also occur by crypt fission of 
neighbouring tissue, and so the contribution of epithelial restitution to clonal expansion 
and field cancerisation is unclear. 
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Figure 1.3 Expansion of a mutated stem cell within the colonic crypt and 
epithelium 
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Non-dysplastic ACF are associated with the formation of hyperplastic polyps 
97, 98
 and 
appear to be initiated by mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) gene; the pre-malignant potential and significance of non-dysplastic 
ACF and hyperplastic polyps in colorectal carcinogenesis is unclear. The serrated 
adenoma pathway has been proposed as an alternative model for the development of a 
small proportion of sporadic colorectal cancers 
99
, here epigenetic silencing of non-
dysplastic ACF, via methylation of genes involved in senescence, apoptosis and DNA 
repair, is thought to enable the initiation of hyperplastic polyps that then may progress 
to serrated adenomas with malignant potential (see section 1.4.2). 
 
Dysplastic ACF can be identified in both FAP and non-FAP patients and are likely to 
represent the histological progression of a monocryptal adenoma to a microadenoma. 
Genetic studies of these lesions in both FAP and non-FAP patients 
98, 100
 have shown 
that in FAP patients all dysplastic ACF contain somatic mutations in APC; in dysplastic 
sporadic ACF APC mutations are infrequently found, but mutations in KRAS are 
common (68% in the study by Takayama et al 
98
). These findings suggest an alternative 
genetic pathway in the initiation of sporadic adenomas that does not involve APC 
mutations as the primary event, although somatic mutations in APC were detected in a 
high proportion of established adenomas in the same patients. 
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Figure 1.4 The histological progression to a visible adenoma 
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Direct clonal analysis of adenomas in an XO/XY individual with FAP demonstrated 
that 76% of adenomas were polyclonal 
73
, and this data was supported by a study in 
APC
min/+
 mice chimeric for the ROSA26 cell lineage marker 
105
 that showed normal 
intestinal crypts to be monoclonal, but estimated that 79% of adenomas had an overtly 
polyclonal structure, even at an early stage. Shibata et al 
106
, were able to identify at 
least two distinct KRAS-mutated sub-clones in four out of seven adenomas studied, 
indicating that a high proportion of adenomas demonstrate heterogeneity; interestingly, 
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all the adenocarcinomas in the same study appeared genetically homogeneous. More 
recently, Thirlwell and colleagues 
107
 performed crypt-by-crypt mutation analysis on 
both FAP and sporadic human adenomas, and were able to identify multiple genetically 
distinct sub-clones within the same lesion. 
 
There are two possible explanations for the polyclonality of adenomas observed in the 
above studies: (1) due to there being a high density of adenomas in both the FAP 
mucosa and the mouse model, random collision of neighbouring lesions may occur; (2) 
In order for a dysplastic clone to escape the inhibitory effects of surrounding normal 
tissue, such as BMP signalling 
61
, and grow, clonal interaction is required for adenoma 
formation 
108
. To assess the contribution of random collision, homozygosity for the 
tumour resistance allele of the Mom1 locus was introduced into ROSA26/chimeric Min 
mice in order to allow analysis of clonality at a much lower tumour burden 
109
.  The 
results showed that the proportion of polyclonal adenomas was much greater than that 
predicted by a random collision hypothesis: examination of clonal interaction using 
spatial statistics indicated that co-operation occurred between clones as close as 1-2 
crypts apart via short-range interactions. Evidence has shown oncogenic genetic 
alterations occurring in surrounding stromal tissue of colorectal adenomas at an early 
stage of carcinogenesis 
110
, and the epithelium immediately adjacent to colorectal 
cancers is known to be hyperplastic 
17
. In addition, concordant mutation of 
TGFBR1*6A – a common hypomorphic variant of the type I transforming growth 
factor (TGF)-beta receptor (TGFBR1) that confers a selective growth advantage to 
normal and cancerous epithelial cells as they are less susceptible to the inhibitory 
effects of TGF-?, and is somatically acquired in colorectal cancer cells - has been 
demonstrated in the stroma and epithelium adjacent to colorectal neoplasms 
111
. Thus, a 
dysplastic clone may induce changes in the surrounding stroma and microenvironment 
that in turn transforms neighbouring crypts, allowing expansion of the lesion to form an 
adenoma, with subsequent progression to a carcinoma (Figure 1.5). 
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Figure 1.5 Polyclonal adenoma growth 
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Therefore, the mechanisms described above detail how a single dysplastic colon crypt 
can arise and expand via crypt fission to become an established adenoma. During 
adenoma growth the normal crypt hierarchy appears to be maintained 
112
, but 
significantly increased rates of crypt fission are occurring and there is an upward 
expansion of the proliferative compartment towards the surface of the crypt 
94
, 
consistent with deregulation of the crypt cycle, to enable rapid growth. Further 
mutations in KRAS and subsequently other critical tumour suppressor genes, such as 
Tumour Protein 53 (TP53), are temporally associated with the progression of the 
adenoma to a carcinoma 
113, 114
 (Figure 1.6). Detailed studies in human adenomas have 
suggested that that they can be polyclonal – distinct APC and KRAS sub-clones can be 
identified in adenomas 
106, 107
, subsequently a selective sweep may occur whereby the 
successful sub-clone sweeps to dominance and the lesion appears monoclonal once 
more (Figure 1.5C). 
 
1.3 Should we always blame the stem cell? 
It is thought that, in renewing systems, the origins of cancer are in the stem cell 
114
, as 
they have been thought to be the only cells that live long enough to acquire the 
necessary multiple mutations required for neoplastic transformation, moreover they 
already possess some of the characteristics of cancer cells, such as self-renewal 
115
. The 
first direct supporting experimental evidence that transformation of stem cells is the 
principal route to intestinal cancer was recently provided by the Clevers’ group 
116
: 
deletion of Apc limited to the Lgr5+ stem cells of the mouse intestine resulted in the 
rapid formation of microadenomas that expanded to large numbers of intestinal macro-
adenomas; however when Apc was deleted in the transit-amplifying cells, adenomas 
were significantly fewer and only able to reach a very small size. Interestingly, they also 
noted that the crypt stem/progenitor cell hierarchy was maintained in the early 
neoplastic lesions that developed after mutating Apc in the stem cell compartment. 
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However, there is definitive evidence for the existence of long-lived committed 
progenitor cells in the mouse intestine
 17
 and stomach 
117 
– cells that are committed to 
the production of a limited repertoire of descendants.  In the intestine, long-lived 
mucous cell progenitors and columnar cell progenitors have been found, which in the 
mouse have a life-span measured in months 
17
.  Similarly, in the gastric epithelium, 
after chemical mutagenesis which labels random epithelial cells by loss of transgene 
function in adult hemizygous ROSA26 mice, clones containing only a single mature cell 
type appear, indicating the presence of long-lived committed progenitors in the gastric 
epithelium. The same phenomenon has been demonstrated in the human stomach for the 
parietal cell series - the only wild-type cell lineage present in occasional CCO-mutated 
glands were parietal cells, strongly suggesting that the human stomach contains long-
lived committed progenitors
 78
. This raises the possibility that the cell that undergoes the 
first mutation and selection event is not always the stem cell, but a committed 
progenitor cell
 118
.  While it has to be said that there is no direct evidence for this, 
particularly in the human model, the possibility that this occurs would explain several 
common observations: tumors arise from the colon which are composed predominantly, 
or exclusively, of mucin-secreting cells
 119
, endocrine cells
 120
 or even Paneth cells
 121
. 
Thus, it may be that it is not only the stem cell that has the potential to initiate the 
sequence of successive mutations and selection demanded by the concept of multistage 
carcinogenesis 
122
. 
 
1.4 Genetic changes and tumorigenesis 
The adenoma-carcinoma sequence is widely accepted as the pathway for evolution of 
cancer in the colon, and has been well defined; it is a classical example of tumorigenesis 
involving the successive accumulation of genetic changes that accompany histological 
progression through dysplasia to adenocarcinoma (Figure 1.6). The study of the genetic 
basis to the two main hereditary syndromes associated with the development of 
colorectal cancer, FAP and Hereditary Non-polyposis Colorectal Cancer (HNPCC), 
have also given many insights into the genetic changes associated with sporadic colonic 
tumorigenesis; in a similar fashion the more recent recognition of the malignant 
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potential of Hyperplastic Polyposis Syndrome (HPS) has resulted in the identification of 
alternative and genetic pathways to cancer 
123
. As molecular techniques have improved, 
the original model proposed by Vogelstein 
114
 is being replaced with a number of 
genetic pathways that may result in colorectal cancer (Figure 1.6). 
 
1.4.1 Mechanisms of fixation 
The processes of niche succession and monoclonal conversion allow tumorigenic 
mutations to be fixed in a number of ways. Due to the small number of stem cells within 
the colonic niche, they are prone to genetic drift, therefore a single stem cell clone can 
come to dominate the niche as a result of stochastic non-selective events. As a result, 
neutral mutations that do not affect the fitness if a cell can, over time, become fixed 
within the population 
124
. Occasionally, mutations in a stem cell, especially those 
involving a tumour suppressor gene such as APC, bestow a selective growth advantage 
to the recipient cell. This allows the processes of niche succession and monoclonal 
conversion to occur rapidly so that the mutated stem cell progeny occupy the whole 
crypt. These mutations often result in what is termed a selective sweep where natural 
selection rapidly drives the advantageous allele to fixation 
125-127
. Although 
tumorigenesis involves the accumulation of mutations that result in a growth advantage 
to the cell, not all confer an immediate selective advantage in isolation, but in 
combination with others they contribute to a malignant phenotype. These mutations 
may become established merely by being linked to or hitchhiking with an allele that 
does provide a selective advantage 
50, 128
. 
 
1.4.2 Sporadic adenomas: A multi-step process 
Patients with FAP have a germ-line mutation in the tumour suppressor APC gene and 
this has been termed the gatekeeper of colonic epithelial cell proliferation 
129
, as once 
both alleles are lost in FAP patients many thousands of polyps are able to form but the 
further genetic changes required for the progression to carcinoma occur at the normal 
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rate. Due to the huge number of adenomas it is inevitable that one of these will 
eventually undergo malignant transformation, hence FAP patients are offered a 
prophylactic colectomy early in life. In HNPCC, or Lynch syndrome, the mechanisms 
are different: Germ-line mutations in the DNA mismatch repair genes (MMR), 
commonly MLH1, MSH2 and MSH6, are linked to microsatellite instability (MSI) and 
result in higher mutation rates of repetitive sequences 
130
. The incidence of adenoma 
formation in these patients is the same as the normal population but there is accelerated 
tumour progression: MMR genes have thus been termed housekeeping genes.  
 
The hereditary syndromes FAP and HNPCC themselves only account for less than 5% 
of colorectal cancers 
131
, but the application of knowledge gained from understanding 
the genetics involved has enabled elucidation of some of the major molecular processes 
involved in the evolution of sporadic carcinomas.  APC mutations are found in up to 
80% of sporadic colorectal adenomas and cancers 
84, 132, 133
 and this is thought to be the 
initiating step in the development of most sporadic adenomas; the remaining 20% may 
contain as yet undetected APC or ?-catenin mutations. Deficiency of MMR repair 
(MSI) is found in approximately 15% of all colorectal cancers, mostly via acquired 
hyper-methylation of the MLHI promoter 
99, 134, 135
, but less than 3% of sporadic 
adenomas; therefore, in sporadic cases, MSI is thought to occur at a more advanced 
stage in adenoma progression. As only a very small population of the thousands of 
adenomatous polyps that form in the colon of FAP patients progress to cancer, it is 
obvious that further oncogenic mutations are required for a tumour to develop. 
Molecular studies of colorectal cancers have confirmed that multiple sequential genetic 
mutations are required for tumour formation, these can be thought of as independent 
events, but the higher intrinsic mutation rates found in those tumours with defects in 
MMR genes, and the gross chromosomal alterations seen within sporadic tumours with 
no MSI results in increased genetic instability and predisposition to subsequent 
mutational events 
129
. 
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The KRAS protein mediates the intracellular transduction of signals from a number of 
growth factor receptors, such as epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor (PDGFR), predominantly via the mitogen-activated 
protein kinase (MAPK) cascade. Activating KRAS mutations, specifically in codons 12 
and 13 of exon 2, are detected in approximately 50% of sporadic colorectal adenomas 
and carcinomas 
113, 136, 137
, and are an important, frequent event in the development of 
early sporadic adenomas. 
 
1.4.3 Mutator phenotype or selection 
 
Mutation and selection are the essential components in the evolution of cancer. 
However, the relative importance of each to tumorigenesis has been the subject of much 
debate 
122, 138, 139
. Mutations in normal cells are rare 
139
, and it has been suggested that 
the development of a mutator phenotype – cells that have intrinsically elevated mutation 
rates due to mutations in genes responsible for DNA fidelity, is required early on in 
tumorigenesis to explain the accumulation of mutations required for multistage 
carcinogenesis 
139, 140
. 
 
However, the evidence as to when the mutation rate can become elevated in colorectal 
cancer is not clear 
138
, and it has been shown that the selection of mutations that confer a 
growth advantage to a cell can enable successive rounds of clonal expansion, or 
selective sweeps 
125-127
. Knudson 
141
, studying hereditary and non-hereditary 
retinoblastoma, proposed what became known as the two-hit hypothesis, whereby the 
initial rate-limiting step in cancer is the loss of two alleles of a tumour suppressor gene, 
one of which is inherited and the other selected for, and this is sufficient to initiate 
clonal expansion, thus a disease with a recessive inheritance could have a dominant 
penetrance if there was a high likelihood of selection for the loss of the second allele. 
Tomlinson et al 
138
 demonstrated that selection, more than an increase in the intrinsic 
mutation rates, is more likely to be the driving force in sporadic tumorigenesis, and 
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Luebeck et al 
142
 argued that genomic instability is not required to explain the clonal 
expansion of an initiated stem cell into an adenoma. The epidemiology of FAP supports 
a low mutation rate: despite FAP patients having a germ-line mutation in APC, only a 
tiny fraction of epithelial stem cells become neoplastic 
129
. Moreover, studying the 
associations of the locations of germ-line and somatic APC mutations in adenomas from 
FAP patients, Lamlum et al 
143
 showed that mutations in codons 1296 or 1309 are 
strongly associated with allelic loss as the second somatic hit, providing evidence that 
APC mutations offer differing selective advantages to a cell that results in a selective 
pressure for a specific mutation in the remaining allele. 
 
Thus, the initiation and expansion of a tumorigenic stem cell clone into an adenoma 
does not necessarily require the presence of a mutator phenotype 
122, 138, 142
. However, it 
may be that as successive rounds of selective sweeps and clonal expansion occur then 
genomic instability increases, either thorough defects in MMR genes or gross 
chromosomal loss, so that both selection and an elevated mutation rate drive further 
evolution to cancer. 
 
1.4.4 Traditional Pathway 
 
The seminal work by Vogelstein and colleagues 
113, 114, 144
 first formulated that 
colorectal cancer was the result of a stepwise accumulation of genetic alterations in at 
least 4 or 5 genes, combining mutational activation of oncogenes and inactivation of 
tumour suppressor genes. They classified adenomas as being early, intermediate or late 
on the basis of overall size and histology: early adenomas were those less than 1cm; 
intermediate adenomas were those greater than 1cm and with no foci of carcinoma; late 
adenomas were those that were greater than 1cm and contained foci of carcinoma. The 
frequency of RAS mutations and chromosomal allelic loss of 5q (APC), 17p (TP53) and 
18q detected in the adenomas and carcinomas, combined with a further study looking at 
TP53 mutations associated with allelic loss of 17p 
144
, led them to propose a sequence 
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of genetic events that occurs during colorectal tumorigenesis 
113, 114
: APC loss is the 
gate-keeping mutation, KRAS mutations develop in intermediate adenomas with TP53 
mutation, 17p and 18q loss of heterozygosity (LOH) occurring in advanced adenomas 
as they progress to cancer (Figure 1.6A). The SMAD4 gene, a member of the 
transforming growth factor-? (TGF-?) pathway, is now regarded as the most likely 
tumour suppressor involved with 18q loss 
145
.  
 
It is worth noting, and this is something that is often ignored, that the model proposed 
by Vogelstein summarised only the most frequent genetic events detected: 17p loss was 
still found in almost 10% of intermediate adenomas and a few early adenomas; regions 
from chromosomes lq, 4p, 6p, 6q, 8p, 9q, and 22q were lost in 25%~50% of the 
colorectal cancer cases studied. Screening was done on DNA digested from entire 
lesions, thus any small sub-clones containing different mutations would not have been 
identified. Also, these studies only looked at conventional adenomas i.e. tubular and 
tubulo-villous, as the malignant potential of hyperplastic and serrated lesions had yet to 
be recognised. 
 
1.4.5 Alternative and serrated pathways 
 
The original model proposed by Vogelstein and colleagues 
114
 has since been expanded, 
with the recognition of alternative genetic pathways to cancer. There is now acceptance 
that activation of the mitogen activated protein kinase pathways, via mutations in either 
the KRAS or BRAF oncogenes, combined with acquired MSI and methylation of 
promoter CpG sites in a number of genes (CpG island methylator phenotype – CIMP), 
are important pathways in the progression to colorectal cancer that are independent of 
APC mutation 
99, 123
 (Figure 1.6).  CIMP refers to specific, age independent, methylation 
of a number of CpG islands in the promoter regions of a panel of genes implicated in 
carcinogenesis (CDNK2A (p16), MLH1, MINT1, MINT2, MINT31, RUNX3, CACNA1G, 
IGF2, NEUROG1, SOCS1) 
135, 146
; lesions are often classified as either CIMP-negative, 
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CIMP-low if one or two CpG islands are methylated or CIMP-high if three or more of 
the panel are methylated. A distinct subset of colorectal cancers display CIMP-high, and 
they tend to be proximally located, poorly differentiated, TP53 wild-type and are highly 
associated with BRAF mutations and MSI 
135, 146, 147
. 
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Figure 1.6 Traditional and alternative genetic pathways in colorectal 
tumorigenesis 
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The common feature of serrated polyps is a saw-toothed infolding of the epithelium. 
Previously these were classed with hyperplastic polyps and thought to have no 
malignant potential, however, a clear association between serrated polyps, especially 
sessile serrated adenomas, and sporadic MSI colorectal cancer has now been 
established, with cancers demonstrated to have directly arisen from adjacent serrated 
polyps with a transition zone of dysplasia 
148
. The serrated pathway is thought to be 
initiated by mutations in either BRAF or KRAS, the two being mutually exclusive 
although BRAF mutations are more common 
149
, this is followed by p16 induced 
senescence which is overcome by methylation with the early development of CIMP; 
MSI is then associated with later progression of the lesions 
123, 149
 (Figure 1.6B). A 
single point mutation (V600E) accounts for nearly all BRAF mutations, resulting in 
constitutive activation of the MAPK pathway downstream of KRAS. Interestingly, 
although BRAF mutations are very common in serrated polyps, they are almost never 
seen in conventional adenomas 
150
. However, there now appears to be a clear, tight 
association between BRAF mutations and the development of CIMP and MSI in 
colorectal cancers 
135, 150
. 
 
In summary, there are multiple genetic pathways involved in colorectal tumorigenesis; 
mutations in APC and KRAS still appear to be the commonest genetic events in early 
adenomas, however alternative pathways, specific to the histology and location of the 
lesion in the colon, exist and are being increasingly recognised. Fearon and Vogelstein 
concluded that ‘it is the accumulation of events, rather than their order of occurrence 
with respect to one another, that is likely to be most important in colorectal tumor 
progression’ 
114
, however it is now thought that the timing of genetic events is crucial in 
determining whether a lesion will be able to progress to cancer 
123, 151
. 
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1.5 Rates of adenoma growth 
 
Although adenomas are the precursor lesion to colorectal adenocarcinoma, they have a 
low malignant potential, with previous studies suggesting it takes in the order of 15 
years for a large adenoma to become malignant 
152
, consistent with the 20-25 years it 
takes for small adenomas to grow into adenocarcinomas in FAP patients. Stryker et al 
153
 demonstrated that the cumulative risk of cancer for large adenomas (>1cm) at 5, 10 
and 20 years was only 2.5%, 8% and 24% respectively. A more recent study 
154
 used 
large-scale sequencing to compare mutations detected in colorectal metastasis, 
adenocarcinomas and adenomas of the same patient – so termed comparative 
sequencing. By quantifying the numbers of mutations acquired as the lesions 
progressed, and combining this with the clinical time points, the authors estimated that 
it may take, on average, 17 years for a benign sporadic adenoma to progress to cancer, 
assuming that mutation rates and cell division times do not change throughout the 
patient’s life. 
 
Early estimates of adenoma growth rates were based on the analysis of size doubling 
times of adenomas using retrospective serial barium enema studies 
155-157
. Welin et al 
155
 
reviewed over 21,000 barium studies over a period of 10 years. They observed that 
adenomas <10mm appeared to grow very slowly, if at all, and, by mathematically 
modelling growth data, concluded that 10mm is the critical size threshold for predicting 
future growth. Of 11 adenomas studied by Tada et al 
157
, 5 did not grow at all during the 
follow-up period, which ranged from 420 to 816 days; doubling times of the other 6 
adenomatous polyps ranged from 146.5 to 398.5 days. 
 
More recent endoscopic studies have supported the original findings by Welin et al 
155
 
that a size of 10mm appears to be critical 
158-160
. Hofstad et al 
159
 conducted a 
prospective colonoscopic study where adenomas <10mm in size where left in-situ for 3 
years and those >10mm were resected, polyp size was accurately measured using a 
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probe inserted through the endoscope and all polyps >5mm were removed at the end of 
the study. Interestingly, the authors found that, for adenomas and hyerplastic polyps, 
lesions <5mm showed a tendency to growth but medium sized polyps of 5-9mm 
demonstrated a net reduction in size. Bersentes et al 
160
 followed thirty polyps of 3-9mm 
endoscopically over two years: they did not find any regression, however only 3 
adenomas showed fast growth rates (2-4mm/year) overall and growth did not follow a 
linear pattern. In an observational study by Knoernschild 
161
 18% of 257 polyps that 
were tattooed and followed up for 3-5 years had completely disappeared. 
 
In summary, it appears that adenomas may not grow in a constant linear manner and 
appear to remain relatively static for many years, with a large proportion of smaller 
lesions even regressing over time, which is consistent with observations that adenoma 
incidence does not increase with age 
162, 163
. 
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Chapter 2. Materials and Methods 
 
General methods used are detailed here. Any variation from the techniques detailed 
below is discussed in the appropriate results chapter. Specific methods that were 
designed and developed as part of a project are also given below, and then referenced in 
the respective results chapters. 
2.1 Tissue collection and sectioning 
 
2.1.1 Fresh frozen tissue 
 
Normal human colon and polyps were obtained from patients undergoing surgery or 
colonoscopy screening at University College Hospital, London. Ethical approval was 
obtained as per the requirements of the United Kingdom Human Tissue Act (2006), 
REC reference number 07/Q1604/17. Fresh tissue was immediately frozen in liquid 
nitrogen using isopentane as a cryoprotectant, and then stored at -80°C until further use. 
 
Serial sections of tissue were then cut either ‘on-edge’ or ‘en-face’ depending on the 
project requirements (detailed later), at thicknesses varying from 8 microns to 20 
microns. If being prepared for laser-capture micro-dissection (LCMD) then sections 
were mounted onto P.A.L.M. laser capture slides (P.A.L.M. Microlaser, Technologies, 
Benried, Germany) that had been pre-treated with ultraviolet radiation, at a wavelength 
of 254 nanometres (nm), to improve section adhesion. For tissue intended for 
immunohistochemistry, sections were cut at 6-8 microns and mounted onto charged 
glass slides (Thermo-Scientific, Germany). 
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2.1.2 Formalin-fixed paraffin embedded tissue 
 
Archived normal human colon blocks were obtained from University College Hospital 
London in accordance with the requirements of the United Kingdom Human Tissue Act 
(2006), REC reference number 07/Q1604/17.  Serial sections were cut at 6 microns onto 
charged glass slides (Thermo-Scientific, Germany). 
 
2.2 DNA extraction 
 
Proteinase K digestion buffer (Arcturus Bioscience, USA) was used for all DNA 
extraction. All equipment, gloves and reagents, excluding proteinase K enzyme, were 
sterilised by 45 minutes of ultraviolet radiation at a wavelength of 254 nanometres 
(Ultraviolet hood, ASTEC Microflow, UK). Prepared proteinase K digestion buffer was 
kept on ice to prevent auto-degradation. 
2.2.1 Tissue macro-dissection 
 
To enable somatic mutation and loss of heterozygosity (LOH) screening of genes 
commonly involved in early adenoma initiation and growth, and global genomic DNA 
methylation analysis, 3 serial sections from the middle of each polyp were needle 
macro-dissected into a 1.5 millilitre micro-centrifuge tube containing 100 microlitres of 
Proteinase K digestion buffer. Tubes were incubated for a minimum of 16 hours at 
65°C, briefly centrifuged and then incubated for 10 minutes at 95°C to deactivate 
proteinase K. Tubes were then centrifuged at maximum speed for 30 minutes and clear 
lysate removed via pipette into a clean 1.5 millilitre micro-centrifuge tube, in order to 
remove residual protein and inert membrane. DNA concentration was then measured 
using a NanoDrop
®
 analyser and lysate diluted to a DNA concentration of 100-200 
nanograms per microlitre as this is optimum for PCR. DNA lysate was then stored at -
20°C until further use. 
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2.2.2 Laser capture micro-dissection (LCMD) 
 
LCMD of single crypts or single cells from normal tissue, adenomas and polyps was 
performed using the P.A.L.M. Laser Micro-dissection system (P.A.L.M., Zeiss, 
Germany). Crypts or single cells were micro-dissected and then catapulted into the 
adhesive caps of the P.A.L.M. laser capture micro-dissection tubes (P.A.L.M., Zeiss, 
Germany). An appropriate volume of freshly prepared Proteinase K buffer was then 
added and the tubes incubated at 65˚C for a minimum of 3 hours for frozen tissue and 
16 hours for paraffin tissue. Tubes were then centrifuged at 1000x g for 1 minute before 
heating at 95˚C for 10 minutes to deactivate Proteinase K. Following further 
centrifugation at 1000x g for 1 minute, DNA lysate was stored at -20˚C until further 
use. 
2.3 DNA amplification and sequencing techniques 
 
2.3.1 Polymerase Chain Reaction (PCR) 
 
Target DNA was amplified using specific primers by PCR. Prior to each reaction, all 
reagents (excluding primers, and DNA lysate) and sequencing apparatus (including 
PCR plates, lids, tips and pipettes) were sterilised by 45 minutes of ultraviolet radiation 
at a wavelength of 254 nanometres (Ultraviolet hood, ASTEC Microflow, UK); first-
round PCR was then prepared in the sterilized ultraviolet hood. Reaction mastermixes 
were prepared and aliquoted into either a 96 or 48-well plate (ABgene, UK). To confirm 
that the PCR reactions were not contaminated, an additional two negative controls of 
master-mix only and DNA digestion buffer only were performed. Plates were sealed 
with adhesive PCR film (Thermo Fisher Scientific, UK) and immediately transferred to 
a thermal cycler. Where appropriate, second-round PCR was performed on ice. 
Reaction efficiency was tested by agarose gel electrophoresis (1.5%) of PCR product 
and successful amplification identified by the presence of a single strong band of 
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appropriate length: only those reactions where the negative controls were blank on the 
agarose gel were taken forward for sequencing. See Appendix 9.1 and 9.2 for details of 
all reagents, primers, PCR and thermal cycler protocols used. 
 
2.3.2 DNA purification and sequencing 
 
PCR products were purified using the ExoSap-IT
®
 (GE healthcare, UK) clean-up kit for 
enzymatic removal of unused primers and nucleotides; ExoSAP-IT
®
 contains 
exonuclease I which removes unincorporated primers, and shrimp alkaline phosphatase 
which removes leftover dNTPs. 2 microlitres of ExoSap-IT
®
 was added to 5 microlitres 
of each PCR product and then run on a thermal cycler using the protocol detailed in 
Appendix 9.2 (Table 9.22).  All sequencing was performed using the BigDye 
Terminator cycle sequencing method on an ABI Prism Genetic Analyzer: automated 
sequencing that uses four terminator nucleotides labelled with distinguishable 
fluorophores. ExoSAP-IT products were diluted in 10-20 microlitres of distilled H20, 
depending on the strength of the PCR product bands on the agarose gel. The sequencing 
reaction was prepared according to the reagent protocol detailed in Appendix 9.2 (Table 
9.20) using the ABI Biosystems BigDye Terminator (Applied Biosystems, USA). For 
sequencing thermal cycler protocols see Appendix 9.2 (Table 9.23 and Table 9.24). 
Purified sequencing products were vacuum dried using an Eppendorf 5301 Concentrator 
(Eppendorf, UK) for 30 minutes at 45°C. Re-suspended residues were transferred to a 
48 capillary ABI 3730 DNA Analyser (Applied Biosystems, USA) for sequencing and 
sequence data analysed with the 4Peaks software (Mekentosj, Netherlands).  
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2.4 Mitochondrial DNA mutation detection 
 
2.4.1 Enzyme histochemistry 
 
Two-colour enzyme histochemistry was used to simultaneously detect the mtDNA-
encoded enzyme cytochrome c oxidase (CCO) and nuclear DNA-encoded succinate 
dehydrogenase (SDH), a component of complex II of the respiratory chain. Mutated 
cells lacking in CCO-activity appear blue; non-mutated cells appear brown. Frozen 
sections were air-dried for 45 minutes and first incubated in cytochrome c oxidase 
medium (100 millimolar cytochrome c, 20 grams per millilitre catalase and 4 millimolar 
diaminobenzidine (DAB) tetrahydrochloride in 0.2 millimolar phosphate buffer, pH 7.0, 
all sourced from Sigma-Aldrich, Poole, UK) for a maximum of 50 minutes at 37°C. 
Crypts or cell populations within crypts with normal activity of CCO subsequently 
appear brown. In order to counter-stain CCO-deficient cells, sections then underwent 3x 
5-minute washes in phosphate-buffered saline (PBS), pH 7.4, before being incubated in 
SDH medium (130 millimolar sodium succinate, 200 millimolar phenazine 
methosulfate, 1 millimolar sodium azide, and 1.5 millimolar nitroblue tetrazolium in 0.2 
millimolar phosphate buffer, pH 7.0, all sourced from Sigma-Aldrich, Poole, UK) for a 
maximum of 45 minutes at 37°C, or until a strong blue stain had developed in the 
unstained crypt cell populations. Sections again were washed in PBS (5 minutes x3) and 
dehydrated in a graded ethanol series (70%, 90%, 100%, 100%). If tissue was for 
LCMD slides were air-dried for 1 hour before being stored at -80°C; sections that were 
on normal glass slides were cleared in Histoclear (Lamb Laboratory Supplies, 
Eastbourne, UK) and mounted with Permount
®
 (Fisher Scientific, FairLawn, NJ). 
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2.4.2 Laser-capture micro-dissection 
 
After enzyme staining for CCO-activity, three different types of intestinal crypts are 
observed: (i) wild-type brown crypts, (ii) wholly-mutated blue crypts and (iii) crypts 
containing populations of both brown and blue cells (mixed or partially-mutated crypts). 
LCMD was then performed from both wholly-mutated and partially-mutated blue 
crypts, and adjacent brown wild-type crypts, in order to sequence the mitochondrial 
DNA and confirm the presence of clonal point mutations in the blue cells. Laser-capture 
slides were allowed to thaw at room temperature for 1 hour before micro-dissection. 
Single cells from CCO-deficient crypts and adjacent wild-type crypts were individually 
micro-dissected. If required for genomic and/or methylation analysis, the remaining 
regions of the whole crypt were then dissected from serial sections. 14 microlitres of 
Proteinase K digestion buffer (Arcturus Bioscience, USA) was added to each tube for a 
minimum of 3 hours digestion. A negative control tube containing only digestion buffer 
and no laser-capture material was also included.  In partially CCO-deficient crypts, 
CCO-deficient cells were micro-dissected separately from CCO-proficient cells, and 
then the remaining blue and brown cell populations from the whole crypt micro-
dissected into two tubes for methylation analysis.  After digestion, tubes were briefly 
centrifuged and proteinase K deactivated by heating to 95˚C for 10 minutes. DNA 
lysate was stored at -20˚C until further use. 
 
2.4.3 MtDNA sequencing 
 
Laser micro-dissection followed by PCR coupled with mtDNA sequencing confirms the 
presence of clonal mitochondrial mutations in wholly or partially CCO-deficient crypts, 
and this has been shown to be a reliable marker for observing the clonal expansion of 
mutated stem cells 
76-78
. Extracted DNA lysate was used to sequence the entire 
mitochondrial genome from micro-dissected areas. A two-round amplification method 
was followed, whereby the first round consisted of amplifying 9 fragments spanning the 
entire mitochondrial genome. These initial large PCR products of approximately 2kb 
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decrease the risk of amplifying pseudo-genes when using DNA extracted from small 
quantities 
164
. The second round consisted of 36 M13-tailed primer pairs to amplify 
overlapping segments of the first-round products, resulting in amplicons of 500-700 
base-pairs that span the entire mitochondrial genome (see Appendix 9.1 and 9.2 for 
primer sequences and detailed PCR protocols). PCR product from the second round 
reaction was run on a 1.5% agarose gel, and only those reactions where the negative 
controls were blank on the agarose gel were taken forward for sequencing. DNA 
purification and sequencing was performed as previously described (see Methods 2.3.2) 
and then compared to the revised Cambridge reference sequence 
(http://www.mitomap.org/MITOMAP) using sequence alignment software of the 
European Bioinformatics Institute (http://www.ebi.ac.uk). Once a potential mutation 
was identified, the PCR was repeated using the original DNA lysate and multiple 
samples from the mutated blue cells and adjacent wild-type, brown cells in order to 
confirm its validity. 
 
2.5 Mapping of stem cell clones 
 
By combining the two-colour enzyme histochemical staining with image analysis and 
computer reconstruction, a method of mapping the origin and spread of stem cell 
progeny and mutated cell populations within the intestinal crypt was devised. Multiple 
serial sections in the transverse plain were taken through frozen samples at thicknesses 
between 8 and 12 microns, depending on the quality of the tissue. Digital images were 
then taken of each serial section and used to create a ‘crypt map’ using image analytical 
algorithms and in-house software developed by Dr Paul J Tadrous (Histopathology 
Dept, Northwick Park Hospital, Harrow, London). A crypt map is a representation of 
the whole 3D tubular crypt unfurled and laid flat – like a map – with colour 
enhancement post-processing designed to increase the contrast between blue-staining 
and non-blue-staining cells. The algorithm for producing such a crypt map is as follows: 
1.  Serial section images of the crypt are registered (aligned) to form a 3D 
reconstruction series of the whole crypt. 
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2.  The centre-point and perimeter of cross sectional image of the crypt in such a series 
is then marked out by hand using freely available interactive image analysis software 
(BiaQIm v 2.5 alpha from www.bialith.com). 
3.  For each cross sectional image a line is then subtended from the centre-point to the 
perimeter at a fixed angle (known as the ‘cut-angle’). The cut-angle is the same for 
all cross sectional images in a given crypt series. 
4.  For each image in the series, the approximately oval cross sectional profile of the 
crypt is then digitally ‘cut’ along the line described in step 3 and is warped into a 
straight profile. 
5.  For each straight profile thus generated, the basal-most pixels (i.e. the pixels starting 
at the basement membrane aspect and continuing towards the centre for a distance of 
about ? of the epithelial thickness) are then averaged into a single pixel strip. This 
step acquired most of the cytoplasmic colour information before the cytoplasm gets 
‘diluted’ by mucin as one gets close to the lumenal aspect of the crypt epithelium. 
6.  These single pixel-strips are then arranged in order of the 3D series – from crypt base 
at the bottom to gut lumenal surface at the top. This forms the basic ‘crypt map’ 
without colour enhancement. 
7.  The colour post-processing of this basic crypt map is as follows (RGB = red, green, 
blue; HSV = hue, saturation, value i.e. intensity value; LUT = look-up table): 
7.1 Transform the 24 bit RGB components into HSV channels 
7.2 Replace the V channel of this transform with a scaled version of the S 
channel (scaled such that the values of the S channel lie in the range of 0 to 
255) 
7.3 Recombine these modified HSV channels and back-transform to give an 
RGB colour image where the intensity of each pixel is now directly 
proportional to the colour saturation of the original image. 
7.4 Select the B channel of this new image and display the intensity values on a 
logarithmic intensity scale to give greater visibility to subtle blue shades. This 
final image is a monochrome image but is displayed in a blue pseudo-colour 
LUT for display purposes. 
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The end result of the above is a crypt map where the intensity value of each pixel is a 
log-transformed representation of the blue component in the original RGB image 
multiplied by its saturation. Thus a pixel that is white in the original image (e.g. mucin 
or other unstained areas) will have lots of blue in it but will be very unsaturated so will 
be dark in this image. A pixel which is brownish, reddish or greenish in the original 
image will have a high saturation value but will not have a hue in the blue range so will 
appear dark in this enhanced image. Only those pixels that have a both a hue in the blue 
range and are also saturated will appear bright in this post-processed image. Thus these 
final crypt maps display a representation of visual blue staining in the crypt.  
 
By this method the mutated (blue) clonal cell lineage is differentiated from the non-
mutated (brown) cells and any non-staining areas – the latter appearing black on the 
final crypt maps. The crypt map thus shows the path taken by the mutated blue clone 
that can be fully visualised from crypt base to crypt lumenal surface. 
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Figure 2.1 Construction of the crypt map 
Multiple serial sections are cut through frozen epithelial tissue and then stained for 
CCO-activity; partially-mutated crypts are identified and serial sections photographed. 
The images series is then aligned to a sub-pixel level (A). For each image, the 
circumference of the crypt is delineated, the centre of the crypt lumen marked and a cut 
angle chosen (B), the image is then sampled along a spoke radiating from the 
circumference to the centre at single pixel intervals (C). Each sampled spoke then 
becomes one vertical line in a new rectangular image (D), where the basement 
membrane (BM) is along the top edge. A section is taken from the BM aspect and 
averaged onto one plane which the forms one scan line of the basic crypt map, this is 
then repeated for each image and the scan lines stacked on top of each other to form the 
basic crypt map (E), all non-blue cells then appear black in the final colour-processed 
map in order to allow better identification of the blue clone (E). 
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2.6 Immunohistochemistry 
 
All formalin-fixed paraffin embedded (FFPE) sections were de-waxed to water, with an 
additional hydrogen peroxide blocking step for endogenous peroxidases if required, and 
antigen retrieval performed by micro-waving in boiling citrate buffer (pH 6.0) for 10 
minutes; sections were then washed in cold water before being transferred to PBS. 
Frozen sections were thawed at room temperature for 30 minutes before fixing in 
cooled Acetone (-20°C) for 10 minutes; sections were then left at room temperature for 
30 minutes to allow for evapouration of acetone before being transferred to PBS. All 
antibodies were diluted in PBS. 
 
2.6.1 Chromogen 
 
Sections were first blocked with a serum-free protein block (Dako, UK) for 10 minutes 
followed by incubating with streptavidin for 15 minutes and then biotin, also for 15 
minutes, at room temperature (Vector Laboratories, Peterborough, UK). The primary 
antibody - mouse anti-human CCO subunit 1 IgM (1:500; Invitrogen, UK) - was applied 
for 35 minutes at room temperature. Sections were then washed in PBS (5 minutes x3) 
followed by 35 minutes incubation with a biotinylated anti-mouse immunoglobulin 
(Dako, UK). After the final PBS washes (5 minutes x3), sections were incubated with 
streptavidin peroxidase (Dako, UK) for another 35 minutes, washed in PBS (5 minutes 
x3), and developed in a solution containing 4 millimoles per litre diaminobenzidine and 
0.2% hydrogen peroxide (Dako, UK) for 2-5 minutes. Sections were then dehydrated 
through alcohol (75%, 95% and 100%), cleared with xylene, and mounted with DePeX. 
 
2.6.2 Fluorescence 
 
Sections were blocked for 10 minutes in serum-free protein block (Dako, UK) and then 
washed in PBS. Incubation with the primary antibody was for 60 minutes, those used 
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were: rabbit anti-human MUC-2 IgG (1:100 dilution; Abcam, UK); mouse anti-human 
MUC-2 IgM (1:100 dilution; Vector Laboratories, UK); sheep anti-human Carbonic 
Anhydrase II (CA-II) IgG (1:100 dilution; Abcam, UK); mouse anti-human CCO 
subunit 1 IgM (1:400 dilution; Invitrogen, UK); mouse anti-human CD-10 (1:100 
dilution; Dako, UK). Sections were then washed in PBS (5 minutes x3). Appropriate 
Alexa Fluor
®
 (Molecular Probes, Invitrogen, UK) secondary antibodies were then 
applied (1:150 dilution) for 60 minutes. Sections were again washed in PBS (5 minutes 
x3) before being cover-slipped using VECTASHIELD
® 
HardSet
TM
 Mounting Medium 
with DAPI (Vector Laboratories, UK). Sections were examined using an Olympus 
BX61 epi-fluorescence microscope system with SmartCaptureX software (Digital 
Scientific, Cambridge, UK) to generate RGB images from multi-channel monochrome 
captures. Negative controls that lacked the primary antibody were run in tandem. All 
primary and secondary antibody dilutions were optimised, and detailed protocols for the 
double and triple immunofluorescence (IF) performed on fresh frozen and FFPE human 
colon respectively in Chapter 4 are given below: 
 
Double immunofluorescence protocol for MUC-2 and CA-II on fresh frozen 
normal human colon: 
Fresh frozen sections were thawed at room temperature for 30 minutes, fixed in cooled 
acetone (-20°C) for 10 minutes and then air-dried at room temperature for 30 minutes 
before being transferred to PBS. Sections were then incubated for 10 minuets in serum-
free protein block (Dako, UK) followed by a further 10 minutes in donkey serum (10% 
diluted in PBS). The primary antibodies mouse anti-human MUC2 and sheep anti-
human CA-II (1:100 dilution in PBS) were applied for 60 minuets and sections then 
washed in PBS (5 minutes x3). The following secondary Alexa Fluor
®
 fluorescent 
antibodies were then applied for 60 minutes: donkey anti-mouse (green/488nm) and 
donkey anti-sheep (Cy5/647nm) all diluted to 1:150 in PBS. Sections were then washed 
in PBS (5 minutes x3), mounted in VECTASHIELD
® 
HardSet
TM
 and left to dry in the 
fridge (+4°C) overnight. 
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Triple immunofluorescence protocol for CCO, MUC-2 and CA-II on FFPE normal 
human colon: 
Sections were de-waxed to water with antigen-retrieval performed as previously 
described, they were then incubated for 10 minutes in serum-free protein block 
followed by a 10 minute block in donkey serum (10% diluted in PBS). The following 
primary antibodies were applied for 60 minutes: mouse anti-human CCO subunit 1 IgM 
at 1:400, rabbit anti human MUC2 IgG at 1:100 and sheep anti-human CA-II IgG at 
1:100 (diluted in PBS). Sections were washed in PBS (5 minutes x3) and then incubated 
with the following secondary Alexa Fluor
®
 fluorescent antibodies for 60 minutes: 
donkey anti-mouse (green/488nm), donkey anti-rabbit (Cy3/555nm) and donkey anti-
sheep (Cy5/647nm) all diluted to 1:150 in PBS. Sections were then washed in PBS (5 
minutes x3), mounted in VECTASHIELD
® 
HardSet
TM
 and left to dry in the fridge 
(+4°C) overnight. 
 
2.7 In-situ hybridization for human LRG5 mRNA 
 
In-situ hybridisation (ISH) for human LGR5 mRNA was performed on FFPE normal 
human colon, all experimental procedures were performed with the kind assistance and 
close supervision of Mrs Rosemary Jeffery (Histopathology Lab, London Research 
Institute, Cancer Research UK, London, UK). 
 
2.7.1 Human LGR5 ISH riboprobe design and synthesis 
 
An ISH probe that was specific to human LGR5 mRNA was kindly provided by Dr 
Stefania Segditsas (The Molecular and Population Genetics Lab, Wellcome Trust 
Centre for Human Genetics, University of Oxford, UK): A 566bp exon-spanning region 
of human LGR5 mRNA was amplified by PCR from human FAP polyp cDNA using 
specific primers and cloned into the pGEM
®
-3Z vector (Promega, UK), that has SP6 
and T7 RNA polymerase primers flanking the multiple cloning sites, using the EcoRI 
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and HindIII restriction enzymes, then inserted into non-competent JM109 cells 
(Promega, UK). Once received, plasmids were then linearized with EcoRI and LGR5 
riboprobes synthesised with Sp6 RNA polymerase using Sulphur-35 (S
35
) labelled 
uridine-triphosphate (UTP). 
 
2.7.2 Tissue preparation 
 
All PBS, ethanol and xylene solutions were pre-treated with 0.1% v/v 
diethylpyrocarbonate (DEPC) in order to inactivate any RNases. FFPE sections were 
cut at 4 ?m, dried overnight at 40°C then de-waxed in fresh xylene for 8 minutes with 
two changes. Sections were rehydrated through 100%, 80%, 60% and 30% ethanol and 
then washed in PBS. Sections were permeabilised using Proteinase K (at a final 
concentration of 20 micrograms per millilitre in PBS) for 10 minutes at 37°C, rinsed in 
PBS containing 0.2% (w/v) glycine for 5 minutes and then PBS for 5 minutes. Slides 
were then post-fixed in 4% para-formaldehyde in PBS for 10 minutes, followed by 
rinsing in PBS (5 minutes x3). Tissue was acetylated with 500 millilitres of 0.1M 
triethanolamine + 1.25 millilitres of acetic anhydride added just before immersing the 
slides, then washed in PBS (5 minutes x3). Sections were dehydrated through graded 
alcohol containing 0.1% DEPC from 30% to 100% then air-dried. 
 
2.7.3 Hybridisation 
 
Hybridisation buffer was prepared as per Table 2.1. The final volume required was 
based on 10-25 microlitres per section, depending on the size of the section and the 
cover-slip to be used. Hybridisation buffer containing the LGR5 probe was heated at 
80°C for 1 minute, spun to reduce aerosols and pipetted onto the sections. Slides were 
then cover-slipped and placed into a humidified plastic slide-mailing box containing 
blotting paper saturated with 1x salts and 50% formamide. These were then put inside a 
lunch box humidified in the same way, sealed with PVC tape and incubated overnight at 
55°C. 
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Proportion Volume for 1ml Ingredient 
10% 100μl 10x salts mix in Denhardt's 
solution. 
50% 500μl Formamide 
3% 30μl rRNA 
20% 200μl Dextran Sulphate 
1% 10μl 1 molar DTT 
16% 160μl Probe + DEPC treated H20 
Table 2.1 Hybridisation buffer mastermix  
?????????????????????????????????? ?????????????????????????????μ???? ????????????
 
2.7.4 Post hybridisation washes 
 
Cover-slips were removed from each of the slides and placed in a clean rack, then 
immersed in 500 millilitres of 50% formamide buffer at 55°C on a rocking table for 3-4 
hours; the formamide was replaced 3 times over the incubation period. Slides were then 
washed in 500 millilitres of TNE buffer at 37°C (5 minutes x9) and incubated with 100 
micrograms per millilitre RNAse A in TNE buffer at 37°C for 1 hour in a plastic lunch 
box. A further 2 washes were then done in 2x SSC for 30 minutes at 65°C with 
agitation. Following this sections were taken through graded ethanols, increasing from 
30% to absolute ethanol, all containing 0.3molar ammonium acetate to ensure that the 
labelled hybrids stay in place, then air-dried overnight. 
 
2.7.5 Autoradiography 
 
All steps were performed in a darkroom using a 902 filter and a 15-watt bulb.  A 40 
millilitre volume of Ilford K5 emulsion (15 millilitres stock emulsion + 25 millilitres 
0.1% v/v DEPC treated H20) was heated to 45°C in a water bath for 5 to 10 minutes. 
The solution was mixed using a glass rod then left for 10-20 minutes. Once the 
emulsion was judged to be of the correct consistency using a test slide, slides were 
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dipped into the emulsion so that the section was completely covered, placed on a cold 
metal surface and allowed to dry for about 2.5 hours until the surface of the emulsion 
had hardened. After drying, slides were placed in a wooden slide rack holder (or plastic) 
and silica gel added. The lid of the rack was then sealed with masking tape, inserted into 
a black plastic bag, sealed again with tape before refrigerating (+4°C) to expose the 
emulsion (7-14 days as appropriate). 
 
2.7.6 Developing 
 
Slides were immersed in pre-prepared Kodak D-19 developer at ~18°C for 4 minutes, 
agitated for one minute before washing in 1% acetic acid for 30 seconds followed by 
tap water for 30 seconds and then 30% sodium thio-sulphate fixer for two changes of 4 
minutes each. Sides then underwent a further 10x 5 minute washes in tap water. 
 
2.7.7 Counterstaining 
 
Slides were immersed for 30-60 seconds in dilute stock giemsa solution (1: 100 with 
distilled water), washed under tap water and then air-dried before mounting under glass 
cover-slips in DPX. Sections were then examined under conventional or reflected light 
dark-field conditions (Olympus BH2 with epi-illumination) that allowed individual 
auto-radiographic silver grains to be seen as bright objects on a dark background. 
 
2.8 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
 
In order to phenotype the clonal cell populations that had been identified by staining for 
CCO-activity, a technique involving CCO-histochemistry combined with RT-PCR for 
lineage specific mRNA was developed. 
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2.8.1 CCO histochemistry, RNA extraction and cDNA synthesis protocol 
 
A protocol was devised to extract RNA from fresh frozen tissue, in combination with 
enzyme histochemistry for CCO-activity, by combining various elements from 
previously published RNA-extraction methods  
165-167
 and Zeiss online protocols 
(http://www.zeiss.de/labs): 
1. All work surfaces and lab equipment was treated for RNase contamination with 
RNaseZAP (Ambion, Applied Biosystems, Warrington, UK). 
2. P.A.L.M slides were treated for any RNase contamination by dipping in 
RNaseZap followed by 2 washes in DEPC-treated (0.1% v/v) H20. Slides were 
then air-dried at 37°C for 2 hours and exposed to ultraviolet radiation (254 
nanometre wavelength) for 45 minutes to improve section adhesion. 
3. Serial sections of fresh frozen human colon were cut in a cryostat at -20°C onto 
the pre-treated P.A.L.M slides and allowed to air-dry at -20°C for 20 minutes. 
4. In order to limit the time sections were exposed to the aqueous phase and, 
therefore, endogenous RNases, enzyme histochemistry for CCO-activity only 
was performed as previously described in section 2.4.1. Counter-staining for 
SDH activity was not done, with absence of CCO-staining used as a marker for 
CCO-deficiency. All staining solutions, PBS and ethanol solutions were pre-
treated for RNases using 0.1% v/v DEPC. 
5. Slides were dehydrated and fixed in graded ethanol: 75% for 1 minute; 95% for 
1 minute; 100% 2x 1 minute. After air-drying for 1-2 minutes, single crypts 
were micro-dissected as previously described (see 2.2.2). 
6. RNA-extraction was then performed using the Arcturus? PicoPure?  RNA 
isolation kit (Applied Biosystems, Arcturus?
 
products, Life Technologies Ltd, 
Paisley, UK). The manufacturers instructions were followed: An extraction 
buffer was pipetted onto the cap of the micro-dissection tube containing the 
micro-dissected tissue, and then incubated for 30 minutes at 42°C; the extract 
was then spun through a purification spin column to capture the RNA, followed 
by centrifugation with a series of wash buffers before the RNA was isolated 
using a low ionic strength elution buffer. 
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7. RNA-extraction was immediately followed by a reverse-transcriptase reaction in 
order to produce complimentary-DNA (cDNA) that could be stably stored at -
20°C before PCR. Reverse transcription was performed using the SuperScript? 
III reverse transcriptase kit (Invitrogen, Paisley, UK) according to the 
manufacturers instructions. To summarise: mRNA was first specifically primed 
with oligo-dTs that bind to the 3’ polyA-tail, following this the primed mRNA 
was incubated with a cDNA synthesis mix containing reverse transcriptase to 
produce cDNA template that could then be directly amplified using PCR. 
 
2.8.2 PCR design and optimisation 
 
As previously described, the human colonic crypt contains terminally differentiated 
cells of either the secretory or absorptive lineage. Therefore, in order to demonstrate the 
multi-potentiality of CCO-negative stem cell clones, primers specific for MUC-2, 
Chromogranin A, CD-10 and VILLIN mRNA were designed using the freely available 
Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast) tool and sourced from 
Sigma-Aldrich, Poole, UK. All first-round primer pairs were exon-exon spanning to 
increase specificity for mRNA rather than DNA, and separated by at least one intron so 
that any DNA that was non-specifically amplified could be clearly seen on the agarose 
electrophoresis gel. Nested second-round primer pairs were then designed, as the initial 
amount of cDNA template was to be of low concentration. The primer pairs were 
optimised and nested-PCR protocols developed using control normal human colonic 
epithelial cDNA (see Appendix 9.1 and 9.2 for primer sequences and thermal cycler 
protocols). The cytoskeletal protein Beta-Actin was used as an internal positive control. 
 
2.8.3 RNA extraction using Trizol® reagent to produce positive control 
cDNA 
 
In order to produce positive-control mucosal cDNA to enable optimisation of the RT-
PCR primers, a 0.5 centimetre x 0.5 centimetre piece of normal human colonic mucosa 
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was homogenised in 1 millilitre of Trizol
®
 reagent (Sigma-Aldrich, UK). RNA was then 
isolated and cDNA synthesised using the following protocol: 
1. 200 microlitres of chloroform was added and the tube shaken vigorously by 
hand for 15-20 seconds. 
2. Samples were centrifuged at 13,000xg for 5 minutes to separate the organic and 
aqueous phases, and the colourless upper aqueous phase was carefully removed 
by pipette. 
3. 500 microlitres of isopropanol was added and the sample incubated at room 
temperature for 15 minutes, followed by centrifugation at 13,000x g for 8 
minutes to precipitate RNA. 
4. The supernatant was removed by pipette to leave the RNA precipitate/ pellet, 
which was then washed once with 500 microlitres of 70% ethanol. The sample 
was mixed by vortexing, centrifuged at 13,000x g for 8 minutes, supernatant 
removed and then the RNA pellet air-dried for 3-4 minutes. 
5. The RNA pellet was re-suspended using ddH20 and reverse transcription 
performed using the SuperScript? III reverse transcriptase kit as detailed above. 
 
2.9 Proteomics 
 
It was hypothesised that matrix-assisted laser desorption ionisation mass spectrometry 
analysis (MALDI-MS) for lineage-specific proteins might enable gene expression 
analysis of CCO-negative clones within crypts. In order to assess the sensitivity of the 
technique for the small quantities of tissue involved, varying numbers of whole crypts 
were LCMD and analysed using the following protocol: 
1. Serial sections of frozen, normal human epithelium were stained for CCO 
activity; Counter-staining for SDH activity was not done, with absence of 
staining for CCO used as a marker for CCO-deficiency. 
2. LCMD of whole CCO-proficient and CCO-deficient crypts was performed. 14 
microlitres of 80% ammonium bicarbonate/20% Acetonitrile was added as a 
lysis buffer and samples were then sonicated on ice. 
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3. The whole crypts were subjected to an overnight in solution tryptic digest 
(protein ratio 20:1) in 10 millimolar ammonium bicarbonate at 37°C. The 
supernantant was then dried down and washed prior to reconstitution in 5 
microlitres of 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid.  
4. 0.3 microlitres of the supernatant digest was spotted on a MALDI target plate 
and mixed with 0.3 microlitres matrix stock (10 milligrams per millilitre alpha-
cyano-4-hydroxycinnamic acid + 1 microlitres 1 molar ammonium 
monophosphate to suppress matrix adducts in 0.1% trifluoroacetic acidin 
acetonitrile/water 50:50.) 
5. The matrix solution was left to crystallize by evaporating the solvent and the 
sample analysed with a 4700 Applied Biosystems MALDI-TOF/TOF (matrix-
assisted laser desorption ionisation tandem time-of-flight). 
 
The mass spectra were initially advanced baseline corrected with a peak width of 32, 
flexibility of 0.5 and Degree of 0.1 using DataExplorer
®
 (Version 4.6) software. A 
peptide "hit" was fragmented by high-energy collision-induced dissociation (CID). The 
resulting mass spectra of peptide masses were searched against the National Centre for 
Biotechnology Information (NCBI) non-redundant database (2010) using a Mascot 
search engine (Matrix Science Ltd) with a mass accuracy of 20 ppm and fragment 
tolerance of 100 ppm. One missed cleavage per peptide with the possible modifications 
of peptide N-terminal Gln to pyroGlu, oxidation of Met, and protein N terminus 
acetylated were considered in each search. Unidentifiable hits were analysed manually. 
 
2.10  Methylation analysis 
 
2.10.1 Laser capture micro-dissection and DNA extraction 
 
Laser capture micro-dissection (LCMD) was performed as previously described (see 
Methods 2.2.2). Whole crypts from both normal colon and polyps were LCMD for 
methylation analysis; at least 3 serial on-edge sections were micro-dissected for each 
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crypt. For CCO-deficient clones within crypts, the blue and brown cell populations were 
separately micro-dissected from all serial en-face sections of the crypt into two laser-
capture tubes. 
 
DNA was extracted using 14 microlitres of proteinase K digestion buffer (Arcturus 
Bioscience, USA) for a minimum of 3 hours digestion. A negative control tube 
containing only digestion buffer and no laser capture material was also included. After 
digestion, tubes were briefly centrifuged and proteinase K deactivated by heating to 
95˚C for 10 minutes. DNA lysate was stored at -20˚C. 
 
2.10.2 Bisulphite treatment 
 
For methylation analysis, extracted DNA was bisulphite treated using the EpiTect
®
 Plus 
Bisulphite Kit (Qiagen, UK) according to the manufacturer’s instructions: A sodium 
bisulphite mix is prepared and run on a thermal cycling programme overnight; the mix 
is then spun through an EpiTect
®
 spin column with a buffer to promote binding of the 
converted DNA to the column membrane; bound DNA is then washed to removed 
residual sodium bisulphite, de-sulphonated, eluted from the spin column into a 1.5 
millilitre micro-centrifuge tube and then stored at -20˚C until further use. An aliquot of 
the digestion buffer was also bisulphite treated as a negative control. Bisulphite 
treatment results in the efficient conversion of un-methylated cytosine to uracil, 
however it yields low DNA concentrations, thus in order to successfully PCR amplify 
the bisulphite treated DNA a two-round, nested PCR was used. CpG islands on the 
following genes were amplified: MYOD1 (Myoblast determination protein 1, 
Chromosome 11p), CSX (Cardiac-specific homeobox, Chromosome 5q) and BGN 
(Biglycan, Chromosome Xq). These genes show limited or no expression in the colonic 
epithelium, age related methylation, and have been previously suggested for use as 
clonal markers in human colon crypts 
18
.  Specific primers flanking the target CpG 
islands for each gene were designed using the Primer 3 website (MIT, Cambridge, 
Massachusetts, USA), and reaction conditions (reagent concentrations and annealing 
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temperatures) were pre-optimised for each primer pair using cell-line DNA. Successful 
PCR amplification was confirmed by gel electrophoresis: only samples with an 
uncontaminated negative control were taken forward for cloning. For details of 
methylation specific primers, PCR programmes and post-bisulphite treatment CpG 
island sequences see Appendix 9.1, 9.2 and 9.3. 
 
2.10.3 TA-cloning of PCR products 
 
To achieve single strand resolution, PCR products were cloned using a TA-cloning kit, 
utilising the pGEM
®
-T vector (Promega, UK), according to the manufacturer’s 
instructions. Taq DNA polymerase adds a terminal 3'-A overhang to the end of each 
PCR product, this enables it to be directly cloned into a linearized cloning vector that 
has single base 3'-T overhangs - TA cloning. The pGEM
®
-T is a linearised vector with a 
single 3'-T overhang at each end, and contains a LacZ gene and ?-Lactamase coding 
region. PCR products are cloned in a ligation reaction containing PCR product, buffer, 
vector and T4 DNA ligase. The recombinant vectors are then transformed into 
competent JM109 cells (Promega, UK) and colonies grown overnight on agar growth 
medium containing ampicllin, X-galactose (X-gal) and Isopropyl ?-D-1-
thiogalactopyranoside (IPTG). Incorporation of the PCR product into the vector disrupts 
the LacZ operon so that successfully transformed clones are easily identified by 
blue/white colour discrimination. White clones were PCR amplified using M13 or 
T7/SP6 primer pairs that flanked the insertion point within the plasmid. The PCR 
product was then purified and sequenced as previously described (see Methods 2.3.2). 
 
2.11 Statistical analysis of methylation patterns 
 
Statistical analysis of methylation patterns was performed as formulated by Shibata and 
colleagues 
18, 44, 168
, with an additional measure – the minimum distance formulated by 
Dr Trevor Graham (Histopathology Lab, London Research Institute, Cancer Research 
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UK, 44 Lincoln’s Inn Fields, London, UK). The pattern of methylated and un-
methylated sites observed in a single strand (at a single locus) is described as a tag, with 
k=1,..,M CpG sites.  For each crypt analysed from each patient, S jk
l denoted the 
methylation status at locus l (BGN, CSX, or MYOD1), in the tag j, at site k. S jk
l
= 0  
denoted that the site was un-methylated, whereas S jk
l
=1 denoted the site was 
methylated.  To describe the methylation present at each locus, in each crypt, three 
summary statistics were used: 
a) Proportion of methylated sites (a proxy for mitotic age of the tissue). 
This was calculated as:  
? Percent methylated = pm = 1NM S jk
l
k=1
M
?
j=1
N
?  
where N was the number of sequences analysed in that crypt at locus l, and M was the 
number of CpG sites at locus l. 
b) Intra-crypt or intra-clone distance (a measure of epigenetic diversity within a crypt 
or clone).  The distance between any two tags was defined simply as the number of sites 
where the methylation pattern differed (the Hamming distance).  For example, the 
distance between the two sequences 1000110 and 0000111 is two, as they differ at the 
first and last CpG sites.  The intra-crypt distance was the average distance between all 
tags from a crypt, calculated as: 
Intra-crypt distance = A = 
1
N(N ?1)
Sik
l ? S jkl
k=1
M
?
j= i+1
N
?
i=1
N
?  
c) Number of unique tags in the crypt (a measure of epigenetic diversity within a crypt), 
denoted as U. 
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The similarity of methylation patterns between crypts was also assessed.  The inter-
crypt distance, the average distance between each tag in the first crypt compared to each 
tag in the second crypt was computed as: 
? Inter-crypt distance = I = 1
N1N2
Sik
l ?C jkl
k=1
M
?
j=1
N2
?
i=1
N1
?  
Where S jk
l and C jk
l  represented the methylation tags from the first and second crypts 
respectively.  N1 and N2 were the respective numbers of tags sampled from each crypt.  
 
Second, the minimum epigenetic distance between crypts, which indicates the average 
number of methylation events required to transform each methylation tag in crypt 1 to 
those in crypt 2, was computed as: 
? Minimum epigenetic distance = E = 1
N1N2
min
j=1
N2
Sik
l ?C jkl
k=1
M
?
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
i=1
N1
?
 
The above statistical measures were designed into a Microsoft Excel spreadsheet by Dr 
Graham to enable analysis of methylation patterns both within and between crypts. In 
addition, a bespoke statistical program that allowed rapid analysis of the methylation 
pattern data was written using Perl programming language by Dr Graham. The 
respective statistical measures were then compared between two groups using the non-
parametric Mann Whitney U-test and graphics produced using the freely available R 
Console platform (version 2.13) (http://www.r-project.org). 
 
2.11.1 Mathematical Model 
 
A mathematical model of colon crypt cell dynamics was used to examine methylation 
pattern divergence between daughter crypts following fission. The model was based on 
that of Yatabe and colleagues 
18
, but was modified in conjunction with Dr Trevor 
Graham to additionally describe crypt fission. 
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Each crypt was assumed to contain a constant N stem cells that divided at the same time 
as each other. At each round of division, each stem cell could produce either 0, 1 or 2 
stem cell offspring, and a corresponding 2, 1 or 0 differentiated stem cell offspring, with 
probability p0, p1 or p2, respectively (where p0+p1+p2=1). Divisions were additionally 
constrained so that exactly N stem cells remained in the crypt following each round of 
division (for details see supplementary materials of 
18
).  
 
Methylation or de-methylation at each CpG site was assumed to occur independently 
and at a basal rate of ?=2?10-5 per CpG site per cell per division. CpG islands were 
assumed to be initially un-methylated.  Each cells contained two alleles of the CSX and 
MYOD1 loci, and single allele of the X-linked BGN locus. Methylation patterns were 
inherited by daughter cells at division. 
 
Crypt fission occurred after a predefined number of divisions (Tf >0).  During fission, 
the stem cells from the parent crypt were divided between the two daughter crypts.  
Parent stem cells were divided according to two segregation schemes. In the first 
scheme, crypt fission was assumed to be symmetric, such that the parent stem cells were 
divided equally between the two daughter crypts.  Each of these N/2 stem cells then 
underwent a symmetric division to form a crypt composed of the usual N stem cells.  In 
the second scheme, a single stem cell from the parent crypt formed one of the daughter 
crypts, the other inherited the remaining N-1 stem cells.  N-1 symmetric stem cell 
divisions restored the full compliment of stem cells in the first crypt, and a single 
symmetric stem cell division of one stem cell restored the full compliment of stem cells 
in the second crypt.  After restoration of the full complement of N stem cells, crypt 
behaviour was as described above.  Repeated simulation of the model, >10
5
 repeats per 
parameter set, was used to investigate model behaviour. 
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2.12  Somatic mutation, LOH and MSI analysis of human polyps 
and adenomas 
 
Fresh frozen human polyps were collected as previously described (see Methods 2.1). 
Serial sections were cut at 20 microns onto laser capture slides, with every 5
th
 section 
cut at 6 microns onto normal glass slides for haematoxylin and eosin staining to enable 
accurate histopathological assessment by an expert GI pathologist (Professor Sir N.A. 
Wright, Histopathology Lab, London Research Institute, Cancer Research UK, 
London). Sections were then stained for CCO-histochemistry as detailed in 2.4.1. 
Tissue macro-dissection, LCMD, DNA extraction, PCR and sequencing were all done 
as previously detailed (see Methods 2.2 and 2.3). For details of all primer sequences, 
PCR reagent and thermal cycler protocols see Appendix 9.1 and 9.2. 
 
2.12.1 Somatic APC mutation screening 
 
DNA lysate from needle macro-dissected tissue and individual crypts was screened for 
somatic mutations in the tumour suppressor APC gene by PCR. Tumorigenic mutations 
in APC tend to cluster in the region between codons 1250-1450, termed the mutation 
cluster region (MCR) 
169
. The MCR has previously been divided into 12 overlapping 
regions, each of around 100-200 base pairs, to facilitate PCR amplification from 
paraffin tissue and low DNA concentrations 
107
 (see Appendix 9.1 and 9.2 for primers 
and PCR protocols). As the quality of DNA in frozen tissue is better preserved than 
paraffin-embedded tissue, with no fragmentation, two sets of primers that amplify the 
whole MCR were designed using the freely available Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) tool and sourced from Sigma-Aldrich, 
Poole, UK (see Table 9.6). PCR protocols were successfully optimized for each primer 
set (see Table 9.6). 
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2.12.2 Somatic KRAS mutation screening 
 
Oncogenic KRAS mutations tend to occur at codons 12 and 13, and occasionally codon 
61 
137, 170
. Therefore, KRAS mutation screening of DNA lysate from whole tissue scrapes 
and/or individual crypts was performed using an established nested, two-round PCR 
specific for this region of the gene (see Table 9.9). 
 
2.12.3 Somatic BRAF mutation screening 
 
BRAF mutations are localised to codon 600. Therefore, mutation screening of DNA 
lysate from whole tissue scrapes and/or individual crypts was performed using an 
established PCR specific for this region of the gene (see Table 9.10). 
 
2.12.4 Somatic TP53 mutation screening 
 
Exons 5-8 of the TP53 tumour suppressor gene, where the vast majority of somatic 
mutations in TP53 occur, were amplified from whole tissue scrapes and/or individual 
crypts using an established nested, two-round PCR specific for these exons (see Table 
9.11). 
 
2.12.5 Microsatellite instability 
 
Microsatellite instability (MSI) was assessed for DNA lysates from needle macro-
dissected adenoma and polyp tissue using a multiplexed PCR for the BAT-25 and BAT-
26 mononucleotide repeats (see Table 9.13). These repeats have been shown to be 
highly sensitive and specific for detecting constitutional defects in the mismatch repair 
(MMR) genes hMLH1, hMSH2, hPMS1 and hPMS2 
171
. The BAT25 marker is a 
poly(A) tract located within the intron of the c-KIT oncogene, and BAT26 is a poly(A) 
Chapter 2. Materials and Methods 
 79 
tract located in the fifth intron of hMSH2. As these repeats are located within the 
introns of genes, they are highly conserved and thus sensitive reporters of DNA 
replication errors. Primers were tagged at the 5’ end with either a FAM or HEX 
fluorescent marker.  Successfully amplified PCR products were then analysed on an 
ABI 3100 Genetic analyser using Genotyper
® 
2.5 software (Applied Biosystems). 
 
2.12.6 LOH analysis 
 
Highly polymorphic microsatellites, located on chromosomes 5q (APC) and 17p (TP53) 
were amplified from DNA lysates using a multiplex PCR kit (Qiagen, UK) (see Table 
9.12). Amplification of constitutional (normal) epithelium and adenomatous crypts was 
done in parallel to control for PCR variability. Marker accession numbers, primer and 
reaction details are all detailed in Appendix 9.1 and 9.2. Primers were tagged at the 5’ 
end with either a FAM or HEX fluorescent marker.  Successfully amplified PCR 
products were analysed on an ABI 3100 Genetic analyser using Genotyper
®
 2.5 
software (Applied Biosystems). LOH was then considered present if the area under one 
allelic peak was more than twice that of the other, after normalising the peak areas 
relative to the constitutional DNA. 
 
2.13  LINE-1 CpG site methylation analysis 
 
Long interspersed nucleotide elements (LINE-1 elements) are highly repeated human 
retrotransposon sequences, and constitute about 17% of the human genome. 
Approximately one-third of DNA methylation occurs in repetitive elements and LINE-1 
CpG site methylation, as measured by Pyrosequencing
®
 (Qiagen, UK), is well 
correlated with global DNA methylation level 
172
 and therefore can be used as a proxy 
marker for global DNA methylation. 
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DNA lysate from needle macro-dissected tissue was first bisulphite treated using the 
Epitect
®
 Plus Bisulphite Kit (Qiagen, UK) according to the manufacturer’s instructions, 
as summarised previously (see Methods 2.10.2). Bisulphite treated DNA was then 
amplified using the PyroMark
®
 CpG LINE-1 PCR kit (Qiagen, UK) according to the 
manufacturer’s instructions. The primers are specific for a 146kb fragment containing 
four CpG sites, and the reverse primer is biotinylated to enable isolation of single 
stranded template DNA for sequencing using streptavidin beads. Pyrosequencing
®
 
(Qiagen, UK) analysis, based on sequencing-by-synthesis technology, to quantify the 
methylation level of the four CpG sites was then performed, according to the 
manufacturers instructions, using the PyroMark
®
 Q96 MD sequencer: the biotinylated 
PCR product was first immobilised to streptavidin sepharose beads before purification 
and denaturation to a single stranded product using the PyroMark
®
 Q96 vacuum 
workstation; the PCR product was then annealed to the sequencing primer before 
transferring to the PyroMark
®
 Q96 MD and running the Pyrosequencing
®
 reaction; the 
nucleotide dispensation order was: ATCAGTGTGTCAGTCAGTTAGTCTG. DNA 
from normal crypts, when available, and polyp tissue were analysed in parallel to 
control for any PCR variability.  Technical assistance for Pyrosequencing
®
 was kindly 
provided by Miss Athina Vidaki and Dr David Ballard of the Forensic Haematology 
Unit, Blizard Institute, Barts and The London School of Medicine and Dentistry, 
London, E3 2AT. 
 
The sequencing data was then used to quantify the global methylation level at the four 
CpG sites. Figure  2.2 shows a trace from one of the samples analysed. Relative heights 
of the C and T peaks at each CpG site, as used in previous studies 
135, 149, 172
 were then 
used to give a quantification of the methylation level. 
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Figure 2.2 LINE-1 methylation as measure by pyrosequencing
® 
Example Pyrosequencing
®
 trace. The four CpG sites within the LINE-1 sequence are 
highlighted in yellow. The relative ratio of the C and T peaks at the CpG sites is used to 
calculate the percentage methylation. 
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Chapter 3. Mapping stem cell clones in human 
intestinal crypts 
 
3.1 Introduction and aims 
 
Although it is now widely believed that there is a small number of related stem cells 
located at the base of the intestinal crypt that give rise to all the cell lineages of the 
crypt, most of the data to support this comes from mouse models due to the technical 
limitations of using human tissue. The aim of this project was to utilise naturally 
occurring, age-related somatic mtDNA mutations, that had previously been shown to 
accumulate in human colonic stem cells 
76, 77
 (see Introduction 1.1.6), as markers of 
clonality for whole human colon crypts. It was hypothesised that enzyme histochemistry 
and laser-capture sequencing combined with image analysis software could enable the 
mapping of long-lived, clonal cell populations within the crypts themselves and thus 
visualise putative stem clones.  
 
As previously discussed (see Introduction 1.1.6. and Methods 2.4), after staining normal 
human colonic mucosa for activity of the mitochondrial encoded enzyme cytochrome c 
oxidase (CCO) three different types of crypts are observed: (i) wild-type, CCO-
proficient brown crypts (ii) wholly CCO-deficient blue crypts and (iii) crypts containing 
populations of both brown and blue cells - mixed or partially-CCO-deficient crypts. 
Figure 3.1A-E demonstrates the different types of staining observed after CCO-
histochemistry of fresh frozen human colonic mucosa. It is the mixed, partially-
deficient crypts that provide a unique opportunity of identifying and mapping the 
progeny of a single stem cell lineage within individual human intestinal crypts.  
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Figure 3.1 CCO-histochemistry of normal frozen human colonic epithelium 
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3.2 CCO-histochemistry identifies long-lived clonal cell 
populations within human colon crypts 
 
In order to prove that these blue cell populations within crypts are indeed clonal and 
derived from a single stem cell lineage, individual cells from within the blue and brown 
cell populations of the crypt were laser capture micro-dissected and the mitochondrial 
genome amplified in order to detect clonal mutations in the blue cells (see Methods 
2.4). Figure 3.2A demonstrates a colonic crypt that, after CCO-histochemistry staining 
of serial en-face frozen sections of human colon, contained a distinct population of blue 
cells that extended from the base of the crypt to the luminal surface. Sequencing the 
mtDNA of cells, from both within the partially-CCO-deficient crypt and neighbouring 
crypts, confirmed that all the blue cells within the crypt, identified by CCO-
histochemistry, were a distinct clonal population (Figure 3.2B-D) and thus the progeny 
of a single stem cell lineage. 
 
More complex mtDNA mutation patterns were observed within crypts. As previously 
discussed, the mutations in the mitochondrial DNA are acquired over a number of years 
by a stem cell via genetic drift 
76
, and this stem cell can then expand stochastically over 
time within the niche by niche succession. Once a high proportion of the mitochondria 
within the stem cell have the mutation,  then this is enough to cause a deficiency in 
oxidative phosphorylation 
81
. In Figure 3.3 a blue cell population is seen occupying a 
large proportion of a colon crypt. After sequencing, the blue cells were found to have a 
clonal mutation in the mitochondrial encoded NADH dehydrogenase 2 (MT-ND2) gene 
(C>A at position 4888) at a high heteroplasmic level - note a small peak of the wild-
type base was also seen in the sequencing trace from the blue cells (Figure 3.3A-B). 
Upon sequencing the brown cells from within the crypt the mutation was also picked 
up, but at a lower, heteroplasmic level, whereas surrounding brown crypts where 
homoplasmic for the wild-type mitochondrial sequence (Figure 3.3A-B). 
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Figure 3.2 CCO-histochemistry identifies a clone from a single stem cell lineage 
within a human colonic crypt 
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Figure 3.3 Crypt niche dynamics 
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For the crypt in Figure 3.3 the mtDNA mutation was located in the MT-ND2 gene that 
encodes for the nicotinamide adenine di-nucleotide (NADH)-ubiquinone 
oxidoreductase chain 2 enzyme (complex 1), this gene is immediately upstream of the 
genes encoding for CCO and the point mutation resulted in a premature stop codon 
(TCA?TAA). As transcription of the circular mitochondrial genome occurs 
uninterrupted once it is initiated at the promoter region 
173
, it is clear how this mutation 
would cause a subsequent deficiency in the cytochrome c oxidase enzyme. However, as 
found by previous studies 
76
, it was not always possible to identify a mitochondrial 
mutation in the blue cell population of partially-deficient crypts. Figure 3.4 
demonstrates such a crypt: there was a clearly defined CCO-deficient blue cell 
population (Figure 3.4A), but after LCMD and sequencing of the entire mitochondrial 
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genome of both blue and brown cells from within the crypt no clonal mutation was 
identified. However, upon checking the polymorphisms detected in the partially-
mutated crypt by sequencing the mtDNA of cells from adjacent blue and brown crypts, 
one of the ‘polymorphisms’ detected in the partially-mutated crypt was found, in-fact, 
to be a clonal mutation for the entire crypt as no surrounding crypts harboured the same 
polymorphism (Figure 3.4B-D). 
 
The mutation in this case, a T>C at position 152, is in the non-coding control region of 
the mitochondrial genome, which contains the promoter binding regions for the 
initiation of both heavy and light-strand mitochondrial DNA transcription 
173
. It is thus 
possible that a secondary clonal epigenetic change that resulted in impaired 
transcription factor binding in the CCO-deficient blue cell population within the crypt 
was the cause of the detectable CCO-deficiency in this case. There are a number of 
technical reasons why clonal mutations in blue, CCO-deficient cells within the crypt 
might be missed: the mitochondrial genome is 16.6kb and, although the primers are 
overlapping, after sequencing there are occasionally small (<10bp) areas at the start or 
end of the amplicon, around the primer binding sites, that cannot be read; very small 
areas of tissue are being LCMD, perhaps 2-3 cells, and CCO staining intensity is 
variable so it is easy to get contamination from brown, wild-type cells; the PCR reaction 
may preferentially amplify the wild-type sequence in those clones that are heterozygous 
for the clonal mtDNA mutation. Importantly, never were blue cells from within clones 
found not to share a mtDNA mutation when one was identified, and no previous authors 
using this technique have reported this either 
76-78, 174
. 
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Figure 3.4 Partially CCO-deficient crypt with no clonal mtDNA mutation in the 
CCO-deficient cells 
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3.3 Mapping of stem cell clones 
 
In order to be able to visualise the path that these stem clones were taking within the 
crypts, a novel method of mapping the origin and spread of the mutated blue cell 
populations within the intestinal crypt was devised by combining the two-colour 
enzyme histochemical staining described with image analysis and computer 
reconstruction (see Methods 2.5), using bespoke software written by Dr Paul Tadrous 
(Histopathology Dept, Northwick Park Hospital, Harrow, London) (www.Bialith.com). 
 
Figure 3.5 illustrates the generation of a ‘crypt map’ from multiple serial transverse 
images through the crypt, the resulting crypt maps are 2D images whereby the 3D 
tubular crypt has been cut open and laid flat to fully illustrate the position and path of 
the clone within the crypt. Serial en-face sections were cut at 8, 10 or 12 microns, 
depending on the quality of the frozen tissue. Only crypts that could be traced from the 
base to the surface were used for mapping. During tissue processing occasional sections 
were of poor quality and these were not subsequently used for constructing the maps. 
To map a single crypt from base to top usually required the processing of around 30-40 
serial sections, depending on the size of the crypt. Once the serial frozen sections had 
been stained for CCO-histochemistry and a partially-deficient crypt identified, an 
individual map could be produced within 7 or 8 hours. The image analysis software 
produces three images: (i) unsaturated: the basic crypt map where none of the staining 
hues have been enhanced; (ii) saturated: here the natural staining hues have been 
enhanced; (iii) blue/black; in this image all blue cells remain blue but all non-blue 
staining cells appear black, this enables the origin and spread of the blue cells within the 
crypt to be clearly visualised.  
 
In total, 32 colon crypt maps and 4 small bowel maps were generated from 11 
anonymised patients who had all undergone surgery for either colorectal polyps or 
cancer; fresh frozen morphologically normal tissue was collected from outside the 
resection margins. The mapping software proved very consistent, as there was no 
variation in the appearance of the blue, CCO-deficient clones if the program was run 
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choosing different points along the crypt circumference at which to cut the crypt to 
obtain the 2-D image. 
 
 
Figure 3.5 Generation of crypt map from a partially CCO-deficient crypt 
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3.3.1 Most CCO-deficient clones arise from the accepted area of the 
human colonic stem cell niche 
 
Mapping of stem cell clones from human colonic tissue revealed a variety of different 
patterns of spread of stem cell progeny within colonic crypts. For the majority of clones 
it can clearly be seen that the first mutated cells appear towards the base of the crypt: 
Figure 3.6A-B show mutated clones arising just above the crypt base, expanding 
upwards in a linear fashion through the crypt to reach the top. In Figure 3.6C-E clones 
are shown that arise from right at the bottom of the crypt, in cell position 1. The crypt 
maps shown in Figure 3.6 are representative of most of the colonic stem cell clones 
observed in this study, with the clonal populations arising from the area of putative 
colonic niche, however there is lateral movement of cells as they progress up the crypt 
which is in contrast to what is observed in mouse lineage tracing studies 
19
. 
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Figure 3.6 Crypt maps of human colonic stem cell clones 
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3.3.2 Complex, atypical clones are seen within human colonic crypts 
 
The pattern of clonal expansion was not always linear, as has been previously suggested 
51
, but clones were observed expanding laterally as they migrated up the crypt, with 
significant mixing of cells seen (Figure 3.7A-B). Occasionally clones arising from 
positions outside the accepted location of the stem cell niche were found: In Figure 
3.7C-D, two clones are illustrated that appear to arise from approximately one-third of 
the way up the crypt, well above cell positions 1-3.  
 
A small number of maps have shown what appear to be more than one mutated clone 
arising within the same crypt (Figure 3.8A-B), the blue cells could all be clonally 
related and we are simply seeing varying patterns of cell migration, or they could 
represent separate, independent stem cell clones providing evidence that there are at 
least 3 stem cells in the human colonic niche. Rarely clones that did not appear to reach 
the luminal surface of the crypt were seen (Figure 3.8B-C), and this could indicate the 
existence of more quiescent stem cells within the niche or variable stem cell cycling. 
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Figure 3.7 Colonic clones demonstrate different patterns of expansion within the 
crypt 
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Figure 3.8 Multiple clones within single crypts and apparent relatively static cell 
populations 
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3.3.3 Small bowel crypt maps 
 
The frequency of wholly CCO-deficient crypts observed in the small bowel is 
significantly less than the colon 
79
, and thus finding partially CCO-deficient crypts is 
very rare. Therefore, fewer crypts from the small bowel were able to be mapped. The 
small bowel crypt maps generated and shown in Figure 3.9 appeared to suggest that the 
location of the stem cell niche in the human small intestine may be indeed above the 
basal Paneth cells, around cell position 4-6, as has been suggested by previous mouse 
studies 
20, 26, 175
. 
 
 
Figure 3.9 Human small bowel crypt maps 
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3.4 Discussion 
 
Taylor et al 
76
 first observed that, in elderly patients, a minority of human colon crypts 
appear deficient in the mitochondrially-encoded enzyme cytochrome c oxidase (CCO), 
and upon sequencing the mtDNA of cells from these CCO-deficient crypts they all 
harboured identical, clonal somatic point mutations in their mtDNA; they also noted the 
existence of CCO-deficient populations within crypts. The authors concluded that, since 
these mutations offer no selective advantage, only a stem cell lineage would have 
sufficient life-span to acquire these mutations over many years by genetic drift. This 
mutated stem cell must then stochastically expand within the niche, via niche 
succession, with subsequent monoclonal conversion resulting in all the progeny of that 
stem cell lineage populating the crypt causing it to appear CCO-deficient. These CCO-
deficient crypts are not seen in patients less than 40 years old 
77
, so it is clear that a cell 
lineage would have to have a lifespan of at least 40 years to enable the accumulation of 
these mutations. 
 
In this chapter, it has been shown that, by staining for the activity of CCO and 
sequencing the mtDNA of CCO-deficient and CCO-proficient cells within human colon 
crypts, long-lived clonal cell populations that represent a single stem cell lineage can be 
identified within crypts themselves. Most mtDNA mutations detected were 
homoplasmic i.e. all the mitochondria within the cell harboured the mutation. However, 
the observation of differing heteroplasmic levels of mtDNA mutations within CCO-
deficient and CCO-proficient cells of the same crypt highlights the dynamics of the 
stem cell niche, whereby all stem cell lineages are related but some more recently than 
others. In Figure 3.3, a clonal mtDNA mutation was detectable in both the blue and 
brown stained cell populations, therefore, it appears that after a number of rounds of 
niche succession cycles all stem cell lineages within the niche had acquired this 
mutation to some degree. However, in the stem cell lineage supporting the CCO-
deficient clone, the mutation has drifted to dominance and is at a high enough 
heteroplasmic level to cause a phenotypic CCO-deficiency. In the remaining stem cells 
of the niche, the mutation has remained at low heteroplasmic levels, thus their progeny 
are CCO-proficient. These results support the conclusions by Yatabe et al 
18
 that the 
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human colon stem cell niche contains multiple, related stem cells that undergo 
successive niche succession cycles, whereby a single stem and its direct progeny will 
inevitably come to take over the niche with extinction of all other stem cell lineages. 
The exact number of stem cells within the niche is not known, but technique has clearly 
demonstrated that the human intestinal crypts contain at least two stem cell lineages, 
and by successfully applying mtDNA sequencing for crypts containing two distinct blue 
cell populations, it may be possible to prove the existence of at least three stem cell 
lineages within the human colonic niche. 
 
By applying image analysis software, it was possible to develop a method for 
reconstructing whole crypts containing CCO-deficient putative stem cell clones, in 
order that the origins and path taken by the clones could be fully visualised. The crypt 
maps in Figure 3.6 are representative of the vast majority of clones seen, indicating that, 
in the human colon, cells capable of forming sustained clones are present in cell 
positions 1-3 in the crypt, which corresponds to the current accepted site of the stem cell 
niche in the human colon. Clones were occasionally observed arising from 
approximately one-third of the way up the crypt, well above cell positions 1-3; these 
could represent mutated stem cell clones that are being flushed from the niche by clonal 
succession, or equally it could represent a mutation occurring in a long-lived committed 
progenitor cell.  Indeed, by marking random intestinal epithelial cells by somatic 
mutation of the Dlb-1 locus in mice, Bjerknes and Cheng 
17
 were able to demonstrate 
short-lived (days) progenitors yielding one or two cell types and long-lived (months) 
mucous cell progenitors and columnar (enterocyte) cell progenitors, as well as 
multipotential stem cells capable of giving rise to all epithelial cell types. Consequently, 
it is quite possible that the clones in Figure 3.7C-D represent a mutation in a committed 
mucous or columnar cell progenitor located in the mid-crypt, a proposal that could be 
tested by lineage analysis of the cells within these rare, atypical clones.  
 
The progression of the progeny of stem cells from the base of the crypt to the luminal 
surface is generally thought to occur in a simple, straight, linear fashion, as this has 
been observed in mice 
19, 20, 51
. However, crypt maps of CCO-deficient clones in human 
intestinal crypts have shown that clones arising from the base of a crypt can take a 
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variety of paths to the luminal surface, with some seen to take a diagonal route, and 
there can be significant lateral movement of cells as they move up the crypt, resulting in 
mixing of progeny from different stem cell lineages. This may be a consequence of 
greater dynamic physical forces upon cells within the human crypt, due to the increased 
numbers of cells compared to murine crypts. 
 
Mapping of putative stem cell clones in the human small intestine suggests that the stem 
cell niche may indeed be around cell position 4, above the basal Paneth cells as has 
been identified in many murine studies 
20, 26, 175
. The idea that the structure and biology 
of the niche may differ as one progresses from the small to the large bowel would be 
consistent with observed clinical phenomenon. Adenocarcinoma is very rare in the 
small intestine, yet the third commonest cause of cancer worldwide in the colon, with 
left sided colorectal cancer more common than proximal adenocarcinoma. Thus, it may 
be that this reflects the differing stem cell biology: clonal stabilisation times in the 
murine intestine are 4 weeks for the colon and 21 weeks for the small intestine 
respectively 
10
, and mutated CCO-deficient clones and crypts are much more frequently 
detected in the human colon versus small bowel 
79
 which may be due to their being 
significantly greater numbers of stem cells within the small bowel niche. A tumorigenic 
stem cell within a colonic stem cell niche with fewer stem cells would have less 
competition, and thus it would potentially be easier for it to take over the niche and 
become fixed within the crypt. 
 
The mtDNA mutations observed in CCO-deficient clones were not always the obvious 
cause of CCO-deficiency, often being outside of the genes encoding for CCO and 
occasionally in the non-coding control region. However transcription of the mtDNA is 
not well characterised and is very different to nuclear DNA. The mitochondrial genome 
is circular and transcription, once initiated by the binding of transcription factors within 
the control region, occurs uninterrupted 
173
, thus mutations anywhere within the genome 
can have downstream effects. The epigenetic regulation of mtDNA transcription is also 
not well understood, the clonal mutation seen in the crypt in Figure 3.4, a T>C within 
the control region at position 152, may well have predisposed to a second, clonal 
epigenetic change that caused the CCO-deficiency within the blue cell population of the 
Chapter 3. Mapping stem cell clones in human intestinal crypts 
 100 
crypt. It is also possible that, when no clonal mtDNA mutations were detected, there 
may have been a mutation in the nuclear genome involving other proteins that regulate 
mtDNA replication and transcription, or form part of complex IV in the respiratory 
chain, as suggested by Taylor et al 
76
. 
 
?
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Chapter 4. Delineating human colonic stem cell 
clones  
 
4.1 Introduction and aims 
 
The results from the previous chapter established a technique for identifying and 
mapping a single stem cell lineage and their direct progeny within crypts. The ‘gold-
standard’ for identifying stem cell populations is demonstrating their multi-lineage 
potential in addition to self-renewal 
176
, and this has been established in recent mouse 
lineage tracing studies of the intestine 
19, 20
. These elegant techniques employed in 
genetically engineering mice obviously cannot be used in humans, therefore the aim of 
this project was to phenotype CCO-deficient clones within human colon crypts in order 
to demonstrate multi-lineage potential.  
 
4.2 Proteomic studies 
 
It was hypothesised that mass spectrometry analysis for lineage-specific proteins might 
enable gene expression analysis of CCO-deficient clones within crypts. A protocol was 
developed, in collaboration with the Proteomics laboratory at The London Research 
Institute, Cancer Research UK, using matrix-assisted laser desorption ionisation mass 
spectrometry analysis (MALDI-MS) (see Methods 2.9). In order to first assess whether 
the technique was sensitive enough to enable analysis of protein expression from crypts 
stained for CCO activity, 10 and 5 whole crypts were micro-dissected for proteomic 
analysis. Only CCO-deficient
 
crypts were micro-dissected as the diaminobenzadine 
(DAB) stain in CCO-proficient cells interferes with MALDI-MS analysis (Figure 4.1). 
No SDH counter-stain was performed in order to prevent interference with the MALDI-
MS analysis, and CCO-deficient crypts were therefore identified by the absence of 
DAB (brown) staining (Figure 4.1A-B). 
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Figure 4.1 LCMD of whole CCO-deficient crypts for MS analysis 
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Tubes containing 10 and 5 whole crypts underwent MALDI-MS analysis as per the 
protocol detailed in Methods 2.9. Unfortunately, no peptides could be detected on 
digests of multiple crypts, so no further studies were carried out since the technique 
would not be sensitive enough to analyse CCO-deficient clones within individual 
crypts. 
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4.3 RT-PCR for lineage markers 
 
Another technique to phenotype cells is to use mRNA transcription as a proxy marker 
for protein expression. RNA extraction and RT-PCR protocols were designed, 
optimised and performed on whole crypts that had been stained for CCO-activity (see 
Methods 2.8). Extracting RNA from frozen tissue presents many more problems than 
that for DNA, since exposure to the aqueous phase activates endogenous RNAses that 
rapidly degrade intracellular RNA. The CCO-histochemistry protocol was therefore 
shortened, in order to limit exposure to the aqueous phase, by omitting the SDH 
counter-stain that turns CCO-deficient cells blue. Nested PCR primers specific for the 
mRNA of the following lineage specific markers were designed: the brush border 
proteins villin and CD10 (enterocytes - absorptive lineage); Mucin glycoprotein 2 
(MUC-2) (goblet cells – secretory lineage); Chromogranin-A (enteroendocrine cells – 
secretory lineage). In order to provide control complementary DNA (cDNA) with which 
to optimise the PCR protocols, a small piece of fresh frozen human colonic mucosa was 
Trizol
®
 digested and cDNA synthesised as detailed in Methods 2.8. 
 
Figure 4.2A demonstrates an agarose gel from an RT-PCR for villin, MUC-2, CD10 
and chromogranin A mRNA using Trizol
®
 digested human colon cDNA of varying 
dilutions. Clear, strong bands of the appropriate size were seen for villin, MUC-2 and 
chromogranin-A (Figure 4.2A). The RT-PCR products were then sequenced and found 
to be specific for the respective target mRNA sequences. To test the sensitivity of the 
technique for individual crypts, whole CCO-proficient
 
and CCO-deficient crypts were 
micro-dissected, followed by RNA extraction and RT-PCR. Unfortunately mRNA for 
villin, MUC-2 and chromogranin-A could not be consistently amplified from individual 
colon crypts (Figure 4.2B), therefore the technique was not considered sensitive or 
reliable enough for determining cell lineages within CCO-deficient clones. 
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Figure 4.2 RT-PCR results for control cDNA and individual colon crypts 
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4.4 Immunohistochemistry and immunofluorescence of CCO-
deficient clones for lineage markers 
 
Most cells within the colonic crypt are derived either from the absorptive (enterocytes) 
or secretory lineages (goblet cells and enteroendocrine cells); Paneth cells are only 
occasionally found in the right colon. Therefore immunohistochemical and 
immunofluorescent staining protocols were designed to combine identification of CCO-
deficient clones within crypts, with lineage labelling for the absorptive and secretory 
lineages (see Methods 2.6) in order to demonstrate multi-lineage potential.  
 
4.4.1 Immunofluorescence for MUC-2 reliably identifies goblet cells of the 
secretory lineage in the human colon crypt 
 
The predominant secretory cell type of colon crypts is the mucin glycoprotein 
producing goblet cell. Therefore immunofluorescence (IF) using an antibody against 
Mucin-2 (MUC-2), which is specific to intestinal epithelial goblet cells, was used as a 
proxy marker for the secretory cell lineage in crypts (See Methods 2.6.2). 
 
Figure 4.3 illustrates MUC-2 IF performed on normal human colon crypts using both 
FFPE and fresh frozen tissue, as detailed in Methods 2.6.2; staining is specific for 
goblet cells, which are easily identified by their intra-cytoplasmic vacuoles. 
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Figure 4.3 Mucin-2 (MUC-2) staining of normal human colon crypts 
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4.4.2 Immunofluorescence for carbonic anhydrase II (CA-II) reliably 
marks cells of the absorptive lineage in human intestinal crypts 
 
Production of the protein Carbonic Anhydrase II (CA-II) has been previously shown to 
be specific for progenitor cells committed to the absorptive lineage and differentiated 
enterocytes of the intestine 
177, 178
. In order to validate this antibody, 
immunofluorescence was performed on human small intestine using CD10, known to 
specifically mark the brush border of small bowel enterocytes, as a positive control 
(Figure 4.4A-B). CA-II demonstrated a similar staining pattern to CD10 in the human 
small bowel (Figure 4.4C-D), specifically marking the differentiated enterocytes of the 
villi. In the human colonic crypt CA-II staining was again specific for non-goblet cells 
(Figure 4.5A-D), marking cells from the mid-crypt consistent with when progenitor 
cells become committed to an absorptive lineage, as validated by previous authors 
177, 
178
. Therefore CA-II staining was used as a proxy marker for the absorptive cell lineage 
in colon crypts. 
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Figure 4.4 Carbonic Anhydrase II (CA-II) staining of normal human small bowel 
crypts 
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Figure 4.5 CA-II staining of FFPE and fresh frozen normal human colon crypts 
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4.4.3 Immunofluorescence demonstrates multi-lineage potential of CCO-
deficient crypts and CCO-deficient clones 
 
Immunohistochemistry for cytochrome c oxidase subunit I, encoded for by the 
mitochondrial genome, has been shown to reliably detect CCO-deficient crypts and 
correspond with the absence of CCO enzyme activity 
76
. Therefore, triple 
immunofluorescence for CCO-subunit I, MUC-2 and CA-II was performed on serial 
sections of normal FFPE tissue, in order to identify cells of the secretory and absorptive 
lineage in wholly and partially CCO-deficient crypts (see Methods 1.6.2). Figures 4.6-
4.8 demonstrate single and patches of CCO-deficient crypts that stained positively for 
both MUC-2 and CA-II, confirming that CCO-deficient crypts contain cells of both 
lineages and appear otherwise identical to adjacent wild-type, CCO-proficient crypts. 
 
In addition, as with enzyme histochemistry, CCO-deficient areas were identified within 
crypts (Figures 4.9A and 4.10A). These CCO-deficient cell populations clearly stained 
for cells of both the secretory and absorptive lineage (Figure 4.9B-D and Figure 4.10B-
D), with no difference in staining patterns observed compared to the CCO-proficient 
areas within the partially-deficient crypts or adjacent wild-type crypts. 
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Figure 4.6 CCO-deficient crypts contain cells of both the secretory and absorptive 
lineages 
????????? ?????? ???? ????? ????? ??????? ?????? ??????? ??????? ??? ???? ????
??????????????? ??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
?? ??????????????? ?????? ???????? ??????? ? ????? ?????? ??? ????? ???? ???? ??????? ?????
?????????????????????????????????????????????????????????????????????????????????
???????????? ????????????????????????????????????????????????????? ??????????????
Chapter 4. Delineating human colonic stem cell clones 
 112 
?
Figure 4.7 Patches of CCO-deficient crypts contain cells of both the secretory and 
absorptive lineages (1) 
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Figure 4.8 Patches of CCO-deficient crypts contain cells of both the secretory and 
absorptive lineages (2) 
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Figure 4.9 CCO-deficient cell populations within crypts contain both secretory and 
absorptive lineages (1) 
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Figure 4.10 CCO-deficient cell populations within crypts contain both secretory 
and absorptive lineages (2) 
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Traditionally, immunohistochemistry and immunofluorescence is best performed on 
FFPE tissue, as the anatomy is better preserved and thus the staining of much better 
quality; however, enzyme histochemistry for CCO-activity to identify CCO-deficient 
clones within crypts can only be done on fresh frozen tissue. Thus, alternate serial 
sections of normal human frozen colon were stained for CCO-histochemistry in order to 
identify partially CCO-deficient crypts containing putative CCO-deficient stem cell 
clones (Figure 4.11A and Figure 4.12A and 4.12C). Once a partial crypt was identified, 
the intervening sections were stained using dual immunofluorescence for MUC-2 to 
mark the secretory cell lineage and CA-II to mark the absorptive cell lineage. CCO-
deficient clones again demonstrated staining for both cell lineages (Figure 4.11B and 
Figure 4.12B), as seen with FFPE tissue. 
 
 
 
 
 
 
Chapter 4. Delineating human colonic stem cell clones 
 117 
 
Figure 4.11 Combined CCO-histochemistry and immunofluorescence confirms 
CCO-deficient populations within human colon crypts contain cells of both the 
secretory and absorptive lineages (1) 
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Figure 4.12 Combined CCO-histochemistry and immunofluorescence confirms 
CCO-deficient populations within human colon crypts contain cells of both the 
secretory and absorptive lineages (2) 
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4.5 In-situ hybridisation for the stem cell marker LGR5 
identifies basal stem cells within CCO-deficient and wild-
type crypts 
 
Expression of the Wnt target gene LGR5 has been shown to be a reliable marker of 
colonic stem cells in mice 
19
. In order to demonstrate that CCO-deficient crypts contain 
stem cells at the base and are no different to CCO-proficient, wild-type crypts, in situ 
hybridisation (ISH) for LGR5 mRNA was performed on serial sections of FFPE normal 
human colon (see Methods 2.7), with immunohistochemistry for cytochrome c oxidase 
subunit I on intervening alternate serial sections. ISH does not work well on fresh 
frozen tissue due to the activation of endogenous RNAses and disruption of the 
anatomy as a result of the multiple digestion steps. In Figure 4.13, both wild-type and a 
CCO-deficient crypt can be seen to exhibit similar signal for LGR5 mRNA that is 
specific to the crypt base and the area of the putative stem cell niche. 
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Figure 4.13 CCO-deficient and CCO-proficient human colon crypts contain basal 
stem cells 
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Figure 4.14 CCO-deficient cell populations within crypts are multi-potential and 
stain for stem cells at the crypt base 
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In order to identify partially CCO-deficient crypts containing multi-potential putative 
stem cell clones, triple IF for MUC-2 and CA-II was performed on FFPE normal human 
colon as previously (Figure 4.14A-D). ISH for LGR5 mRNA performed on intervening 
serial sections marked the stem cell population at the base of CCO-deficient clones, 
with no difference observed between the remaining CCO-proficient cells within the 
crypt or adjacent wild-type crypts (Figure 4.14E-F). The background ISH staining, 
representing low-level LGR5 expression and non-specific binding of the riboprobe, is 
high in Figure 4.14, however a high intensity signal specific to the crypt base can 
clearly be seen in both the bright and dark-field images. 
 
4.6 Discussion 
 
Previous studies have shown that all cells within CCO-deficient crypts harbour 
identical, clonal somatic point mutations in their mtDNA as a result of their 
accumulation in stem cells 
76
, and that patches of adjacent CCO-deficient crypts contain 
identical mutations in their mtDNA 
77
. The minimal odds of this occurring by chance 
are ?2.48 x109:1, thus this can only be the consequence of crypt fission. In Chapter 3, it 
has been shown that CCO-deficient cell populations within crypts represent the progeny 
of a single stem cell lineage, since all CCO-deficient cells harbour clonal mutations in 
their mtDNA, not present in the remaining CCO-proficient, wild-type cells of the same 
crypt. However, are the CCO-deficient cell populations behaving normally? More 
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recent studies demonstrating the clonality of CCO-deficient glands in the human small 
intestine and human stomach 
78, 79
 have shown that CCO-deficient glands here do 
contain all the expected differentiated cell types. Noteboom et al 
82
 have shown there to 
be a small but significant decrease in the proliferative index in human colonic CCO-
deficient crypts versus wild-type crypts (average decease 16% as measured by Ki-67) 
and increase in the apoptotic frequency in colonic CCO-deficient cells (0.33%) versus 
CCO-proficient cells (0.29%). However, there is now direct evidence to show that 
significant respiratory chain defects are neutral and do not adversely affect epithelial 
stem cells: Baris et al 
179
 selectively ablated the respiratory chain in epidermal 
progenitor stem cells and did not find any alteration in differentiated cell types, 
proliferation or apoptotic indices, despite there being a complete absence of respiratory 
chain complexes. 
 
The results of the IF studies presented in Figures 4.6-4.8 demonstrate that individual 
and patches of wholly CCO-deficient crypts contain both secretory and absorptive 
lineages, and that staining patterns are no different to that of adjacent wild-type, CCO-
proficient crypts. Again, when studying CCO-deficient cell populations within crypts, 
using triple IF and IF combined with CCO-histochemistry, both cell lineages are clearly 
seen, with similar staining patterns to that of the wild-type cells within the crypt 
(Figures 4.9-4.12). Thus, CCO-deficiency does not appear to alter the cell population 
within human colon crypts, and the progeny of distinct CCO-deficient clones within 
colon crypts have multi-lineage potential. 
 
The Wnt target gene LGR5 has been shown to be a robust intestinal stem cell marker in 
mice in both the small and large intestine 
19
 and is analogous in humans. In–situ 
hybridisation (ISH) for LRG5 mRNA was specific for the base of the crypts in both 
CCO-deficient and CCO-proficient crypts (Figure 4.13), supporting this as the location 
of the stem cell niche in human colon crypts. Unfortunately, no small bowel tissue was 
available for analysis. Furthermore, LGR5 ISH also marked putative stem cells at the 
base of CCO-deficient clones within crypts (Figure 4.14), with no difference in signal 
Chapter 4. Delineating human colonic stem cell clones 
 124 
observed between the two populations, again suggesting that CCO-deficiency does not 
alter the stem cell architecture. There is evidence that the intestinal stem cell niche is a 
heterogeneous population: Montogomery et al 
29
 identified mTert expression as marking 
multipotent, long-lived stem cells, distinct to the Lgr5+ population, in both the mouse 
small bowel and colon, thus further work using a panel of putative stem cell markers on 
CCO-deficient stem cell clones in both the small and large bowel might give insights 
into whether distinct sub-populations of stem cells exist within the human intestinal 
niche. 
 
In summary, the results from this chapter demonstrate that, not only are human colonic 
CCO-deficient clones the progeny of a single stem cell lineage within the crypt, they 
contain both committed secretory and absorptive cells, thus proving their multi-lineage 
potential and fulfilling the criteria for identifying these as stem cell clones. The niche, 
as identified by ISH for the putative intestinal stem cell marker LGR5, is at the base of 
human colonic crypts, consistent with observations from mouse lineage tracing studies 
19, 29
. 
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Chapter 5. Clonal expansion of normal human 
colonic crypts 
 
5.1 Introduction and aims 
 
Stem cell dynamics in human epithelial tissues, such as the colonic crypt, remain 
uncertain, due to the inherent limitations of using human tissue. However, methylation 
patterns of non-expressed genes at CpG island loci offer a serendipitous means to study 
dynamics and infer rates of clonal expansion in human tissues 
18, 45, 168
 (see Introduction 
1.1.3). Methylation at these CpG loci is somatically inherited, and the CpG islands are 
initially un-methylated in the zygote but acquire de-novo methylation stochastically at 
mitosis.  Therefore, comparison of the methylation patterns between two cells should 
reveal their clonal relation: cells with a recent common ancestor should have similar 
methylation patterns whereas unrelated, or more distantly related cells, are unlikely to 
share similar patterns of methylation. This makes methylation patterns an attractive 
means to study the ancestry and dynamics of cells within the human body, without the 
need for invasive labelling techniques. 
 
The aim of this project was to study the methylation patterns at these CpG islands of 
clonal, CCO-deficient cell populations in the colonic mucosa, in order to investigate the 
dynamics of the colonic stem cell and rates of clonal expansion. It was hypothesised 
that (i) analysis of the methylation patterns of CCO-deficient clones within crypts 
would enable the dynamics of niche succession to be estimated, and (ii) by comparing 
methylation patterns of adjacent, wholly CCO-deficient crypts, previously shown to be 
clonally derived by fission 
77
, with unrelated CCO-proficient crypts, the dynamics of 
clonal expansion in the normal epithelium could be investigated. 
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Tissue was collected from 9 patients who were undergoing surgery for either a 
colorectal polyp or cancer (see Appendix 9.4), and morphologically normal tissue was 
obtained from outside the resection margins of the polyp or cancer. 
5.2 Validation of methylation methods in human colon crypts 
 
The CpG loci studied, within non-expressed genes, were the same as those used by 
previous studies to analyse human colon crypt stem cell dynamics: (i) CSX: Cardiac 
specific homeobox, expressed specifically during the differentiation of cardiac 
myocytes; (ii) MYOD1: Myoblast determination protein-1, specifically expressed during 
myoblast differentiation; (iii) BGN: Biglycan, an X-chromosome cellular matrix 
proteglycan expressed in connective tissue. The CSX, MYOD1 and BGN CpG islands 
have eight, five and ten CpG sites respectively, and are located in the coding sequence 
of these non-expressed genes. PCR amplification of bisulphite-treated DNA using 
methylation specific primers followed by cloning of individual PCR strands allows the 
methylation status of each gene-specific CpG island for a defined cell population – an 
individual crypt or clones within crypts - to be sampled (see Methods 2.10 & Figure 
5.1A-B). This can then be represented as a binary code termed a methylation tag, where 
‘1’ represents a methylated CpG site and ‘0’ an un-methylated CpG site (Figure 5.1C). 
Similarly, the methylation tags are also represented visually whereby a methylated CpG 
site is marked with a filled circle, and un-methylated CpG site by an un-filled circle 
(Figure 5.1D). 
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Figure 5.1 Bisulphite treatment allows the methylation status of gene-specific CpG 
islands to be sampled 
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Since very small amounts of DNA were being bisulphite-treated when micro-dissecting 
clones from within crypts, sometimes perhaps only 400-500 cells, the ability of the 
assay to reliably measure methylation pattern diversity in small clonal populations was 
tested.  Following DNA extraction of the clone or crypt, the DNA lysate was split into 
two aliquots and each was subjected to independent bisulphite-sequencing analysis. The 
two aliquots always produced near-identical methylation patterns (Figure 5.2A-D), 
confirming the sensitivity and reliability of the assay. Further, exhaustive cloning 
analysis showed that the summary statistics: the percent methylation and intra-crypt 
distance, were largely independent of the number of methylation tags analysed per crypt 
(Figure 5.3A-F), whereas the number of unique tags per crypt increased asymptotically 
with clone number (Figure 5.3G-I).  These results are consistent with the validation of 
these techniques performed by previous authors 
18
, and demonstrated that the accuracy 
of the summary statistics are not significantly improved if more than 8 cloned PCR 
products are successfully sequenced. 
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Figure 5.2 Sensitivity of clonal bisulphite sequencing assay 
???? ???????? ??? ???? ?????? ??? ??????? ?????????? ??????? ?????? ??????? ???????????? ????
??????????? ??? ?????????? ???? ??????? ?????? ???????????? ??????????? ???? ???? ???????
???????????? ??? ??????????? ?????? ???? ????????? ???? ???? ???????? ????????? ?????
?????????? ????????? ??????????? ???? ???????????? ??? ???? ??????? ???? ???????????? ?????
????????????????????????????????????????????????????????????????????????????????????
????????? ?????? ???????? ???????? ?????????? ?????????????? ?????? ????? ????????? ??? ??
???????????????????????????????? ???????????????????
 
Chapter 5. Stem cell dynamics of normal human colonic crypts 
 130 
 
Figure 5.3 Cloning sufficiency 
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5.3 Stem cell dynamics are unaltered by CCO-deficiency 
 
In order to demonstrate that the stem cell dynamics of CCO-deficient crypts were no 
different to wild-type, CCO-proficient crypts, statistical analysis of crypt methylation 
tags comparing blue and brown crypts was performed. The percent methylation - a 
proxy for the mitotic age of the crypt stem cells, showed no significant difference 
between CCO-proficient and CCO-deficient crypts (Figure 5.4A-C), indicating that 
CCO-deficient crypts were derived from stem cells with the same mitotic age as wild-
type crypts.  Intra-crypt distance and the number of unique tags per crypt reflect stem 
cell number and tendency for stem cells to divide asymmetrically: no significant 
difference was seen between CCO-proficient and CCO-deficient crypts for either 
statistic (Figure 5.4D-I), confirming stem cell dynamics were unaltered by CCO-
deficiency. 
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Figure 5.4 Epigenetic comparison of CCO-deficient and CCO-proficient crypts 
???? ?? ??????????????????? ???????????????????????????? ???? ??????? ??? ??????? ?????
???????????????? ??????????????????????????????????????????????????????????????
??????? ??????? ??? ????? ??? ???? ?????? ???? ???????? ?????????? ??????????? ???????????
???????????????????????????????????????????????????? ?????????????????????? ??????
?????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ??????????????????????
??????????????????????????????????????????????????????????????????????????????
??? ????????????????????????????????????????
?
?
?
?
Chapter 5. Stem cell dynamics of normal human colonic crypts 
 133 
5.4 Analysis of methylation patterns of colonic stem cell 
clones gives insights into niche dynamics 
 
En-face serial sections of fresh frozen human colonic mucosa were stained for CCO 
activity and partially-deficient crypts were identified, genotyped and mapped as detailed 
previously (see Methods 2.4-2.5 and Chapter 3).  The clonal, blue CCO-deficient cells 
and remaining brown, wild-type cell populations within the crypt were then separately 
laser capture micro-dissected (LCMD) and the methylation patterns at CpG islands of 
non-expressed genes of the two distinct cell populations sampled (see Methods 2.10).  
Clones of varying sizes within the crypt were sought in order to reflect different stages 
of clonal expansion and thus stem cell niche succession within the crypt. Statistical 
analysis was then performed (see Methods 2.11) to compare the methylation patterns of 
the clonal blue cells to the brown, wild-type population of the crypt, with clone size 
used as a measure of the time interval since formation of the clone: small clones were 
assumed to be newly formed.  
 
Figure 5.5 illustrates a clone within a crypt where, after staining for CCO-activity, the 
mitochondrial genome of the blue cells was sequenced to confirm clonality (Figure 
5.5A). The serial sections of the crypt were then photographed and a crypt map 
constructed (Figure 5.5B). Blue cells were then separately LCMD from the brown cells 
on each serial section (Figure 5.5C) and the methylation patterns at the CpG island of 
the non-expressed CSX gene sampled (Figure 5.5D). Mapping of the clones also allows 
the size of the clone within the crypt to be accurately measured by analysing the number 
of blue versus non-blue/black pixels in the crypt map. In this case the blue clone 
occupied 23% of the total crypt and had a relatively conserved methylation pattern at 
the CSX locus, with an intra-clone distance of only 0.36 compared to an intra-clone 
distance of 3 for the brown, wild-type cells within the crypt (Figure 5.5D), with only 
two distinct methylation tags detectable in the blue cells versus 4 in the brown cell 
population. 
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Figure 5.5 CCO-histochemistry enables dynamics of stem cell clones within crypts 
to be analysed 
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It was found that small CCO-deficient clones, which occupied less than one third of the 
crypt, had conserved methylation patterns, whereas the remaining wild-type population 
had diverse methylation patterns (Figure 5.6A-C) when analysing the intra-clone 
distance. However larger clones within crypts tended to have more diverse methylation 
patterns with intra-clone distances comparable to that of the wild-type population 
(Figure 5.6D): note that even when the brown cell population occupies only a small 
proportion of the crypt (< 30%), multiple distinct methylation tags are still picked up 
(Figure 5.7E-F), proving that the technique is sensitive enough to detect methylation tag 
diversity in very small cell populations.  
 
Statistical analysis was then performed to look at the variance of methylation tags of 
clones as a function of the size of the clone within the crypt, in order to be able to infer 
the approximate time course of clonal expansion within the crypt, and hence the rate of 
niche succession. The intra-clone distance is a measure of the average similarity of all 
methylation tags within the CCO-deficient clone or wild-type cell populations of the 
crypt, and number of unique tags seen in a defined cell population is another measure of 
epigenetic diversity (see Methods 2.11). There was a general trend for more epigenetic 
diversity with larger clone size (Figure 5.7C-F) for CSX and MYOD1, significant for 
CSX (p<0.003) when looking at the most sensitive marker – the intra-clone distance; 
given the low rate of de-novo methylation, this increase in methylation pattern diversity 
with clone size indicates a low rate of niche succession in human colon crypts of many 
years. Again, importantly, the same trend was not seen when looking at the methylation 
tags of the brown, wild-type cells within the crypts (Figure 5.7C-F). 
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Figure 5.6 Methylation diversity increases with increasing clone size 
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Figure 5.7 Statistical analysis of methylation tags of clones as a function of size 
within the crypt 
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5.5 Dynamics of crypt fission in human colonic epithelium 
 
It had been previously demonstrated that patches of adjacent CCO-deficient crypts are 
clonally derived from an ancestral CCO-deficient crypt that has undergone fission 
77
.  
Thus, by then analysing the methylation tags of crypts that have undergone fission, it 
was hypothesised that the dynamics of this important mechanism of clonal expansion 
could be explored.  
 
In Figure 5.8 LCMD and mtDNA sequencing of a patch of two adjacent CCO-deficient 
crypts demonstrates the presence of the same, clonal mtDNA point mutation in both 
crypts, confirming that they are clonally derived by fission (Figure 5.8A-B).  However, 
these crypts have different, distinct methylation patterns (Figure 5.8C).  Similarly in 
other patients, patches of adjacent CCO-deficient and therefore clonally-derived crypts 
had dissimilar methylation patterns, and similarity appeared independent of CCO-
deficiency (Figure 5.8D-E).  The minimum distance between the methylation patterns of 
two crypts, which compares each methylation tag in the first crypt to only its most 
similar methylation tag in the second crypt, indicates the epigenetic similarity between 
crypts.  The minimum distance of adjacent CCO-deficient crypts were comparable to 
the distance between any pair of CCO-proficient
 
crypts within the same colon for all 
loci studied (Figure 5.9D-F), indicating that adjacent CCO-deficient crypts appear as 
epigenetically unrelated as any other pair of random crypts sampled.  The inter-crypt 
distance, which measures the average similarity of all methylation patterns in the first 
crypt to all the methylation patterns in the second crypt, did indicate that the CSX 
methylation patterns were more similar in adjacent CCO
- 
crypts (p=0.001) (Figure 
5.9B).  However, no significant difference was observed at the MYOD1 locus (p=0.8) 
and the converse relation was seen for BGN tags (p=0.007) (Figure 5.9A & C).  In 
addition, although the means for the inter-crypt distance at CSX were significantly 
different, there was a wide standard deviation. 
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Therefore, the clonal relation indicated by adjacent crypts both having CCO-deficiency 
was not mirrored by increased similarity of the methylation patterns of the crypts across 
all the loci analysed. As the rate of change in the methylation status at CpG sites is very 
low, thought to occur only every 1:200,000 cell divisions 
18
, the data suggests that crypt 
fission events occur infrequently in the normal colon and there are sufficient years 
between fission events for the methylation patterns to diverge. 
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Figure 5.8 Adjacent crypts have different methylation patterns irrespective of 
their clonal relation 
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Figure 5.9 Methylation patterns of crypts that have undergone fission do not 
reflect crypt ancestry 
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5.5.1 Stem cell segregation during crypt fission causes methylation 
pattern divergence 
 
Using en-face serial sections from patient 6, stained for CCO activity, partially-mutated 
bifurcating crypts were observed (Figure 5.10). Sections towards the crypt base 
revealed that one arm was CCO-deficient whilst the other was CCO-proficient, 
demonstrating that the segregation of stem cells at fission could result in the production 
of phenotypically distinct daughter crypts.  Cells from the two arms where then 
separately micro-dissected and their methylation patterns compared.  The CCO-
proficient and CCO-deficient arms of each bifurcating crypt showed distinct patterns of 
methylation, indicating that segregation of stem cells during fission could result in 
daughter crypts with very different patterns of methylation (Figure 5.10A-B).  The 
inter-crypt distances between the two arms of the bifurcating crypt were comparable to 
the inter-crypt distance between two unrelated crypts (A: MYOD1 = 2.13; B: CSX = 
3.95, MYOD1 = 1.92).  Notably, in Figure 5.10B, the CSX patterns of the two arms were 
very different, whereas the MYOD1 patterns were similar, suggesting the stem cells in 
the ancestral crypt had homogeneous patterns of MYOD1 methylation but 
heterogeneous CSX methylation. 
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Figure 5.10 Segregation of stem cells at crypt fission causes rapid divergence of 
methylation patterns 
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5.5.2 Mathematically modelling suggests there is at least 10 years 
between crypt fission events 
 
A mathematical model of crypt stem cell methylation pattern dynamics was developed 
to assess how methylation patterns would diverge over time following fission, and the 
likely upper and lower time intervals between fission events that would result in patches 
of crypts clonally derived by fission appearing dissimilar. In their seminal paper, Yatabe 
et al 
18
 designed a mathematical model of crypt stem cell dynamics that was consistent 
with the methylation data at the CSX, MYOD1 and BGN loci for normal individual 
human crypts. The Yatabe model was adapted in conjunction with Dr Trevor Graham 
(London Research Institute, Cancer Research UK) in order to assess crypt fission 
dynamics, further incorporating the potential effects of asymmetrical segregation of 
stem cells at fission. 
 
The model was designed to investigate the rate of methylation pattern divergence in 
crypts dividing by fission. Crypts were assumed to contain exactly N synchronously 
dividing stem cells that tended to divide asymmetrically (probability p1=0.95).  Each 
stem cell had M CpG sites susceptible to methylation errors (methylation or de-
methylation) at rate ?=2x10-5 per CpG site per cell division, as used by Yatabe et al 18 
(Figure 5.11A).  During fission at a predetermined time, stem cells were segregated 
between daughter crypts and symmetric divisions were assumed to restore the full stem 
cell compliment.  Stem cells were either segregated symmetrically, whereby N/2 of the 
total stem cells were segregated to each crypt, or asymmetrically whereby a single stem 
cell was inherited by one daughter crypt and the other N-1 cells were placed in the 
second daughter crypt. Simulated daughter crypts with N=8 stem cells and M=8 CpG 
sites showed rapid divergence of methylation their patterns following symmetric fission 
of their parent crypt (Figure 5.11B).  
 
In-silico power calculations were performed to indicate the ability of methylation to 
record ancestry.  The inter-crypt distance between 10 pairs of related crypts was 
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compared to 10 pairs of unrelated crypts using a t-test. Statistical power was 
approximated repeatedly computing the model and counting the proportion of 
comparisons that gave a p-value less than 0.01.  The power fell exponentially as a 
function of the time since crypt fission (Figure 5.11C).  At 10 years post fission, with 
N=8, M=8 bi-allelic loci and symmetric crypt fission, a t-test would show pairs of 
related crypts to have smaller pair-wise inter-crypt distances than unrelated crypts at 
p<0.01 in only around 50% of tests. Asymmetric segregation of stem cells at fission had 
little effect on the ability to discern crypt relatedness. Divergence was slowed if an X-
linked locus was probed (Figure 5.11C). A larger number of CpG sites (M=64) meant 
that daughter crypts were initially distinguishable by their methylation patterns, though 
after 10 years post fission, this record of ancestry was still rapidly lost  (Figure 5.11C). 
 
The mean inter-crypt distance between 8 crypts composing a patch found in a 90-year 
old colon (mean of inter-crypt distances computed between all possible pairs) that had 
formed through fission of ancestral crypts every 25 years was comparable to the mean 
inter crypt distance between 8 unrelated crypts (Figure 5.11D-E).  Simulated power 
calculations suggested that a significant difference between the methylation pattern 
diversity of the eight related crypts to the eight unrelated crypts would be detected by a 
t-test in only 37% of comparisons. Thus a fission rate of once every 25 years would 
result in patches of clonally derived crypts being indistinguishable from random, 
neighbouring crypts by their methylation patterns. 
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Figure 5.11 Crypt fission model of methylation pattern divergence 
?????????????????? ???????????? ?????????????? ??????????????????????????????????
??????? ??? ???? ????? ??????? ? ??????????? ?????????? ????? ?????????? ?????????? ????
???????????????????? ?????????????????????????????????????????????????????? ????????
???????????????????????????? ?????????????????? ????????????????????????????????????
?? ????? ??? ????????? ???? ????? ???? ?????????? ????? ???????????? ????????? ???????? ????
?????????????????????? ??????????????????????????????? ???????????????????????????
????? ?????????? ???????? ?????? ?????? ????????? ?????? ?????????????? ?????????? ??????
????????????????????????????????????????????????????????????????????????????????????
??? ???? ?????????? ???????? ???? ?????????? ?????? ??? ??????? ??? ????? ????? ??? ?????? ???
??????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????? ?????????????????????
????????????????????????????????????????????????????????????? ?????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
????????? ??? ?? ?????????? ???????????? ????????? ??? ???????????????? ????????? ??? ??
??????? ????? ??????? ???????? ????????? ??????? ??? ???????? ??????? ??? ??????? ??? ???
?????????? ??????? ???????? ??????? ??? ?? ?????? ??????? ???????? ?????????????? ??? ??????
??????????????????????????????????????????????
Chapter 5. Stem cell dynamics of normal human colonic crypts 
 149 
Experimental measurements suggest that the methylation error rate of non-expressed 
loci may be as high as ?=0.005, although precise estimates of the methylation error rate 
are locus dependent 
180, 181
.  Using this higher methylation error rate, the simulations 
showed extremely rapid divergence of daughter crypts following fission, and 
concomitant significant reductions in the power of a t-test to distinguish the methylation 
pattern diversity of 8 pairs of related and unrelated crypts. 
 
5.6 Discussion 
 
Individual human CpG sites are estimated to change their methylation status at a low 
rate (approximately 2x10
-5
 per CpG site per cell division) 
18
.  However, CCO-deficient 
clones occupying large areas of a crypt (>50%) showed multiple, distinct methylation 
patterns (Figure 5.6 and Figure 5.7), indicating that niche succession occurs sufficiently 
slowly to permit de-novo methylation, likely over many years.  Direct inferences of the 
niche succession rate from methylation patterns requires a more precise knowledge of 
both the methylation rate and stem cell division rates.  Previous human studies have 
supported the concept that niche succession occurs over many years: the proportion of 
wholly O-acetyltransferase (OAT) defective crypts in radiotherapy treated OAT
-/+
 
individuals increases slowly over 30 years post radiation therapy, indicating OAT
-
 cells 
can take over a decade to reach dominance in some crypts 
74
. 
 
Adjacent CCO-deficient
 
crypts tend to be derived from a single founder crypt that 
undergoes fission in the adult colon 
77
. Despite this recent relationship, adjacent CCO-
deficient
 
crypts usually appeared no more related by their methylation patterns than 
physically disparate crypts (Figure 5.8 and 5.9). Thus the time periods between crypt 
fission events are sufficiently long for methylation patterns of two daughter crypts to 
diverge. This is consistent with the study by Kim et al 
168
 where randomly selected 
adjacent crypts, in the absence of a clonal marker, appeared no more similar by their 
methylation patterns than crypts up to 15cm away. 
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How long is the methylation pattern divergence time of related crypts?  An upper bound 
can be estimated by considering the time elapsed since a patch of related crypts was 
formed.  The patches analysed in this chapter were from patients aged between 68-78 
years at the time of resection.  CCO-deficient crypts are rarely observed in colonic 
mucosa from individuals aged less than 40, therefore we can assume that a patch of two 
CCO-deficient crypts formed as a result of a fission event in the bowel aged more than 
40 years 
77
. This implies that the crypts within a patch are separated by at most 35 years 
from their most recent common ancestor.  However, the mathematical analysis predicts 
a significantly lower bound for the divergence time: even with a low methylation error 
rate, after approximately 10 years the probability of distinguishing ten pairs of related 
crypts from 10 pairs of unrelated crypts has dropped to 0.5 (Figure 5.11), though this 
prediction can be considered no more than an estimate due to the uncertainty about the 
precise methylation error rate. This rapid divergence of methylation patterns is the 
result of stem cell dynamics within the niche and can be exaggerated by stem cell 
segregation at fission. Modelling the methylation patterns of a parent crypt in the zygote 
that has divided by fission every 25 years, demonstrates that a patch of 8 crypts in a 90 
year old would appear no more related by their methylation patterns than a patch of 8 
random, unrelated crypts (Figure 5.11) - consistent with the biological data. Thus, from 
the data collected here it appears that crypt fission in the normal human colon occurs 
with a lower interval of approximately 10 years and an upper interval in the region of 25 
years. 
 
Choice of methylation-susceptible locus also influences ability to infer clonality.  
Notably, in this study, CSX tags appeared to record ancestry more effectively than 
MYOD1 tags: Adjacent CCO-deficient
 
crypts had more similar CSX methylation 
patterns than unrelated crypts, and CSX methylation pattern diversity scaled with clone 
size in partially-mutated crypts, whereas these trends were not observed for MYOD1.  
This differential ability to record ancestry is likely to result from both the locus and 
CpG-site specific (de-)methylation rates.  Perhaps counter-intuitively, simply increasing 
the number of CpG sites probed does not, in the long-term, lead to a decrease in the 
average pair-wise distance between the methylation tags from related crypts, as 
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epigenetic drift through random methylation is more marked when a greater number of 
CpG sites are considered.  Summary statistics to describe methylation pattern diversity 
must also be chosen with care.  For example, sampling more tags from a clone will find 
occasional new methylation patterns (Figure 5.3), which may represent de-novo 
methylation events in the non-stem cell compartment.  Average measures, such as the 
intra-clone distance, are more robust descriptors of methylation pattern diversity. 
 
A rapid change in the phenotype of crypts due to the segregation of cells at fission is a 
process termed clonal purification. Examples of clonal purification have been 
previously observed in the budding crypts of mice with induced somatic mutations of 
the Dlb-1 locus 
17
 and in mutagen treated mice heterozygous for a G6PD mutation 
71
. 
The epigenetic diversity (as measured by the inter-crypt distance) between the two arms 
of crypts in fission was comparable to that of two unrelated crypts (Figure 5.10), this 
could be due to asymmetric stem cell segregation or increased stem cell number or 
cycling within crypts in fission. Kim and Shibata 
168
 observed that, on average, 
methylation patterns of crypts in fission appeared as diverse as the methylation of two 
unrelated crypts, concluding that fission may often disrupt the epigenetic record in 
normal crypts. It has been shown that increased cellular proliferation is not associated 
with increased crypt fission events 
83, 182
, thus the increased diversity between the 
bifurcating arms could be evidence that expansion of the stem cell zone initiates fission 
events in the colon, as has been proposed to explain the increased crypt fission rates 
observed in APC mutated crypts 
83, 85
. It is unclear whether the segregation of the CCO-
deficient portion of the crypt is a random process, these were very rare events and no 
partially-deficient crypts in fission were observed where there was mixed populations of 
cells in the bifurcating arms. 
 
The dynamic nature of methylation patterns severely restricts their use as a clonal 
marker per-se.  However, here clonality has been inferred by the presence of clonal 
point mutations in mtDNA, a robust marker, and the additional analysis of methylation 
patterns of non-expressed genes provide an attractive means to estimate the rates of 
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recent clonal expansions in human tissues. Precise estimates are precluded, however, 
due to the inherent uncertainty over exact cell division and methylation error rates.  
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Chapter 6. Dynamics of human colorectal sporadic 
adenoma initiation and growth 
 
6.1 Introduction and aims 
 
Most of our current data on the dynamics of adenoma growth is based on longitudinal 
endoscopic and barium studies (see Introduction 1.5). These did not look at the detailed 
genetics of the adenomas they were assessing, and observed that adenomas less than 1 
cm appear to be static in their growth, with many demonstrating a tendency to regress. 
 
The aims of this project were to use the techniques developed in the previous chapters 
for assessing clonal expansion in the normal epithelium to investigate, at a microscopic 
and molecular level, the dynamics of adenoma initiation, growth and clonal expansion. 
Crypt fission is thought to be the predominant mechanism by which a mutated crypt can 
clonally expand within the epithelium to form an adenoma 
93
, and it has been shown 
that crypt fission rates are elevated in hyperplastic polyps and adenomas 
94
. If the 
mechanism by which a single mutated stem cell expands within a crypt is niche 
succession, with subsequent monoclonal conversion and crypt fission, it was 
hypothesised that these events would be significantly up-regulated within adenomas to 
enable accelerated clonal expansion. 
 
Previous studies have established that adenoma growth is accompanied by a step-wise 
accumulation of oncogenic mutations over time 
113, 114
, and that genetically distinct sub-
clones can be found within adenomas 
106, 107
. It was thus hypothesised by using both 
mutations in mtDNA and nuclear genes as clonal markers, combined with methylation 
analysis of CpG islands within non-expressed genes, the dynamics of clonal evolution 
within adenomas could be investigated. 
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6.2 Mutation screening and global DNA methylation status 
 
Fresh frozen sporadic human adenomas and polyps were collected as described (See 
Methods 2.1). Only early adenomas with low-grade dysplasia were selected, along with 
hyperplastic polyps, as the crypt structures are relatively maintained and there are less 
confounding factors, such as CIMP, global hypo-methylation or chromosomal 
instability that are found in more advanced adenomas and cancers 
114, 123, 135, 183
. The 
adenomas and polyps were assessed for size and histology, and screened for mutations 
in APC, KRAS, BRAF, TP53 and loss of heterozygosity (LOH) in 5q (APC) and 17p 
(TP53); MSI status was also determined (see Methods 2.12). This was important in 
order that the dynamics could be related to the specific genomic changes and also to try 
to identify those adenomas where it may be possible to define sub-clones with differing 
oncogenic mutations, specifically in KRAS or APC, as has been shown in previous 
studies 
106, 107
. When mutations were detected on screening, this was confirmed on each 
individual crypt before determining the methylation status of the CpG islands in CSX 
and MYOD1. Due to the conflicting results obtained with BGN obtained when looking 
at normal tissue this locus was not used for further analysis. 
 
The commonly mutated areas within the APC, KRAS, BRAF and TP53 genes were 
sequenced by PCR (see Methods 2.12.1-2.12.4), and MSI status determined using a 
multiplex PCR for the BAT25 and BAT26 mononucleotide repeats (see Methods 2.12.5). 
The results are summarised in Table 6.1: 8/9 (88%) adenomas harboured mutations 
within the MCR of the APC gene, and 2/9 (22%) had additional KRAS mutations. A 
possible confounding factor when comparing the methylation status at CpG loci 
between lesions is that increased methylation may be due to global increased 
methylation rates within the adenoma, rather than a difference in dynamics. The CpG 
island methylator phenotype (CIMP) (see Introduction 1.4), a mechanism whereby 
progression of the adenoma is associated with methylation of the promoter regions of a 
number of genes, is closely associated with BRAF mutations and microsatellite 
instability 
135, 146, 147
 (MSI). Therefore all lesions were screened for these, and found to 
be BRAF wild-type and microsatellite stable (MSS) (Table 6.1 and Figure 6.1), thereby 
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making it less likely elevated methylation rates within these adenomas would be 
confounding the results. 
 
Molecular screening Lesion Location, Size 
& Histology 
APC KRAS BRAF TP53 MSI 
Polyp 1 
Patient 10 
Sigmoid colon 
1.1cm;hyperplastic 
WT WT WT WT MSS 
Adenoma 1 
Patient 11 
Ascending colon 
2.2cm;TVA;LGD 
c.4348 C>T            
p.R1450* 
c.35 G>A 
p.G12D 
WT WT MSS 
Adenoma 2 
Patient 12 
Sigmoid colon 
2.2cm;TA;LGD 
c.3964 G>T            
p.E1322* 
WT WT WT MSS 
Adenoma 3 
Patient 13 
Rectum 
1.3cm;TVA;LGD 
c.3956delC         
p.A1299fs*1 
c.38 G>A 
p.G13D 
WT WT MSS 
Adenoma 4 
Patient 14 
Sigmoid colon 
1.2cm;TVA;LGD 
c.4118_4126delCTGAACC 
p.P1371fs*10 
WT WT WT MSS 
Adenoma 5 
Patient 15 
Splenic flexure 
2cm;TVA;LGD 
c.4474_4475delGCinsT 
p.A1492fs*14 
WT WT WT MSS 
Adenoma 6 
Patient 16 
Sigmoid colon 
1.7cm; TVA;LGD 
c.3925_3929delGAAAA 
p.E1309fs*4 
c.35 G>A 
p.G12D 
WT WT NR 
Adenoma 7 
Patient 17 
Sigmoid colon 
1.4cm;TVA;LGD 
WT WT WT WT MSS 
Adenoma 8  
Patient 18 
Sigmoid colon 
1.1cm;TA;LGD 
c.4461_4468delTTTATTAC
p.T1487fs*6 
WT WT WT NR 
Adenoma 9 
Patient 19 
Rectum 
1.2cm;TA;LGD 
c.3927_3931delAAAGA 
p.E1309fs*3 
WT WT WT NR 
Table 6.1 Summary of mutation screening results 
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Figure 6.1 MSI status analysis 
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All lesions were screened for LOH at 5q (APC) and 17p (TP53) using a panel of 
microsatellite markers; the data is summarised in Table 6.2 and examples of the LOH 
analysis demonstrated in Figure 6.2. Mutations in TP53 and 17p LOH tend to occur 
later on in adenoma development, and are associated with the progression to high-grade 
dysplasia and cancer 
113, 114, 144
. All the adenomas in this study were of low-grade 
dysplasia, thus, unsurprisingly no mutations in TP53 or 17p LOH were detected (Table 
6.1 and Table 6.2). Once APC is mutated, LOH of the wild-type allele may the process 
by which function of the second allele is lost 
184
. None of the adenomas demonstrated 
LOH at APC by the markers used here (Table 6.2). It may be that the second hit in APC 
was outside of the MCR, or missed during the analysis, or that the area of LOH was not 
detected by the microsatellite markers. 
LOH marker  
Lesion 
APC 
(5q/D5S346) 
APC  
(5q/D532001) 
APC 
 (5q/D5S489) 
TP53  
(17p/D17S1832) 
Polyp No LOH NI No LOH NI 
Adenoma 1 No LOH No LOH No LOH No LOH 
Adenoma 2 No LOH No LOH No LOH NI 
Adenoma 3 No LOH No LOH No LOH NI 
Adenoma 4 NI No LOH NI NI 
Adenoma 5 NR NR NR NR 
Adenoma 6 NR NR NR NR 
Adenoma 7 No LOH NR NR NR 
Adenoma 8 No LOH No LOH No LOH NI 
Adenoma 9 No LOH No LOH No LOH No LOH 
Table 6.2 Summary of LOH results 
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Figure 6.2 Multiplex PCR LOH analysis 
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In order to further assess the lesions for global hyper-methylation that might potentially 
confound the analysis of CpG islands in adenomas, the methylation status at CpG 
islands of long interspersed nucleotide elements (LINE-1) within genomic DNA, shown 
to be a surrogate marker of global genomic DNA methylation 
135, 149, 172
, was quantified 
in order to see if there was any evidence for genome-wide hyper-methylation within the 
adenomas compared to normal controls (see Methods 2.13). The results are summarised 
in Figure 6.3, importantly there was no significant difference between the mean 
methylation levels across the four LINE-1 CpG sites sampled when comparing normal 
versus adenoma tissue (p=0.591), or between paired adenoma and normal colonic 
mucosal tissue from the same patient (p=0.5469). 
 
 
Figure 6.3 CpG methylation status of LINE-1 elements as measured by 
Pyrosequencing® 
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The adenoma tissue for the LINE-1 analysis was macro-dissected from slides 
containing only adenomatous crypts, and no normal epithelial tissue. In order to check 
whether stromal tissue within the adenoma might be confounding the results, for 
adenoma 2 both a macro-dissected and LCMD sample of adenomatous crypts only were 
run in parallel; the mean methylation level across the four CpG sites was 72.08% for the 
macro-dissected tissue and 72.23% for the LCMD sample, suggesting that any normal 
stromal cells present within the macro-dissected adenoma samples did not significantly 
affect the Pyrosequencing
® 
analysis. 
 
6.3 Large clonal patches that remain similar by their 
methylation patterns can de identified within human 
adenomas and polyps 
 
After staining for CCO-activity, multiple, large patches of CCO-deficient crypts were 
seen within some of the lesions. Laser capture micro-dissection and PCR of the 
mitochondrial genome (see Methods 2.4) was then performed on the blue and 
surrounding brown crypts in order to confirm clonal somatic point mutations in 
mtDNA. Using DNA from the same crypt, methylation patterns at the CpG islands of 
CSX and MYOD1 were determined using clonal bisulphite sequencing and statistical 
analysis, performed as before, in order to infer the dynamics of these clonal expansions 
(see Methods 2.10 and 2.11). 
 
The polyp from patient 10 was a hyperplastic polyp of the goblet cell variety with some 
serrated features. There were 3 distinct CCO-deficient patches that all had differing 
clonal mutations in their mtDNA (Figure 6.4A-E). The whole mitochondrial genome 
was sequenced for blue crypts in each patch in order to confirm that they were indeed 
clonally distinct from each other by their mtDNA; mtDNA of cells from adjacent 
brown, wild-type crypts to each patch was also sequenced. Crypts within adenomas and 
polyps are atypical and often convoluted, therefore each crypt that was LCMD within a 
Chapter 6. Dynamics of human colorectal adenoma initiation and growth 
 161 
patch was carefully followed on serial sections throughout the lesion to ensure that is 
was indeed distinct, and that the same crypt was not simply being micro-dissected on 
multiple occasions. One of the patches harboured four clonal mutations (Figure 6.4C), 
and the patches all contained a large number of clonally related crypts, with at least 6 
crypts per patch. 
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Figure 6.4 Clonally distinct patches within a hyperplastic polyp 
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Patch (E) (Figure 6.4E) from the hyperplastic polyp contained two clonal point 
mutations, but these were present at different heteroplasmic levels within crypts from 
each side of the patch. Figure 6.4E shows sequencing from 6 blue crypts spread across 
the patch, a 16145 G>A mutation was found at high heteroplasmic levels in crypt 1, 
however, progressing across the patch the level of the mutation reduced. In crypt 4 the 
wild-type was seen at high heteroplasmic levels with only a small level of the mutation 
detected, and the mutation could not be detected in crypt 6. Interestingly, the CCO-
deficient crypts 4-6 harboured a separate, homoplasmic clonal mutation within their 
mtDNA (4632 G>A) that was not seen in any of the other crypts within the patch. 
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Figure 6.5 MYOD1 methylation patterns for patch (C) from polyp 1 shown in 
Figure 6.4 
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Figure 6.6 CSX methylation patterns for patch (D) from polyp 1 shown in Figure 
6.4 
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Methylation patterns at CSX and MYODI were highly conserved within blue crypts of 
each of the three clonal, CCO-deficient patches within polyp 1 (Figure 6.5 and Figure 
6.6), compared to adjacent, clonally distinct, CCO-proficient crypts. Pairs of crypts 
within these large, clonally expanded CCO-deficient patches appeared significantly 
more related to each other by their methylation patterns at the CSX locus when 
compared to adjacent brown, wild-type crypts, by both the inter-crypt distance (p=5.25 
x 10
-9
) and minimum distance (p=7.52 x 10
-7
) measurements (Figure 6.7A-B). For the 
MYOD1 locus there was a similar trend but this did not achieve significance (Figure 
6.7C-D): there were less data points collected for the MYOD1 locus, and it appeared to 
be a less sensitive marker than CSX when studying normal crypts (see Chapter 5), likely 
due to differences in site-specific methylation rates. 
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Figure 6.7 Statistical analysis of methylation patterns for all patches within 
hyperplastic polyp from patient 10 (polyp 1) 
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Figure 6.8 and Figure 6.9 show adenoma 2 from patient 12. This was a 2.2cm tubular 
adenoma from the sigmoid colon, displaying low-grade dysplasia (Figure 6.8A). 
Mutation screening of this adenoma revealed a point mutation in APC (c.3964 G>T) 
that resulted in a premature stop codon (p.E1322*), no additional mutations were 
identified and the adenoma was MSS (Table 6.1). Two patches of multiple, blue CCO-
deficient crypts were seen after histochemistry of serial sections (Figure 6.8B), each 
containing at least 10 distinct crypts when followed on serial sections. The two patches 
were seen to become almost continuous on serial sections. LCMD and mtDNA 
sequencing of cells from multiple blue crypts and adjacent brown, wild-type crypts 
demonstrated that all blue crypts shared a common, somatic clonal point mutation in 
their mtDNA (Figure 6.8C-E). 
 
Whole blue and brown crypts were then LCMD for further mutation and methylation 
analysis (Figure 6.9A). Sequencing confirmed the APC mutation was present in all 
crypts sampled, and was thus clonal for the whole adenoma, and that all crypts were 
KRAS wild-type (Figure 6.9B). The methylation patterns at the CSX locus for the 
adenomatous blue crypts within the patches were similar and conserved, being distinct 
from those of random, neighbouring brown crypts within the adenoma (Figure 6.9C). 
Statistical analysis confirmed this, with pairs of adenomatous, clonally-derived blue 
crypts appearing significantly more related by their methylation patterns when assessing 
both the inter-crypt distance (p=1.17 x10
-17
) and minimum distance (p=0.005) (Figure 
6.10A-B). 
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Figure 6.8 Large, clonal patch of CCO-deficient crypts within a human adenoma 
(patient 12) 
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Figure 6.9 Methylation patterns at the CSX locus for crypts within the clonally 
expanded patch from adenoma 2 
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Figure 6.10 Statistical comparison of methylation patterns for blue versus brown 
crypts within adenoma 2 
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6.4 Adenomas clonal for APC and KRAS mutations 
demonstrate significantly less methylation pattern diversity 
 
Whole crypts, spaced at regular intervals throughout adenomas 1, 3, 4, 5 and 6 were 
LCMD from serial sections and their methylation patterns at the CSX and MYOD1 locus 
determined. For each crypt micro-dissected, the genomic mutations detected at 
screening were confirmed by PCR before taking forward for methylation analysis. 
 
Figure 6.11 shows the 2.2cm tubulo-villous adenoma (TVA) with low-grade dysplasia 
from patient 11 (adenoma 1), and Figure 6.12 the 1.3cm TVA from patient 13 (adenoma 
3). Mutation screening revealed both adenomas had mutations in APC and KRAS, and 
this was confirmed in all of the individual crypts micro-dissected for methylation 
analysis (Figure 6.11A & 6.12A). Methylation patterns at the CSX and MYOD1 loci 
were relatively conserved between crypts when compared to adenomas with mutations 
in APC only (Figure 6.15), showing little diversity across the whole adenoma in both 
cases (Figure 6.11C & 6.12B). 
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Figure 6.11 Methylation patterns at the CSX locus for adenoma 1 
????? ???? ???? ??????????? ?????? ??? ??????????? ??????? ??????? ???? ???????? ????
???????????????????????????????????????????????????????????????????????? ????????
??????? ????????????????? ??????????????? ??????????????????????????????????????
?????????????????????????????????????????????????? ?????????? ??????? ??????????????
???? ???????? ??? ???? ????????? ????? ???????????? ????????? ??? ???????? ?????? ???? ?????
?????????????????????????????????????
Chapter 6. Dynamics of human colorectal adenoma initiation and growth 
 174 
?
Figure 6.12 Methylation patterns at the CSX locus for adenoma 3 
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Adenomas 2, 4 and 5 had mutations in the APC gene but were otherwise wild-type for 
KRAS, BRAF and TP53, MSS and there was no evidence of LOH (Table 6.1). In 
contrast to the adenomas harbouring KRAS mutations, methylation patterns between 
crypts within these adenomas demonstrated significantly more variance (Figure 6.15). 
Repeat PCR for all individual crypts micro-dissected for methylation analysis from 
adenomas 2, 4 and 5 was performed to confirm they were indeed clonal for the APC 
mutation found at screening, and were all wild-type for KRAS. Figure 6.13 and Figure 
6.14 show the methylation patterns at the CSX locus for crypts from adenoma 2 and 
adenoma 5 respectively. 
 
The inter-crypt and minimum distances – the measurements of methylation pattern 
diversity between crypts within each adenoma - was calculated for all crypts sampled 
within adenomas 1, 2, 3, 4 and 5. The data for adenomas 1 and 3 was then compared to 
adenomas 2, 4, and 5 (Figure 6.15A-D).  Crypts within adenomas clonal for APC and 
KRAS mutations demonstrated significantly less inter-crypt diversity, and thus appeared 
significantly more related by their methylation patterns than crypts with adenomas 
clonal only for an APC mutation at the CSX locus (p=4 x 10
-26
 for inter-crypt distance 
and p=1.8 x 10
-25
 for minimum distance) (Figure 6.15A-B).  When assessing the 
MYOD1 locus, the same trend was seen for the inter-crypt distance (p=0.04), although 
no significant difference between the adenoma types was detected when using the 
minimum distance (Figure 6.415C-D). 
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Figure 6.13 Methylation patterns at the CSX locus for adenoma 2 
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Figure 6.14 Methylation patterns at the CSX locus for adenoma 5 
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Figure 6.15 Crypts within adenomas that are clonal for APC and KRAS mutations 
appear significantly more related by their methylation patterns 
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6.5 Adenomas appear to display punctuated growth 
 
The methylation data across the adenomas was analysed in order to infer patterns of 
overall growth, by correlating the physical distances of crypts within an adenoma to 
their respective epigenetic distances, as measured by the inter-crypt distance at 
methylation tags of the CSX locus. Each crypt within adenomas 1, 3 and 5 was ranked 
according to the physical number of crypts separating it from all the other crypts within 
the lesion (physical distance), this was then plotted against the respective ranked 
epigenetic distance for the same pairs of crypts. If the lesions had grown in a constant, 
linear fashion the physical distances would be expected to correlate with the epigenetic 
distances between pairs of crypts over short length scales. However, for the adenomas 
analysed, no obvious correlation was seen (Figure 6.16), suggesting that there had been 
punctuated growth: Methylation patterns of crypts across the whole adenoma would 
appear equally similar after a period of rapid expansion, and tags of crypts in close 
spatial proximity would diverge during quiescent stages. 
 
 
Figure 6.16 The physical separation of crypts within adenomas is not reflected by 
their epigenetic distances 
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6.6 KRAS sub-clones can be identified and appear to be 
expanding rapidly 
 
On screening adenoma 6 from macro-dissected tissue, a small peak of mutant KRAS 
was identified (c.35G>A), in addition to a mutation in APC (c.3925_3929delGAAAA). 
Subsequent LCMD of individual crypts from across the adenoma identified two small, 
clonally distinct areas of adenomatous crypts that harboured the KRAS and APC 
mutations, whereas remaining crypts where clonal only for APC and KRAS wild-type 
(Figure 6.17A-B). Subsequent methylation analysis was unfortunately only successful 
for two crypts from the KRAS sub-clone, however this did show them to have very 
similar CSX methylation patterns, whereas methylation tags were quite divergent 
amongst randomly selected KRAS wild-type crypts (Figure 6.17B). 
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Figure 6.17 Methylation patterns at the CSX locus for the KRAS sub-clone within 
adenoma 6 
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6.7 Discussion 
 
Crypt fission has been shown to be the major mechanism by which early adenomas 
grow 
93
, so-called bottom-up spread, with dysplastic cells invading adjacent normal 
crypts occurring later on in adenoma development – top-down spread. Wong et al 
94
 
demonstrated that crypt fission events are significantly more frequent in both 
hyperplastic polyps and adenomas compared to normal tissue, with an upward 
expansion of the proliferative compartment in adenomas. However, there is limited data 
on how adenomas grow, with longitudinal barium and endoscopic studies showing that 
many smaller adenomas appear to be static over many years. This project aimed to 
identify clonal sub-populations within polyps and adenomas in order to investigate 
growth dynamics by analysing methylation patters at CpG islands of non-expressed 
genes. 
 
All of the sporadic adenomas were greater than 1cm in size (measured post-resection by 
a pathologist) and 88% (8/9) had mutations in the APC MCR, higher than that reported 
in other studies 
84, 133
. The tissue used in this study was fresh frozen which enables 
much more efficient PCR of DNA, almost all other studies that have looked at the 
frequency of APC mutations in sporadic adenomas have used FFPE tissue, a fixing 
process that fragments DNA and makes PCR of the entire MCR much more 
challenging. Thus mutations may have been missed in previous studies due to 
incomplete amplification of the MCR of APC. It has been reported that in FAP patients, 
due to the differing functional consequences of mutations in the MCR of APC, germ-
line mutations around codon 1296 or 1309 are highly selective for LOH in the other 
allele 
143
. Of the nine adenomas screened, one had a mutation in codon 1299 and two in 
codon 1309 of APC and surprisingly none had evidence of LOH by the microsatellites 
used here; however this does not exclude LOH, since focal chromosomal losses may not 
be detected by LOH markers. In this study 33% (3/9) of the adenomas screened were 
found to have mutations in the KRAS oncogene, which is lower than that reported by 
Vogelstein 
113
 (58%). However, the incidence of KRAS mutations in colorectal cancer 
does vary from 20-50% between studies 
137, 170
. The absence of mutations in TP53 and 
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17p LOH is consisted with previous work associating these with more advanced (high-
grade dysplasia) adenomas and the progression to cancer 
113, 114, 144
. None of the 
adenomas had evidence of MSI or contained mutations in the BRAF oncogene, 
suggesting that there was no CIMP in these lesions, and no difference in global genomic 
DNA methylation level as measured by LINE-1 Pyrosequencing
®
 was seen between 
normal and adenomatous crypts. 
 
Multiple, large, clonally distinct CCO-deficient patches of crypts were seen within a 
hyperplastic polyp. Crypts within these patches appeared significantly more related by 
their methylation patterns compared to random brown, wild-type crypts from within the 
same lesion.  This is in contrast to what was seen in normal tissue (see Chapter 5), and 
thus these crypts must have expanded rapidly by fission in order for the methylation 
patterns to remain similar over such large patches of crypts. Similarly, a large CCO-
deficient sub-clone was identified within an adenoma: All crypts within the adenoma 
harboured the same, clonal mutation in APC, however the CCO-deficient crypts were 
clonally distinct by sharing a common somatic mutation in their mtDNA. Analysis of 
the methylation patterns again suggested that the CCO-deficient sub-clone had 
expanded rapidly within the adenoma. The reason for the CCO-deficient sub-clone 
having a selective advantage in this case is not clear, as no additional tumorigenic 
mutations other then the APC mutation were detected within the adenoma at screening. 
However, there are likely many more tumorigenic changes occurring in adenomas that 
were not screened for in this study, and LOH analysis on a crypt-by crypt basis might 
reveal a selective advantage.  
 
Methylation data from crypts micro-dissected across adenomas with a clonal APC 
mutation were compared to adenomas with a clonal APC and KRAS mutation 
(APC/KRAS) in all crypts; pairs of crypts within APC/KRAS adenomas appeared 
significantly more related by their both their inter-crypt distance and minimum distance. 
As adenomas grow the time to the most recent common ancestor between crypts 
increases and individual crypt methylation patterns will diverge, thus the APC/KRAS 
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adenomas appeared a much younger population by their methylation patterns, 
suggesting they had not yet had time to diversify, consistent with their being a recent 
selective sweep and rapid clonal expansion in these lesions. It is not possible to say 
whether the KRAS or APC mutation initiated this, as both mutations were found in all 
crypts. These observations could have been tested further by immunohistochemical 
staining for markers of cellular proliferation such as KI-67 and GEMININ expression, 
in addition to assessing levels of apoptosis using CASPASE-3 expression or TUNEL 
(terminal deoxynucleotidyl dUTP transferase nick end labelling) assays. Comparing the 
spatial distances of crypts within adenomas to their respective epigenetic distances, as 
measure by the inter-crypt distance, suggested that growth had not occurred in a 
constant linear fashion and was consisted with a punctuated growth pattern, thus periods 
of rapid clonal expansion may be followed by periods of relative quiescence.  
 
There is evidence for significant interaction between the Wnt and MAPK pathways: Li 
et al 
185
 showed that expression of oncogenic KRAS mutations stimulates Wnt signalling 
in colon cancer cell lines, and compound transgenic mouse models have demonstrated 
that expression of oncogenic KRAS, in addition to APC loss, promotes adenoma and 
tumour progression in the intestines and further up-regulates Wnt/?-catenin signalling 
pathways 
186, 187
. The KRAS sub-clone identified within adenoma 6 does allow clonal 
ordering however, and the initial methylation data suggests this is a rapidly expanding 
population, providing potential direct evidence for a growth advantage provided by a 
KRAS mutation in addition to APC in human adenomas for the first time. Further work 
examining the dynamics of KRAS sub-clones within adenomas will allow more 
substantiated conclusions and relative growth rates to be estimated.  
 
It was demonstrated in Chapter 5 that CSX methylation tags appeared to record clonal 
ancestry more effectively than MYOD1 tags: clonally-derived CCO-deficient
 
crypts had 
significantly more similar CSX methylation patterns than unrelated crypts (Figure 5.9), 
and CSX methylation pattern diversity scaled with clone size in partially-mutated crypts 
(Figure 5.7), whereas these trends were not consistently observed for MYOD1.  The 
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methylation patterns at the BGN locus were more similar for unrelated crypts than those 
derived by fission (Figure 5.9), suggesting it is not able to accurately record clonal 
ancestry over long time periods. This differential ability to record ancestry is likely to 
result from both the locus and CpG-site specific (de-)methylation rates. The same trends 
for both CSX and MYOD1 were observed when statistically analysing the methylation 
patterns for crypts within adenomas, supporting the validity of the findings presented in 
this chapter, however no data is presented here for the BGN locus as, for reasons that 
were not clear, it was not possible to amplify this locus efficiently enough from the 
adenoma tissue in order to sample the methylation status.  
 
It is widely accepted that tumorigenesis is a form of somatic evolution, and it has been 
suggested that selection, without increased mutation rates, is sufficient to explain the 
initiation and expansion of colorectal adenomas 
138, 142
. Although adenomas less than 
1cm in size do not appear to be actively growing when assessing their size, dynamic 
clonal expansion might go unnoticed if any increase in crypt number is balanced by 
crypt death 
188
 – a hypothesis that could be tested by looking at apoptotic indices in sub-
clone populations. The results presented here provide evidence that sub-clones within 
adenomas and polyps can be identified that are rapidly expanding by fission compared 
to neighbouring crypts, and APC mutated adenomas with oncogenic KRAS mutations 
appear to have undergone recent clonal expansions. In addition, adenomas appear to 
have periods of little or no growth that enable the methylation patterns of adjacent 
crypts to diverge. Thus, adenoma growth may be characterised by cycles of rapid clonal 
expansion as new, selectively advantageous mutations are acquired, followed by periods 
of little or no growth; during the apparent static phases there may be dynamic 
competition between sub-clones that drives the further evolution of the lesion. 
However, there are several limitations of the data set presented in this chapter: the 
number of adenomas studied so far is small, and further work needs to be done to 
validate the findings presented here, in addition growth dynamics are being inferred 
from a snapshot in time - an experimental animal model could be developed that would 
allow the hypotheses generated to be tested further under more controlled conditions 
with the collection of temporal data. 
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Chapter 7. Conclusions 
 
7.1 Delineating stem cell clones in normal human intestine 
The results presented here have enabled, for the first time in human tissue, the 
identification of a single stem cell lineage and their direct progeny within human colon 
crypts. There appear to be at least 2 stem cell lineages within the human colonic niche, 
located at the base of the colon crypt and around the +4 position in the small bowel. 
Mapping of clones has allowed the visualisation of niche succession and clonal expansion 
within human intestinal crypts. 
7.2 Niche succession in the normal human colon crypt occurs 
over many years  
Analysis of the methylation patterns of CCO-deficient stem cell clones occupying 
different areas of the crypt, and thus at different stages of niche succession, suggests that 
this is slow process, taking many years in the human colon. 
7.3 There are at least 10 years between crypt fission cycles in 
normal human colon  
Patches of CCO-deficient crypts, known to be clonally-derived by fission events, appear 
disparate by their methylation patterns, thus there is sufficient time (years) between 
fission events to allow divergence. Mathematical modelling suggests that approximately 
10 years is the lower limit for crypt fission events in normal human colon. 
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7.4 Human colorectal adenomas may exhibit punctuated 
growth, with clonal competition driving the evolution of 
these lesions 
Genetically distinct sub-clones have been identified within human adenomas and polyps 
that are expanding rapidly compared to surrounding crypts within the lesion. Adenomas 
with mutations in APC and KRAS appear to have undergone recent clonal expansions, 
and there is evidence that oncogenic KRAS expression on the background of APC 
mutations offers a growth advantage in human adenomas. Analysis of methylation 
patterns within adenomas suggests they may display punctuated growth, with cycles of 
rapid clonal expansion followed by relative quiescence.  
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Chapter 8. Summary Discussion 
 
Much of the current knowledge on the location of the intestinal stem cell niche, stem cell 
number and dynamics of clonal expansion within crypts is based on mutagenic studies 
10, 
17, 70, 71
 and, more recently, genetic lineage tracing experiments in transgenic mice 
19, 20, 29
, 
employing techniques that are impractical in humans. No experimental evidence has yet 
conclusively demonstrated the stem cell niche in the human intestine. The ‘gold standard’ 
criteria for identifying tissue-specific stem cells is now established as: (i) self-renewal 
and (ii) multi-lineage potential. Thus, the aims of Chapters 3 and 4 were to use naturally 
occurring clonal somatic point mutations in mtDNA to identify and map, for the first 
time, the progeny of a putative single stem cell lineage within human crypts, and then to 
demonstrate the multi-lineage potential of these clones, thus providing evidence that they 
are, indeed, stem cell populations. 
 
Why is stem cell biology important? It has long been proposed that cancer is a 
consequence of tumorigenic mutations accruing in a single, tissue-specific stem cell 
115
, 
based mainly on hypothetical reasoning that these are the only cell lineages with 
sufficient life-span to accumulate the multiple mutations required for tumorigenesis. 
However, there is now experimental evidence to support stem cells as the cells of origin 
in colorectal carcinogenesis: Knocking out Apc in Lgr5+ stem cells results in rapid 
adenoma formation, whereas knocking out Apc in non-stem cells does not 
176
. 
Furthermore, a recent study has demonstrated that non-steroidal anti-inflammatory drugs 
(NSAIDS) are able to target stem cells that have accumulated tumorigenic mutations, and 
can eliminate them by the induction of apoptosis 
189
: In an Apc 
Min/+
 mouse model, dietary 
sulindac (an NSAID) induced apoptosis in intestinal stem cells with nuclear or 
phosphorylated ?-catenin, and in human colonic polyps NSAIDS were shown to induce 
apoptosis in cells with aberrant Wnt signalling 
189
. Thus, understanding the stem cell 
biology of the human intestine, and the key mechanisms that are dysregulated in the 
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initiation of dysplasia, may enable the development of effective chemoprevention by 
targeting aberrant stem cell populations. Indeed, studies have consistently demonstrated 
that the use of aspirin 
190-193
 and cyclo-oxygenase-2 enzyme (COX-2) inhibitors 
194, 195
 is 
associated with around a 20% reduction in adenoma recurrence in patients. A recent 
meta-analysis pooling long-term follow up data from four randomized, double-blind, 
placebo-controlled trials of aspirin treatment 
196
 demonstrated that regular aspirin 
significantly reduced long-term risk of colon cancer – interestingly, this reduction was 
almost entirely due to a decrease in the incidence of proximal colorectal cancers. The 
biology of the stem cell niche has long been shown to differ with progression from the 
small bowel to the rectum, with the proximal colon itself appearing more like the small 
intestine 
27, 32, 33
, thus it is interesting to wonder whether the apparent chemo-preventative 
effects of aspirin confined to the proximal human colon are due to specific effects on the 
stem cells and their niche here, a hypothesis that could be explored in mouse models. 
 
The data presented for the human colon in Chapters 3 and 4 was consistent with the 
prevailing dogma from murine studies, that there are multiple, related stem cells located 
at the base of the colonic crypt that undergo successive niche succession cycles. Only a 
small amount of data was presented for the small intestine, due to difficulty in obtaining 
fresh frozen tissue, however the limited results did indicate that the niche in the human 
small bowel is around cell position 4, above the basal Paneth cells. The Barker et al 
19
 
Lgr5 lineage tracing study was a series of seminal experiments, and re-defined the criteria 
for identifying putative stem cells, providing robust evidence that, as proposed thirty 
years previously 
5, 24
, the crypt based columnar cells were a stem cell population in the 
small bowel. However, the situation in the small bowel niche is still as debated as ever, 
with further studies employing the techniques used by Barker et al 
19
 to perform lineage-
tracing using other markers such as Bmi1 demonstrating putative stem cells concentrated 
around the +4 position 
20, 29
. Thus, there does appear to be a heterogeneous stem cell 
population in the mouse small bowel, with actively cycling stem cells at the base below 
more quiescent stem cells around cell position 4 – an organisation not too far removed 
from the hierarchical arrangement of the niche proposed by Potten and colleagues almost 
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fifteen years ago 
27
. In the human small and large intestine, further work combining 
mapping of CCO-deficient cell populations within crypts with the new panel of putative 
stem cell markers developed in mouse lineage studies might allow further 
characterisation of the human niche. 
 
In Chapter 5, the rates of niche succession and crypt fission, the methods by which 
tumorigenic mutations in stem cells are thought to initially become established within the 
epithelium, were investigated in normal human colon by studying the methylation 
patterns at CpG loci of non-expressed genes in CCO-deficient cell populations. Similar 
techniques were then applied in Chapter 6 to investigate the dynamics and clonal 
expansion of early human adenoma growth. The methylation patterns of stem cell 
lineages expanding within the normal crypt at different stages of clonal succession 
suggested that niche succession can take many years, furthermore crypt fission events in 
normal human colon appear to be separated by at least 10 years. The situation observed in 
early human adenomas and polyps was quite the opposite, with large patches of clonally 
expanded CCO-deficient crypts identified that appeared very similar by their methylation 
patterns, indicating that the clonal expansion rates are significantly up-regulated to allow 
the rapid fixation and spread of mutations during early tumorigenesis. 
 
The dynamic nature of methylation patterns severely restricts their use as a clonal marker 
per-se, as demonstrated in Chapter 5. However, in situations when clonality can be 
inferred by an alternative means, such as by rare somatic point mutations in mtDNA, the 
additional analysis of methylation patterns of non-expressed genes provide an attractive 
means to estimate the rates of recent clonal expansions. Thus, the principles and 
techniques presented here could easily be applied to study the dynamics of clonal 
expansion in many other human tissues. 
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All the human intestinal tissue used in Chapters 3, 4 and 5 was obtained form patients 
who had undergone bowel resections for either colorectal polyps or cancer, and 
morphological normal tissue was obtained from outside of the resection margins. It has 
been reported that the colonic epithelium in patients with colorectal cancer demonstrates 
a generalised increase in cell proliferation 
197
 and thus, it could be argued that the tissue 
used in these studies was not ‘normal’. However, Potten and colleagues 
198-200
 have 
demonstrated variable results when analysing morphological normal crypts both 
immediately adjacent to and at a distance from tumour sites, initially reporting generally 
depressed proliferative activity in crypts adjacent to tumours 
198, 199
 and then observing no 
evidence of any proliferative differences in a subsequent study 
200
. In the study by 
Becciolini et al 
200
, morphologically normal colon crypts taken at a distance of both 5 cm 
and 20cm from above and below tumours demonstrated no differences when assessing 
crypt total cell number, the 
3
H thymidine labelling index and mitotic indices, in addition 
normal colon tissue from cancer patients did not demonstrate the generalised increase in 
proliferative activity reported by Terpstra et al 
197
. 
 
Despite colorectal adenomas being one of the most clinically relevant pre-neoplastic 
lesions in epithelia, and vast amounts of expertise and money currently being invested in 
establishing widespread endoscopic screening programmes, very little is known about 
how they grow. Large adenomas, greater than 1cm, have been shown to have a 
significant malignant risk 
153
, but the clinical relevance of smaller lesions has been the 
subject of much debate due to studies suggesting they show little or static growth over 
many years 
155, 158-160
. Furthermore, the follow up of patients with adenomas detected at 
colonoscopy has been predominantly determined by non-evidence based opinions of best 
practice. The data from Chapter 6 suggests that there may be rapid clonal expansion 
occurring within adenomas, both over small areas of adenomatous crypts and involving 
the entire lesion, and that adenomas grow in a punctuated manner. Therefore, the 
macroscopic size of an adenoma may be clinically irrelevant, since even small adenomas 
that appear to be quiescent may possess significant malignant potential. Further work, 
perhaps incorporating next generation sequencing techniques that enable the rapid 
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sequencing of large amounts of the genome, could be applied to adenomas in order to 
better define the dynamics of genetically distinct sub-clones within adenomas, and this 
may allow improved stratification of risk in patients with polyps detected at endoscopy. 
 
There are a number of limitations to the data presented in this study. The numbers of 
samples analysed are small, and further work needs to be done to ensure a representative 
data set has been obtained. The estimates of the dynamics of clonal expansion using the 
methylation status at CpG islands of non-expressed genes, and the mathematical model 
employed in Chapter 5, depend on the validity of the various assumptions made, thus the 
data has to be interpreted with caution. Importantly, observational data has inherent bias 
associated with study design and data collection, analysis and interpretation, therefore 
further work to validate the conclusions, perhaps using experimental mouse models or 
tissue culture methods, is needed. 
 
In summary, more work needs to be done to understand the stem cell biology of the 
intestine, and how this may be altered in very early tumorigenesis, as this may be crucial 
in enabling the development of targeted chemoprevention for colorectal cancer, and 
further studies to delineate the dynamics of adenoma growth should help to better inform 
the clinical management of patients with these important lesions. 
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Chapter 9. Appendix 
9.1 PCR primer sequences and reaction conditions 
 
All primers were ordered dry from Sigma-Aldrich, UK, and re-suspended in water to 
form a 20 micromolar working solution. 
9.1.1 Primer details for sequencing of entire mitochondrial genome 
 
Name Sequence 5’ to 3’ 
A(F) GCTCACATCACCCCATAAAC 
A(R) GATTACTCCGGTCTGAACTC 
B(F) ACCAACAAGTCATTATTACCC 
B(R) TGAGGAAATACTTGATGGCAG 
C(F) CCGTCATCTACTCTACCATC 
C(R) GGACGGATCAGACGAAGAG 
D(F) AATACCCATCATAATCGGAGG 
D(R) GGTGATGAGGAATAGTGTAAG 
E(F) AACCACTTTCACCGCTACAC 
E(R) AGTGAGATGGTAAATGCTAG 
F(F) ACTTCACGTCATTATTGGCTC 
F(R) ATAGGAGGAGAATGGGGGATAG 
G(F) ACCCCCCACTATTAACCTACTG 
G(R) GGTAGAATCCGAGTATGTTGG 
H(F) TATTCGCAGGATTTCTCATTAC 
H(R) AGCTTTGGGTGCTAATGGTG 
I(F) CCCATCCTCCATATATCCAAAC 
I(R) GGTTAGTATAGCTTAGTTAAAC 
Table 9.1 Forward (F) and reverse (R) primers for first-round nested mitochondrial 
PCR.  
???????????????????????????????????????????????????????????????????????? ????????
?????????????????????????????????????
?
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Name Sequence 5’ to 3’ 
1(F) TGTAAAACGACGGCCAGTCACACACACCGCTGCTAAC 
2(F) TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC 
3(F) TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG 
4(F) TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC 
5(F) TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC 
6(F) TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 
7(F) TGTAAAACGACGGCCAGTACCATCACCCTCTACATCAC 
8(F) TGTAAAACGACGGCCAGTTCGCCCTATTCTTCATAGCC 
9(F) TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG 
10(F) TGTAAAACGACGGCCAGTCTCACTCTCTCAATCTTATCC 
11(F) TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC 
12(F) TGTAAAACGACGGCCAGTAGATTTACAGTCCAATGCTTC 
13(F) TGTAAAACGACGGCCAGTTAGCAGGTGTCTCCTCTATC 
14(F) TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC 
15(F) TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG 
16(F) TGTAAAACGACGGCCAGTTCCTAACACTCACAACAAAAC 
17(F) TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC 
18(F) TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC 
19(F) TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC 
20(F) TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG 
21(F) TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC 
22(F) TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC 
23(F) TGTAAAACGACGGCCAGTTATCCAGTGAACCACTATCAC 
24(F) TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG 
25(F) TGTAAAACGACGGCCAGTCTCCCTCTACATATTTACCAC 
26(F) TGTAAAACGACGGCCAGTCTCTTCCCCACAACAATATTC 
27(F) TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC 
28(F) TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC 
29(F) TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC 
30(F) TGTAAAACGACGGCCAGTATTAAAGTTTACCACAACCACC 
31(F) TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC 
32(F) TGTAAAACGACGGCCAGTCATCTTGCCCTTCATTATTGC 
D1(F) TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG 
D2(F) TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG 
D3(F) TGTAAAACGACGGCCAGTCCTTAAATAAGACATCACGATG 
D4(F) TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC 
Table 9.2 Forward (F) primers for second-round nested mitochondrial PCR.  
?????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
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Name Sequence 5’ to 3’ 
1(R) CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG 
2(R) CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG 
3(R) CAGGAAACAGCTATGACCATTGGTGGCTGCTTTTAGG 
4(R) CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG 
5(R) CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC 
6(R) CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG 
7(R) CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC 
8(R) CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG 
9(R) CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG 
10(R) CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG 
11(R) CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC 
12(R) CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG 
13(R) CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC 
14(R) CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG 
15(R) CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG 
16(R) CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG 
17(R) CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC 
18(R) CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG 
19(R) CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG 
20(R) CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG 
21(R) CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG 
22(R) CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG 
23(R) CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC 
24(R) CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG 
25(R) CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG 
26(R) CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC 
27(R) CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG 
28(R) CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG 
29(R) CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG 
30(R) CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC 
31(R) CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG 
32(R) CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG 
D1(R) CAGGAAACAGCTATGACCAGGGTGATAGACCTGTGATC 
D2(R) CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG 
D3(R) CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG 
D4(R) CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG 
Table 9.3 Reverse (R) primers for second-round nested mitochondrial PCR.  
?????????????????????????????????????????????????????????????????????????????????????
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9.1.2 Primer details and reaction conditions for RT-PCR 
 
Name Sequence 5’ to 3’ Reaction notes 
Villin1st F CAAGACAGGCTCACTCACCA 
Villin 1st R ATCCCCTCGGTTGAAACTCT 
Mg 2.5/60˚C 
Villin  2nd F CACCTTTGGAAGCTTCTTCG 
Villin 2nd R TCCAGCTACCACGTTCCTCT 
Mg 1.5/60˚C 
CD-10 1st F GCTGAGGGGTCACGATTTTA 
CD-10 1st R AGCTGTCCAAGAAGCACCAT 
Mg 2.5/60˚C 
CD-10 2nd F TCCACTGCAGATCAGCCTCT 
CD-10 2nd R TGCTTTTGCTTTCTGCACTG 
Mg 2.5Q/55˚C 
Muc-2 1st F CTCCAGACAGAGGGCAGAAC 
Muc-2 1st R GATCCTCACACACCACATCG 
Mg 2.5/60˚C 
Muc-2 2nd F AAGGAATTTGCTGTGCACCT 
Muc-2 2nd R GCCGTCAGAGAGGAATTCTG 
Mg 2.5Q/60˚C 
Chrom A 1st F GGGATACCGAGGTGATGAAA 
Chrom A 1st R TCCACCAGACCCTGAGAGAG 
Mg 2.5Q/60˚C 
Chrom A 2nd F TTGAGGTCATCTCCGACACA 
Chrom A 2nd R TTTTCTCTGCCTCCTTGGAA 
Mg 2.5/60˚C 
?-Actin F AGCACAGAGCCTCGCCTTT 
?-Actin R CCCACATAGGAATCCTTCTGAC 
Mg 2.5Q/60˚C 
Table 9.4 Lineage specific primers for cDNA nested PCR 
?????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
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9.1.3 Primer details and reaction conditions for PCR, cloning and 
sequencing of target CpG loci within CSX, BGN and MYOD1  
 
Name Sequence 5’ to 3’ Reaction notes 
CSX 1st F GAGTTTGGTAGGGAAGGGATT 
CSX 1st R AAAACACTCCTAAAAAAACAACTA 
Mg 1.5/55˚C 
CSX 2nd F GGAGATTTAGGAATTTTTTTTGTTTT 
CSX 2nd R CACCAAACTACAAAATCACTCATTACA 
Mg 1.5/60˚C 
BGN 1st F TTTTTTTGAAGTTGTTAGGG 
BGN 1st R AACCAAAAACATCTCTAAATTACT 
Mg 1.5/55˚C 
BGN 2nd F TAAATTGTTTAGGAGTGAGTAGTTGTTT 
BGN 2nd R AAAAACAACTTAAAACCAACCCTACC 
Mg 2.5/60˚C 
MYOD 1st F GGGTTTTTTTTTTAGTTGAAGAGGT 
MYOD 1st R ACCTAAAAATTACTCAACAAAT 
Mg 2.5Q/60˚C 
MYOD 2ndF TGGAGGGGATTTTTAATTTGG 
MYOD 2nd R AACCCAATCCTTCTTCCCTAA 
Mg 1.5Q/55˚C 
M13F GTAAAACGACGGCCAGT 
M13R CAGGAAACAGCTATGAC 
Mg 1.5/55˚C 
T7 TAATACGACTCACTATAGGG 
SP6 TATTTAGGTGACACTATAG 
Mg 1.5/55˚C 
Table 9.5 Methylation nested PCR, cloning and sequencing primers 
?????????????????????????????????????????????????????????????????????????????????????
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9.1.4 Primer details and reaction conditions for APC, KRAS, BRAF and 
TP53 sequenced loci 
 
Name Sequence 5’ to 3’ Reaction notes 
APC MCR1 F GAGTTTGGTAGGGAAGGGATT 
APC MCR1 R AAAACACTCCTAAAAAAACAACTA 
Mg 2.5Q/60˚C 
APC MCR2 F GGAGATTTAGGAATTTTTTTTGTTTT 
APC MCR2R CACCAAACTACAAAATCACTCATTACA 
Mg 2.5Q/55˚C 
Table 9.6 APC mutation cluster region (MCR) PCR primer sequences for frozen 
tissue 
??????????????????????????????????????????????????????????????????????????
?????????? ??? ?????????????? ??????? ????????? ?????? ?????? ??? ????????? ???? ????????
??????????????????????????????????????????????????????????????
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Name Sequence 5’ to 3’ Reaction notes 
APC 1st 1F GGACAAAGCAGTAAAACCGAAC 
APC 1st 1R AACTACATCTTGAAAAACATATTGGA 
Mg
 
1/55˚C 
APC 1st 2F AAGTGGTCAGCCTCAAAAGG 
APC 1st 2R GCTATTTGCAGGGTATTAGCA 
Mg 3Q/60˚C 
APC 1st 3F GATACTCCAATATGTTTTTCAAGATG 
APC 1st 3R GCCTGGCTGATTCTGAAGAT 
Mg 1/55˚C 
APC 1st 4F CCCTGCAAATAGCAGAAATAAAA 
APC 1st 4R AACATGAGTGGGGTCTCCTG 
Mg 1/55˚C 
APC 1st 5F CAGACTGCAGGGTTCTAGTTTATC 
APC 1st 5R CATTCCACTGCATGGTTCAC 
Mg 2/60˚C 
APC 1st 6F CCAAAAGTGGTGCTCAGACA 
APC 1st 6R CATGGTTTGTCCAGGGCTAT 
Mg 2/60˚C 
APC 1st 7F TTTGAGAGTCGTTCGATTGC 
APC 1st 7R TCTCTTTTCAGCAGTAGGTGCTT 
Mg 1/60˚C 
APC 1st 8F CATGCAGTGGAATGGTAAGT 
APC 1st 8R GCAGCATTTACTGCAGCTT 
Mg 2/55˚C 
APC 1st 9F CAAGCGAGAAGTACCTAAAAA 
APC 1st 9R TTCTGTATAAATGGCTCATCG 
Mg 2/55˚C 
APC 1st 10F GGTTCTTCCAGATGCTGATA 
APC 1st 10R CTTGGTTTTCATTTGATTCTTT 
Mg 2/55˚C 
APC 1st 11F AATTAAGAATAATGCCTCCAGT 
APC 1st 11R TTTACGTGATGACTTTGTTGG 
Mg 2/55˚C 
APC 1st 12F CCAAGAGAAAGAGGCAGAAAAA 
APC 1st 12R TGATGGTAGAAGTTTGTACACAGG 
Mg 1Q/55˚C 
Table 9.7 APC MCR PCR nested first-round primer sequences 
???????? ????? ???????????? ??????????????????????????????????? ?????? ??? ?????????
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Name Sequence 5’ to 3’ Reaction notes 
APC 2nd 1F CAAGCAGTGAGAATACGTCCA 
APC 2nd 1R TTTCTTGGTTAATAGAAGAAACTTTGC 
Mg 1/55˚C 
APC 2nd 2F GCCACTTGCAAAGTTTCTTCT 
APC 2nd 2R TGCTTCCTGTGTCGTCTGA 
Mg 2Q/60˚C 
APC 2nd 3F CAGACGACACAGGAAGCAGA 
APC 2nd 3R TGGAACTTCGCTCACAGGAT 
Mg 1 /55˚C 
APC 2nd 4F GAAGATCCTGTGAGCGAAGTTCC 
APC 2nd 4R CAAGTCCTCTGGGGTGAGTA 
Mg 1/55˚C 
APC 2nd 5F AGAATCAGCCAGGCACAAAG 
APC 2nd 5R GCAATCGAACGACTCTCAAA 
Mg 1/60˚C 
APC 2nd 6F CACTATGTTCAGGAGACCCCA 
APC 2nd 6R TGGAAGATCACTGGGGCTTA 
Mg 1/60˚C 
APC 2nd 7F GTGAACCATGCAGTGGAATG 
APC 2nd 7R ACTTCTCGCTTGGTTTGAGC 
Mg 1/60˚C 
APC 2nd 8F GCTTAGGTCCACTCTCTCTCTT 
APC 2nd 8R GGCATTATAAGCCCCAGT 
Mg 1/55˚C 
APC 2nd 9F CCTAAAAATAAAGCACCTACTGCTG 
APC 2nd 9R CACTCAGGCTGGATGAACAA 
Mg 3/55˚C 
APC 2nd 10F ACATTTTGCCACGGAAAGTA 
APC 2nd 10R GGCTGCTCTGATTCTGTTTC 
Mg 2/55˚C 
APC 2nd 11F CAGGAAAATGACAATGGGAAT 
APC 2nd 11R TGGCATGGCAGAAATAATACA 
Mg 2/55˚C 
APC 2nd 12F GGACCTATTAGATGATTCAGATGATG 
APC 2nd 12R ACTTGGTTTCCTTGCCACAG 
Mg 2Q/55˚C 
Table 9.8 APC MCR PCR nested second-round primer sequences and reaction notes 
?????????????????????????????????????????????????????????????????????????????????????
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Name Sequence 5’ to 3’ Reaction notes 
KRAS 1 F GAGTTTGTATTAAAAGGTACTGGTGGA 
KRAS 1 R ATCAAAGAATGGTCCTGCAC 
Mg 2Q/60˚C 
KRAS 2 F TTTGATAGTGTATTAACCTTAT 
KRAS 2R TATTAAAACAAGATTTACCTC 
Mg 2Q/55˚C 
Table 9.9 KRAS nested PCR primer sequences 
???? ???????? ?????? ??? ???? ????????? ????????????????????????????????????? ????????
??????????????????????????????????????????????????????????????????????????????????????
???????????????????????????
 
 
Name Sequence 5’ to 3’ Reaction notes 
BRAF  F TCATAATGCTTGCTCTGATAGGA 
BRAF  R GGCCAAAAATTTAATCAGTGGA 
Mg 1.5 /55˚C 
Table 9.10 BRAF PCR primer sequences 
??????????????????? ???????????????????????????????????????????????????????????????
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Name Sequence 5’ to 3’ Reaction notes 
TP53 5 1F CACTTGTGCCCTGACTTTCA 
TP53 5 1R GAGCAATCAGTGAGGAATCAGA 
Mg
 
1Q /55˚C  
TP53 5 2F TCTGTCTCCTTCCTCTTCCTACA 
TP53 5 2R AACCAGCCCTGTCGTCTCT 
Mg 1Q /60˚C 
TP53 6 1F AGAGACGACAGGGCTGGTT 
TP53 6 1R TGGAGGGCCACTGACAAC 
Mg
 
2Q /60˚C 
TP53 6 2F CAGGCCTCTGATTCCTCACT 
TP53 6 2R CTTAACCCCTCCTCCCAGAG 
Mg 1/60˚C 
TP53 7 1F TGCTTGCCACAGGTCTCC 
TP53 7 1R GGTCAGAGGCAAGCAGAGG 
Mg 1Q /60˚C 
TP53 7 2F CTTGGGCCTGTGTTATCTCC 
TP53 7 2R GTGTGCAGGGTGGCAAGT 
Mg 1Q /60˚C 
TP53 8 1F TTTTTAAATGGGACAGGTAGGA 
TP53 8 1R CACCCTTGGTCTCCTCCAC 
Mg
 
2Q /60˚C 
TP53 8 2F GCCTCTTGCTTCTCTTTTCC 
TP53 8 2R GCTTCTTGTCCTGCTTGCTT 
Mg
 
2/60˚C 
Table 9.11 TP53 nested PCR primer sequences 
???? ? ???????? ?????? ???????????????? ????????????????????? ???????????????????????
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9.1.5 Microsatellite loss of heterozygosity analysis: primers and reaction 
details for multiplex PCR 
 
Primer Sequence 5’ to 3’ Reaction notes 
Multiplex 1   
D5S2001 F GCCAAGATGGTCTCGATCTC 
D5S2001 R TCTGAACAGGTGATGGCAAC 
D17S1832 F ACGCCTTGACATAGTTGC 
D17S1832 R TGTGTGACTGTTCAGCCTC 
D5S346 F ACTCACTCTAGTGATAAATCGGG 
D5S346 R AGCAGATAAGACAGTATTACTAGTT 
MP57 
   
Multiplex 2   
D5S489 F GGGCTTTTGTGTTGTTTCTA 
D5S489 R GAAAACCCATAACCAGACTTG 
MP57 
Table 9.12 Microsatellite LOH primers 
??? ???????? ???????? ??? ???????? ???????? ????????? ?????? ?????? ??? ?????????? ????
???????? ???? ???????? ??????? ????????? ??????? ????????? ????????? ????? ???? ??????????
??????????????
 
9.1.6 Microsatellite instability (MSI) primers and reaction details 
 
Name Sequence 5’ to 3’ Reaction notes 
BAT25 F  [HEX]TCGCCTCCAAGAATGTAAGT 
BAT25 R TCTGCATTTTAACTATGGCTC 
MP57˚C 
BAT26 F [6FAM]TGACTACTTTTGACTTCAGAA 
BAT26 R AACCATTCAACATTTTTAACCC 
MP57˚C 
Table 9.13 MSI primers for multiplex PCR 
??? ???????? ??? ??????????????? ???????? ????????? ?????? ?????? ??? ???????????????????
???? ???????? ???? ???????? ??????? ????????? ??????? ????????? ??? ?????? ????? ????
????????????????????????
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9.2 PCR reagent and thermal cycling protocols 
 
All volumes are in microlitres (μl) and temperatures in °C unless otherwise stated. 
Reagent Manufacturer Working concentration 
Nucleotides Promega, UK 10mM of each 
Buffer Promega, UK As supplied 
Magnesium Qiagen, UK 25mM 
Taq Qiagen, UK 5units/μl 
Q solution Qiagen, UK 5x (as supplied) 
Table 9.14 Standard PCR reagents 
???? ?????? ?????????????? ????? ??? ???? ???? ?????????? ?????? ????? ??????????????????
?????????
 
 
Reagent Manufacturer Working 
concentration 
Nucleotides Applied Biosystems 10mM of each 
Buffer* Applied Biosystems As supplied 
Magnesium Applied Biosystems 25mM 
AmpliTaq Gold Applied Biosystems 5units/μl 
Table 9.15 MtDNA PCR reagents 
??????????????????? ???????????????? ???????????????????????????????????????????
???????????
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First-round mtDNA PCR protocol 
Reagents per well         
(total = 50 μl) 
Thermal cycler 
programme 
H20 33.65 μl 95°C 10 min 
Nucleotides 
 
5.0 μl 94°C 45 
sec 
Buffer 5.0 μl 58°C 45 
sec 
Mg
2+
 (25mM) 2.0 μl 72°C 2 
min 
 
38 
cycles 
 
AmpliTaq 
gold 
0.35 μl 72°C 8 min 
DNA lysate 1.0 μl 4°C thereafter 
Primers 1.5 μl of 
each 
  
Table 9.16 Mitochondrial DNA PCR first-round protocols 
???????????????????????????????????????????????
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Second-round mtDNA PCR protocol 
Reagents per well       
(total = 25 μl) 
Thermal cycler 
programme 
H20 16.87 μl 95°C 10 min 
Nucleotides 
 
2.5 μl 94°C 45 
sec 
Buffer 2.5 μl 58°C 45 
sec 
AmpliTaq 
gold 
0.35 μl 72°C 1 
min 
 
30 
cycles 
DNA lysate 1.0 μl 72°C 8 min 
Primers 1.0 μl of 
each 
4°C thereafter 
Table 9.17 Mitochondrial DNA PCR second-round protocols 
???????????????????????????????????????????????
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Standard PCR reagent protocols 
Reagents per well 
(all volumes in μl, total = 25 μl per well) 
 Mg 1 Mg1.5 Mg 2 Mg2.5 Mg3 Mg1
Q 
Mg1.5Q Mg2
Q 
Mg2.5Q Mg3
Q 
H20 18.25 17.75 17.25 16.75 16.25 13.25 12.75 12.25 11.75 11.25 
Nucleotides 
 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Buffer 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Mg
2+
 
(25mM) 
1.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 
Q 0 0 0 0 0 5 5 5 5 5 
Taq  0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
DNA lysate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
(F) primer 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
(R) primer 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
Table 9.18 Standard PCR reagent protocols 
?????????????????????????????????????????????????????????????????????????????
?????????? ??????????????? ????? ??? ???????? ?? ????????? ????? ???????? ???????
??????????? ???????? ???????????????°???????°??????????????????????????????????
?????????? ???????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????
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KRAS/TP53 PCR reagent protocols 
Reagents per well 
(all volumes in μl, total = 25 μl per well) 
 Mg 1 Mg2 Mg1Q Mg2Q 
H20 18.3 17.3 13.3 12.3 
Nucleotides 
 
0.5 0.5 0.5 0.5 
Buffer 2.5 2.5 2.5 2.5 
Mg
2+
 (25mM) 1.0 2.0 1.0 2.0 
Q 0 0 5 5 
Taq  0.2 0.2 0.2 0.2 
DNA lysate 2.0 2.0 2.0 2.0 
(F) primer 0.25 0.25 0.25 0.25 
(R) primer 0.25 0.25 0.25 0.25 
Table 9.19 KRAS/TP53 PCR reagent protocols 
???? ????????? ??????????? ?????????? ??????? ?????? ??? ?????? ??????????
??????????????? ??????? ????????????????????????????????????????????????? ????????
????????????????°???????°???????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
?????????????????????
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DNA sequencing reaction reagent 
protocol 
Reagents per well                        
(all volumes in μl, total = 20 μl per well) 
BDT 10 
H20 5 
Primer* 1 
PCR product** 4 
Table 9.20 PCR product sequencing reaction protocol 
???????????? ??????????? ????????? ???????????? ?????? ????????? ??? ???????? ???????
????????????????????????????????????????????????
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Standard thermal cycler PCR programme 
Step Temperature Time 
Temperature 
1 
95°C 5 min 
Denaturing 94°C 1 
min 
Annealing* 55, 57 or 
60°C* 
1 
min 
Elongation 72°C 1 
min 
 
35 
cycles 
Temperature 
2 
72°C 10 min 
Hold 4°C thereafter 
Table 9.21 Standard thermal cycler programmes 
????? ?????????????? ????? ???? ???? ???? ?????????? ?????? ????? ??????????????? ?????
?????????????????????????????????????????????????????????????????????
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ExoSap-IT thermal cycler 
programme 
Step Temperature Time 
Temperature 1 37°C 15 min 
Temperature 2 80°C 15 min 
Hold 15°C  thereafter 
Table 9.22 ExoSap thermal cycler programme 
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Standard thermal cycler DNA sequencing 
programme 
Step Temperature Time 
Temperature 
1 
96°C 5 min 
Denaturing 96°C 30 
sec 
Annealing 50°C 45 
sec 
Elongation 60°C 4 
min 
 
35 
cycles 
Hold 8°C thereafter 
Table 9.23 Thermal cycling programme for standard sequencing of PCR products 
???????? ????????????????????????????????????????
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mtDNA thermal cycler sequencing 
programme 
Step Temperature Time 
Temperature 
1 
96°C 1 min 
Denaturing 96°C 10 
sec 
Annealing 50°C 5 
sec 
Elongation 60°C 4 
min 
 
25 
cycles 
Hold 4°C thereafter 
Table 9.24 Thermal cycling programme for sequencing of mtDNA PCR products 
???????? ????????????????????????????????????????
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Multiplex PCR protocol (MP57) 
Reagents per well     (total 
= 50 μl) 
Thermal cycler programme 
H20 18μ 95°C 
 
10 min 
Primer mix 5μl  95°C 45 
sec 
Multiplex   
mastermix 
25μ 57°C 45 
sec 
DNA template 2μ 95°C 1 
min 
 
30 
cycles 
  72°C 8 min 
  4°C thereafter 
Table 9.25 Multiplex PCR protocol MP57 
????????????????? ?????????????????????????? ?????????
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9.3 Methylation gene CpG island target sequences 
 
Locus Sequence 
BGN 
(10 CpGs) 
TaaaTtgTTTaggagtgagtagTtgTtttCGgtTCGTCGgaTaTaTCGgaTagatag
aCGtgCGgaCGgTTTaTTaTTTTagTTCGTTaaTtagtTagTTtgCGTTtgg
CGTTtTTTTtTtTTaggtagggTtggTttTaagTtgTTtTT 
CSX 
(8 CpGs) 
GgagaTTtaggaaTtttttTtgtTTTaCGCGCGtttgttTttgCGTaCGggagagtttgt
ggCGgCGattatgTagCGtgTaatgagtgatTTtgTagTTtggtg 
MYOD 
(5 CpGs) 
tggaggggattTTtaaTTtgggTaggatTCGagtttggagagattggCGCGaagTtttagT
agTaatTtTCGattTTtgtaTaaTTatagTtgggtttTtaagCGtTtagggaagaaggaTtg
ggTT 
Table 9.26 Reference sequences of CSX, BGN and MYOD 
????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????
????????????
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9.4 Patient details 
 
ID Age Sex Reason for resection 
1 78 M Colorectal cancer 
2 73 M Tubulo-villous adenoma 
3 75 F Colorectal cancer 
4 76 F Colorectal cancer 
5 68 M Ileo-caecal valve polyp 
6 73 M Tubulo-villous adenoma 
7 54 F Colorectal cancer 
8 76 F Colorectal cancer 
9 83 M Colorectal cancer 
10 73 M Polyp 
11 61 M Polyp 
12 66 M Polyp 
13 64 M Polyp 
14 69 F Polyp 
15 62 F Polyp 
16 60 M Polyp 
17 65 F Polyp 
18 64 M Polyp 
19 60 M Polyp 
Table 9.27 Patient details for normal human colonic tissue and resected polyps from 
Chapters 5 and 6 
????????????????? ?????? ?????????????????????????????????????? ????????????????????
??????? ???????? ?????? ??????? ??????? ???? ????????? ????? ??????? ???? ?????????? ????
????????????????
?
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9.5 Publications 
Work presented within this thesis has been published in the following, international, peer-
reviewed scientific journals: 
? Humphries A, Wright NA. Colonic crypt organisation and tumorigenesis. Nature 
Rev Cancer. 2008 Jun;8(6):415-24. Epub 2008 May 15. Review. 
 
? Fellous TG, McDonald SA, Burkert J, Humphries A, Islam S, De-Alwis NM, 
Gutierrez-Gonzalez L, Tadrous PJ, Elia G, Kocher HM, Bhattacharya S, Mears L, 
El-Bahrawy M, Turnbull DM, Taylor RW, Greaves LC, Chinnery PF, Day CP, 
Wright NA, Alison MR. A methodological approach to tracing cell lineage in 
human epithelial tissues. Stem Cells. 2009 Mar 19;27(6):1410-1420. [Epub ahead 
of print]. 
 
? Graham TA, Humphries A, Sanders T, Rodriguez-Justo M, Tadrous PJ, Preston 
SL, Novelli MR, Leedham SJ, McDonald SA, Wright NA . Use of Methylation 
Patterns to Determine Expansion of Stem Cell Clones in Human Colon Tissue. 
Gastroenterology 2011 Apr;140(4):1241-1250.e9. Epub 2010 Dec 28. 
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